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Abstract 
Abstract 
Members of the Interferon Regulatory Factor (IRF) family of transcription factors have essential 
roles in developmental pathways, as well as immune function and host defence. IRF6 has a well-
characterized role in epithelial cell differentiation, but has not been studied in the context of 
immune function. In this thesis, I investigated IRF6 involvement in Toll-like Receptor (TLR) 
responses in epithelial cells. In contrast to the ubiquitous and myeloid-restricted expression patterns 
of IRF3 and IRF8, respectively, IRF6 was selectively expressed in a range of human epithelial cell 
types, particularly keratinocytes. Keratinocyte differentiation also increased IRF6 mRNA and 
protein expression. Primary human keratinocytes, as well as the keratinocyte cell line HaCaT, 
responded weakly to most TLR ligands, with the exception of the TLR3 agonist poly(IC). Poly(IC) 
robustly upregulated mRNA expression of IFN-β, as well as the chemokines IL-8, CCL5 and 
CCL20 in both of these cell types. Surprisingly, poly(IC) also selectively upregulated mRNAs 
encoding IL-23p19 and EBI3, two members of the IL-12 family that have not been shown to 
heterodimerize. Although IRF6 enhanced poly(IC)-inducible IFN-β promoter activity in HEK-
TLR3 cells, silencing IRF6 expression did not decrease poly(IC)-inducible IFN-β mRNA 
expression in primary keratinocytes. Several other inducible genes were also unaffected, however 
knock-down of IRF6 did impair poly(IC)-inducible IL-23p19 mRNA expression in primary 
keratinocytes. Conversely, ectopic expression of IRF6 in the bladder epithelial cell line T24 
conferred poly(IC)-inducible IL-23p19 mRNA expression. To investigate the mechanisms 
responsible, the IL-23p19 promoter was cloned and transient transfection analyses were performed. 
These experiments indicated that IRF6 enhanced IL-23p19 promoter activity upon poly(IC) 
stimulation. Poly(IC) also trigged nuclear translocation of IRF6 in keratinocytes. However, IL-
23p19 protein was not detected in supernatants or cell lysates from poly(IC)-activated 
keratinocytes. Therefore, the effect of inflammatory stimuli, like IFN-γ, on keratinocyte responses 
to poly(IC) was examined. IFN-γ priming enhanced poly(IC)-inducible gene expression but still did 
not license IL-23p19 secretion. Interestingly, keratinocyte differentiation increased poly(IC)-
inducible IL-23p19 mRNA expression, but decreased poly(IC)-inducible IFN-β mRNA expression 
upon IFN-γ priming. Collectively, these data suggest that IRF6 promotes a sub-set of TLR3 
responses in human keratinocytes.  
Studies were also undertaken to determine whether IRF6 is involved in MyD88-dependent 
signalling responses in keratinocytes. Most MyD88-dependent TLR agonists were generally 
ineffective at triggering inflammatory responses in these cells. Investigation of other MyD88-
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dependent ligands revealed that the TLR7 agonist imiquimod and the TLR2/6 agonist FSL-1 did 
upregulate inflammatory chemokine expression in keratinocytes. Knock-down studies suggested 
that IRF6 contributed to TLR7-inducible CCL5 and IFN-β mRNA expression in these cells. Given 
the modest effects of most MyD88-dependent TLR agonists on inflammatory responses in 
keratinocytes, factors that may enhance these responses were also investigated. Keratinocyte 
differentiation increased imiquimod-inducible CCL5 mRNA expression in keratinocytes, whereas 
there was no clear effect of IFN-γ priming. The role of IRF6 in promoting TLR2/6 responses in 
keratinocytes remains unresolved. In total, my findings posit IRF6 as a transducer of a sub-set of 
MyD88-dependent and -independent TLR responses in keratinocytes, implicating it as a sentinel 
transcription factor in pathogen sensing by the skin.  
iv 
 
Declaration by author 
 
This thesis is composed of my original work, and contains no material previously published or 
written by another person except where due reference has been made in the text. I have clearly 
stated the contribution by others to jointly-authored works that I have included in my thesis. 
 
I have clearly stated the contribution of others to my thesis as a whole, including statistical 
assistance, survey design, data analysis, significant technical procedures, professional editorial 
advice, and any other original research work used or reported in my thesis. The content of my thesis 
is the result of work I have carried out since the commencement of my research higher degree 
candidature and does not include a substantial part of work that has been submitted to qualify for 
the award of any other degree or diploma in any university or other tertiary institution. I have 
clearly stated which parts of my thesis, if any, have been submitted to qualify for another award. 
 
I acknowledge that an electronic copy of my thesis must be lodged with the University Library and, 
subject to the General Award Rules of The University of Queensland, immediately made available 
for research and study in accordance with the Copyright Act 1968. 
 
I acknowledge that copyright of all material contained in my thesis resides with the copyright 
holder(s) of that material. Where appropriate I have obtained copyright permission from the 
copyright holder to reproduce material in this thesis. 
 
v 
 
Publications during candidature 
Conference Abstracts 
Ramnath, D., Bergot, A.S., Scholz, G.M., Sweet, M.J. (2011) IRF6: An epithelial cell-specific 
component of TLR signalling? Brisbane Immunology Group 12th Annual Meeting, Sea-world 
Resort, Gold Coast, QLD, Australia. 
Ramnath, D., Bergot, A.S., Scholz, G.M., Sweet, M.J. (2012) IRF6: An epithelial cell-specific 
component of TLR signalling. TLROZ 2012 conference, Melbourne, VIC, Australia. 
Ramnath, D., Bergot, A.S., Sturm, R.A., Scholz, G.M., Sweet, M.J. (2013) IRF6: An epithelial 
cell-specific component of TLR signalling. Australasian society of Immunology 43rd Annual 
Scientific Meeting, Wellington, New Zealand. (I was unable to attend this conference since I did not 
receive a visa for travel. This talk was kindly presented by Dr. Katryn Stacey, University of 
Queensland, on my behalf). 
  
Publications included in this thesis 
 
No publications included. 
 
vi 
 
Contributions by others to the thesis  
 
A/Prof. Matthew Sweet made a significant and substantial contribution to the conception and design 
of this project, as well as interpretation of data and critical revision of the thesis. A/Prof. Glen 
Scholz also provided significant input in project design and provided plasmids used in these studies. 
A/Prof. Richard Sturm provided support in technical work related to culturing of human 
keratinocytes and critically revised this thesis. Dr. Anne-Sophie Bergot, Dr. Makrina Totsika, Dr. 
Timothy Barnett, Dr. Nilesh Bokil and A/Prof. Kiarash Khosrotehrani provided cells or tissue 
samples used in these studies, as indicated in materials and methods. Dr. Kolja Schaale and Dr. 
Ronan Kapetanovic also contributed to critical revision of this thesis. Mr. Daniel Hohenhaus and 
Mr. John Griffin provided technical support with microscopy studies and Russell Medical Centre, 
Queensland provided skin samples used in this thesis. 
  
Statement of parts of the thesis submitted to qualify for the award of another degree 
 
None. 
 
vii 
 
Acknowledgements 
I have been privileged to work with a number of people during my PhD, who have supported and 
inspired me during this challenging duration of my study. I would first like to give my appreciation 
and thanks to my PhD advisor, A/Prof. Matt Sweet for his invaluable support, encouragement and 
guidance throughout my PhD, without which I would never have made it to the end. I would also 
like to thank my co-supervisors A/Prof. Glen Scholz and A/Prof. Rick Sturm for their help and 
guidance in my project. I would also like to extend my sincere thanks to my thesis committee 
members, Dr. Kate Schroder, A/Prof. Stuart Kellie and Prof. Mark Walker, for their comments and 
criticism that were very useful for improving my project. I would also like to thank UQ and IMB 
for providing me this wonderful opportunity to pursue my PhD here. 
My experience working in the Sweet group has been both comfortable and stimulating, for which I 
would like to thank all the members of Group Sweet, past and present. Thanks Dan, Greg, Juliana, 
Kolja, Katja, Mel, Nabilah, Nilesh, Ronan, Selene, Sian and Tam; you have been a fantastic group 
to work with and made it such an enjoyable and memorable experience to work in the lab. I would 
also like to thank the people who shared the PhD “Fishbowl” office with me for your cheerful chats 
and being such great friends. Also thanks to all the members of Groups Schroder and Stacey for the 
useful discussions and comments during lab meetings. Thank you to all the fellow scientists on 
Level 5, IMB for just being around and the many conversations that made working late at night or 
on weekends more bearable. Many thanks to everyone who provided technical support and/or 
reagents that were essential for this work. Thanks to all the support staff, in particular Dr. Amanda 
Carozzi and Mrs. Anne Tobin, and the scientists in the IMB for being such a pleasure to work with. 
A special thanks to Dr. Terry Russell and his staff at Russell Medical Centre for their support 
throughout my PhD. 
I would also like to give my appreciation to Dr. David Pennisi, Dr. Richa Dave and Dr. Steve 
Broomfield for their cordial support and guidance, before and during my PhD, and sharing their 
valuable experience in science with me. It has really helped me understand my potential and 
develop myself into a better scientist.  
Many thanks to all my friends, (too many to list here, but you know who you are!) for your 
friendship and much needed distractions from work. It has been an incredible journey, and I am 
glad that you were with me making this an amazing and fun experience!   
Lastly, I thank almighty, my parents, my brother and sister-in-law, and my extended family for their 
constant encouragement, for believing in me and not letting me quit when times were tough! 
viii 
 
Thanks for being so understanding and lifting my spirits when things were just not right. It would 
have been impossible to pursue this without your patience and support. I would also like to thank 
my family in Brisbane, my late cousin Uma, her husband and two girls Manasa and Sharada for 
their support. Thanks for being so tolerant when I failed to visit/call due to busy work schedule. 
Finally, I would like to thank my Grandfather, who has always been there cheering me up, and 
stood by me through the good times and bad. For him, this is a dream come true. 
 
  
ix 
 
Keywords 
 
interferon regulatory factor, toll-like receptor, inflammation, epithelial cell, keratinocytes, barrier 
defence   
 
Australian and New Zealand Standard Research Classifications (ANZSRC) 
 
ANZSRC code: 060111, Signal Transduction, 50% 
ANZSRC code: 110707, Innate Immunity, 30% 
ANZSRC code: 110304, Dermatology, 20% 
 
Fields of Research (FoR) Classification 
 
FoR code: 1107, Immunology, 80% 
FoR code: 0601, Biochemistry and Cell Biology, 20% 
 
  
x 
 
Table of Contents 
 
ABSTRACT ........................................................................................................................................ ii 
LIST OF FIGURES ......................................................................................................................... xv 
LIST OF TABLES .......................................................................................................................... xvi 
LIST OF ABBREVIATIONS ...................................................................................................... xviii 
1 INTRODUCTION ...................................................................................................................... 1 
1.1 BARRIER DEFENCE .................................................................................................................... 2 
1.2 PATHOGEN EVASION OF BARRIER DEFENCE .............................................................................. 3 
1.3 PATTERN RECOGNITION RECEPTORS ......................................................................................... 4 
1.3.1 Toll-like Receptors (TLRs) ............................................................................................... 5 
1.3.2 Nod-like receptors (NLRs) ............................................................................................... 9 
1.3.3 RIG-I-like receptors (RLRs) ............................................................................................. 9 
1.3.4 C-type lectin receptors (CLRs) ...................................................................................... 10 
1.3.5 The PYHIN family .......................................................................................................... 10 
1.4 INTERFERON REGULATORY FACTORS (IRFS) .......................................................................... 11 
1.4.1 IRFs in TLR Signalling .................................................................................................. 14 
1.4.2 Major Target of IRFs ..................................................................................................... 16 
1.5 INTERFERON REGULATORY FACTOR 6 .................................................................................... 19 
1.5.1 Developmental functions of IRF6 .................................................................................. 20 
1.5.2 IRF6 Regulation ............................................................................................................. 22 
1.6 TLRS IN EPITHELIAL CELLS .................................................................................................... 23 
1.6.1 TLR localization in epithelial cells ................................................................................ 28 
1.6.2 TLR responsiveness of keratinocytes ............................................................................. 28 
1.7 PROJECT AIMS AND HYPOTHESIS ............................................................................................ 31 
1.7.1 Hypothesis ...................................................................................................................... 32 
1.7.2 Research Aims ................................................................................................................ 32 
2 MATERIALS AND METHODS ............................................................................................ 33 
2.1 MATERIALS ............................................................................................................................. 34 
2.1.1 General Reagents ........................................................................................................... 34 
2.1.2 Primers ........................................................................................................................... 34 
2.1.3 Plasmids ......................................................................................................................... 35 
xi 
 
2.1.4 Antibodies....................................................................................................................... 35 
2.1.5 TLR agonists .................................................................................................................. 36 
2.1.6 siRNAs ............................................................................................................................ 37 
2.2 METHODS ................................................................................................................................ 37 
2.2.1 Cell lines and culture conditions ................................................................................... 37 
2.2.2 Primary Cells ................................................................................................................. 40 
2.2.3 Storage of cells ............................................................................................................... 41 
2.2.4 Sub-culturing techniques................................................................................................ 41 
2.2.5 PAMP stimulation .......................................................................................................... 41 
2.2.6 RNA extraction and reverse transcriptase PCR ............................................................ 42 
2.2.7 Real-time PCR (qPCR) .................................................................................................. 42 
2.2.8 Western blotting ............................................................................................................. 42 
2.2.9 Gene silencing ................................................................................................................ 43 
2.2.10 Enzyme-linked Immunosorbent Assays (ELISA) ........................................................ 43 
2.2.11 PCR Cloning .............................................................................................................. 44 
2.2.12 Plasmid purification ................................................................................................... 45 
2.2.13 Transient transfection analysis and reporter gene assays ......................................... 45 
2.2.14 Nuclear and Cytoplasmic fractionation ..................................................................... 46 
2.2.15 Immunofluoresence microscopy ................................................................................. 46 
2.2.16 Flow Cytometry .......................................................................................................... 47 
2.2.17 Immunohistochemistry (IHC) ..................................................................................... 47 
2.2.18 Pathogen infection assays .......................................................................................... 47 
2.2.19 Data presentation and statistical analyses ................................................................ 48 
3 IRF6 EXPRESSION AND TLR RESPONSES IN EPITHELIAL CELL 
POPULATIONS. .............................................................................................................................. 49 
3.1 INTRODUCTION ....................................................................................................................... 50 
3.2 RESULTS ................................................................................................................................. 51 
3.2.1 Human keratinocytes express high levels of IRF6 mRNA and protein .......................... 51 
3.2.2 The TLR3 agonist poly(IC) triggers IL-8 production from human keratinocytes.......... 53 
3.2.3 Poly(IC) upregulates the expression of a sub-set of TLR target genes in primary  
human keratinocytes .................................................................................................................. 54 
3.2.4 HaCaT cells behave similarly to primary keratinocytes in responsiveness to different 
TLR agonists .............................................................................................................................. 56 
xii 
 
3.2.5 Poly(IC)-inducible IL-23p19 mRNA expression does not occur in IRF6-deficient T24 
cells 56 
3.2.6 Confirmation of activity of TLR agonists on RAW-ELAM cells ..................................... 59 
3.2.7 IRF6 expression during keratinocyte differentiation ..................................................... 60 
3.2.8 Differentiation status of primary human keratinocytes does not affect TLR mRNA 
expression................................................................................................................................... 61 
3.2.9 Differentiation status of primary human keratinocytes does not greatly influence 
poly(IC)-responsiveness ............................................................................................................. 63 
3.3 SUMMARY AND DISCUSSION OF CHAPTER 3 ............................................................................ 63 
3.3.1 IRF6 expression is enriched in keratinocytes ................................................................ 63 
3.3.2 Human keratinocytes are responsive to the TLR3 agonist poly(IC) .............................. 64 
3.3.3 The differentiation status of keratinocytes does not affect TLR3 responsiveness .......... 67 
4 IRF6 INVOLVEMENT IN POLY(IC)-REGULATED GENE EXPRESSION IN 
KERATINOCYTES......................................................................................................................... 69 
4.1 INTRODUCTION ....................................................................................................................... 70 
4.2 RESULTS ................................................................................................................................. 71 
4.2.1 IRF6 activates the IFN-β promoter ................................................................................ 71 
4.2.2 IRF6 expression enhances poly(IC)-mediated IFN-β promoter activity ....................... 71 
4.2.3 IRF6 knockdown selectively impairs TLR3-induced IL-23p19 expression in primary 
keratinocytes .............................................................................................................................. 74 
4.2.4 IRF6 over-expression in T24 cells enhances poly(IC)-inducible IL-23p19 expression . 76 
4.2.5 IRF6 enhances IL-23p19 promoter activity upon poly(IC) stimulation ........................ 77 
4.2.6 Poly(IC) stimulation may promote IRF6 nuclear translocation .................................... 79 
4.2.7 Attempts to detect IL-23p19 protein in poly(IC)-stimulated keratinocyte supernatants 
and cell lysates ........................................................................................................................... 81 
4.2.8 IFN-γ priming enhances keratinocyte responses to poly(IC)......................................... 82 
4.2.9 Differentiation status of keratinocytes partially affects TLR3 responses after IFN-γ 
priming ....................................................................................................................................... 83 
4.3 SUMMARY AND DISCUSSION OF CHAPTER 4 ............................................................................ 85 
4.3.1 IRF6 involvement in regulation of IFN-β expression .................................................... 85 
4.3.2 Regulation of poly(IC)-inducible IL-23p19 expression by IRF6 ................................... 86 
4.3.3 Effects of IFN-γ-priming on poly(IC) responses in keratinocytes.................................. 89 
5 INVESTIGATION OF THE ROLE OF IRF6 IN MYD88-DEPENDENT TLR 
SIGNALLING IN KERATINOCYTES......................................................................................... 91 
xiii 
 
5.1 INTRODUCTION ....................................................................................................................... 92 
5.2 RESULTS ................................................................................................................................. 93 
5.2.1 Primary keratinocytes are responsive to the TLR7 agonist Imiquimod ......................... 93 
5.2.2 IRF6 knockdown impairs TLR7-mediated IFN-β and CCL5 gene induction in primary 
keratinocytes .............................................................................................................................. 94 
5.2.3 Keratinocyte differentiation enhances imiquimod inducible CCL5 expression............. 95 
5.2.4 IFN-γ priming does not affect imiquimod-inducible gene expression ........................... 96 
5.2.5 Differentiation status of keratinocytes has little effect on IFN-γ priming of TLR7 
responses .................................................................................................................................... 97 
5.2.6 Primary keratinocytes respond to the TLR2/6 agonist FSL-1 ....................................... 98 
5.2.7 Effect of IRF6 knockdown on TLR2/6 responses in primary keratinocytes ................... 99 
5.2.8 Investigation of FSL-1-mediated IRF6 nuclear expression in primary keratinocytes . 100 
5.3 SUMMARY AND DISCUSSION OF CHAPTER 5 .......................................................................... 102 
5.3.1 Involvement of IRF6 in TLR7 responses in keratinocytes ............................................ 102 
5.3.2 Involvement of IRF6 in TLR2/6 responses in keratinocytes ........................................ 104 
6 FINAL DISCUSSION ............................................................................................................ 108 
6.1 INTRODUCTION ..................................................................................................................... 109 
6.2 ROLES OF IRF6 IN TRIF-DEPENDENT TLR SIGNALLING IN KERATINOCYTES ........................ 109 
6.2.1 The functions of TLR3 in keratinocytes........................................................................ 109 
6.2.2 The role of IRF6 in TLR3 signalling ............................................................................ 110 
6.2.3 Possible role(s) of IL-23p19 in skin homeostasis and pathology ................................ 112 
6.2.4 A proposed model for IRF6 involvement in TLR3 signalling ...................................... 114 
6.3 THE ROLES OF IRF6 IN MYD88-DEPENDENT TLR SIGNALLING IN KERATINOCYTES ............. 114 
6.3.1 Why are most of the MyD88-dependent TLRs inactive in keratinocytes? ................... 114 
6.3.2 The role of IRF6 in MyD88-dependent TLR signalling ............................................... 117 
6.3.3 The roles of TLR7 in skin pathology ............................................................................ 119 
6.3.4 The role of IRF6 in TLR7 signalling ............................................................................ 119 
6.3.5 Role of TLR2/6 signalling in keratinocytes .................................................................. 120 
6.3.6 Role of IRF6 in anti-bacterial responses of keratinocytes ........................................... 121 
6.3.7 A proposed model for the role of IRF6 in MyD88-dependent TLR signalling ............ 122 
6.4 COMPARISON OF TRIF- AND MYD88-DEPENDENT TLR RESPONSES IN KERATINOCYTES ...... 123 
6.4.1 IRF6 expression in proliferating versus differentiated keratinocytes .......................... 123 
6.4.2 Interplay between IFN-γ priming and differentiation status on TLR responses .......... 124 
6.5 FUTURE DIRECTIONS ............................................................................................................. 126 
xiv 
 
6.5.1 Limitations of this thesis and future experiments......................................................... 126 
6.5.2 Conclusion ................................................................................................................... 128 
7 REFERENCES ....................................................................................................................... 129 
 
  
xv 
 
List of Figures 
List of Figures 
Figure 1.1. MyD88-dependent and -independent TLR4 signalling pathways.  8 
Figure 1.2. Overview of the IRF family.  12 
Figure 1.3. IRFs impart specificity to TLR signalling. 15 
Figure 2.1. A schematic diagram indicating IRF6 siRNA targeting sites.  37 
Figure 2.2. Plasmid map of pIL-23p19-luc. 44 
Figure 3.1. Human keratinocytes express high levels of IRF6.  52 
Figure 3.2. The TLR3 agonist poly(IC) triggers IL-8 production from human 
keratinocytes.  54 
Figure 3.3. Poly(IC) triggers robust gene expression changes in primary keratinocytes.  55 
Figure 3.4. HaCaT cells respond to TLR agonists in a similar way to primary 
keratinocytes.  57 
Figure 3.5. T24 cells respond to poly(IC), but do not induce IL-23p19 mRNA expression 
upon poly(IC) stimulation.  58 
Figure 3.6. Zymosan, Pam3Cys and LPS were active on RAW-ELAM cells.  59 
Figure 3.7. IRF6 expression in primary keratinocytes during differentiation.  61 
Figure 3.8. TLR mRNA expression is not regulated during primary human keratinocyte 
differentiation. 62 
Figure 3.9. Differentiation status does not affect poly(IC)-inducible IL-8 production from 
primary keratinocytes.  63 
Figure 4.1. IRF6 activates the IFN-β promoter in HEK293 cells. 72 
Figure 4.2. IRF6 expression enhances poly(IC)-mediated activation of the IFN-β promoter 
activity.  73 
Figure 4.3. IRF6 knockdown selectively impairs TLR3-inducible IL-23p19 mRNA 
expression in primary keratinocyte.  75 
Figure 4.4. Effects of IRF6 knock-down on inducible gene expression in human 
keratinocytes are apparent with independent siRNAs.  76 
Figure 4.5. IRF6 over-expression in T24 cells confers poly(IC)-inducible IL-23p19 mRNA 
expression.  77 
Figure 4.6. IRF6 enhances poly(IC)-inducible activity of the IL-23p19 promoter in 
 
xvi 
 
RAW264.7 cells.  78 
Figure 4.7. Poly(IC) stimulation may promote IRF6 nuclear translocation.  80 
Figure 4.8. IL-23p19 protein was not detected in poly(IC)-stimulated keratinocyte 
supernatants or cell lysates.  82 
Figure 4.9. IFN-γ priming enhances poly(IC)-regulated inflammatory responses in 
keratinocytes.  83 
Figure 4.10. Differentiation status differentially affects the ability of IFN-γ to prime 
poly(IC) responses in keratinocytes.  84 
Figure 5.1. Primary keratinocytes are responsive to the TLR7 ligand imiquimod. 94 
Figure 5.2. IRF6 knock-down impairs TLR7-mediated IFN-β and CCL5 gene induction in 
primary keratinocytes.  95 
Figure 5.3. Keratinocyte differentiation enhances imiquimod-inducible CCL5 expression.  96 
Figure 5.4. IFN-γ priming does not enhance imiquimod-inducible gene expression. 97 
Figure 5.5. Differentiation of keratinocytes does not permit IFN-γ priming of TLR7 
responses.  98 
Figure 5.6. Primary keratinocytes respond to the TLR2/6 ligand FSL-1.  99 
Figure 5.7. Effect of IRF6 knock-down on FSL-1 responses in primary keratinocytes. 100 
Figure 5.8. FSL-1 increases IRF6 protein expression in primary human keratinocytes. 101 
Figure 5.9. Phosphorylation sites in IRF6.  103 
Figure 6.1. IRF6 IHC in wounded skin of mice.  112 
Figure 6.2. A proposed model for IRF6 involvement in TLR3 signalling.  115 
Figure 6.3. IRF6 does not affect intracellular survival of GAS within primary 
keratinocytes.  122 
Figure 6.4. A proposed model for IRF6 involvement in MyD88-dependent TLR signalling.  123 
Figure 6.5. A proposed model for IRF6 involvement TLR signalling upon keratinocyte 
differentiation.  125 
  
List of Tables 
  
xvii 
 
List of Tables 
Table 1.1. TLR Recognition of Microbial Components. 6 
Table 1.2. The expression of various human (h) and mouse (m) TLRs in epithelial 
cells from different anatomical locations.  
25-27 
Table 1.3. TLR responses in keratinocytes.  29-31 
Table 2.1. List of Primers used for qPCR. 34-35 
Table 2.2. List of Antibodies used in this thesis.  35-36 
 
  
xviii 
 
List of Abbreviations 
List of Abbreviations 
µg microgram 
µl microlitre 
µm micrometre 
µM micromolar 
aa amino acid 
AD atopic dermatitis 
AIM2 absent in melanoma 2 
AMP anti-microbial peptide 
ANOVA analysis of variance 
AP-1 activator protein-1  
ASC apoptosis-associated speck-like protein containing a CARD 
bp base pairs 
Ca2+ calcium 
CARD caspase recruitment domain 
CBP CREB-binding protein 
CCL C-C motif ligand  
CCR C-C motif receptor 
cDC conventional dendritic cells 
cDNA complementary DNA 
CLR C-type Lectin like Receptor 
cm2 centimetre square 
CTLD C-type lectin like domain 
CXCL C-X-C motif ligand 
d day 
DAMP danger associated molecular patterns 
DAPI 4', 6-diamidino-2-phenylindole  
DBD DNA binding domain 
xix 
 
DC  dendritic cells 
DMSO dimethyl sulfoxide  
DNA deoxyribonucleic acid 
ds double stranded 
E. coli  Escherichia coli 
EBI Epstein-Barr virus induced gene 
ELISA enzyme-linked Immunosorbent Assay  
ERK extracellular signal-regulated kinases  
FBS foetal bovine serum 
FSL-1 Pam2CGDPKHPKSF 
g grams 
g gravity 
GAS Group A Streptococcus 
GFP green fluorescent protein 
gp130 glycoprotein-130 
h hour(s) 
HIV human immunodeficiency virus 
HMDM human monocyte derived macrophages 
HPRT hypoxanthine-guanine phosphoribosyltransferase 
HPV human papilloma virus  
HRP horseradish peroxidase 
HSV herpes simplex virus 
IAD IRF-associated domain 
IEC intestinal epithelial cells 
IFI interferon inducible protein 
IFN interferon 
IHC immunohistochemistry 
IKK  IκB Kinase 
IL interleukin 
IRAK IL-1R-associated kinase  
xx 
 
IRF interferon regulatory factor 
ISRE IFN-stimulated response element 
ITAM immunoreceptor tyrosine-based activation motif 
IVL involucrin 
IκB inhibitor of NF-κB  
JAK Janus kinase 
JNK c-Jun N-terminal Kinase 
K or Lys lysine 
K14 keratin 14  
l litre 
LGP2 laboratory of genetics and physiology 2  
LPS lipopolysaccharide 
LRR leucine rich repeat 
LTA lipoteichoic acid 
M molar 
MAL MyD88 adaptor-like 
MAP3K mitogen-activated protein kinase kinase kinase  
MAPK mitogen-activated protein kinase 
Maspin mammary serine protease inhibitor 
MCS9.7 multi-species conserved enhancer sequence 9.7  
MDA-5 melanoma differentiation-associated gene 5 
MEE medial edge epithelial 
mg milligram 
min minute(s) 
ml millilitre 
mM millimolar 
MOI multiplicity of infection 
mRNA messenger RNA 
MyD88 myeloid differentiation primary response gene 88 
NES nuclear export signal 
xxi 
 
NF-κB nuclear factor kappa B 
ng nanogram 
NK natural killer cell 
NLR nod-like receptor 
nm nanometre 
nM nanomolar 
NSCLP non-syndromic cleft lip/palate  
Pam3Cys tripalmitoyl-S-glycerylcysteine 
PAMP pathogen-associated molecular pattern 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
pDC plasmacytoid dendritic cells 
PGN peptidoglycan 
pM picomolar 
PMA phorbol 12-myristate 13-acetate  
Poly(IC) polyinosinic-polycytidylic acid 
PPS popliteal pterygium syndrome 
PRE positive regulatory element  
PRR pattern recognition receptors 
PYD pyrin domain 
qPCR quantitative real-time PCR 
R receptor 
RANTES regulated on activation, normal T cell expressed and secreted  
RIG-I retinoic acid-inducible gene – I  
RIP receptor-interacting protein 
RLR RIG-I-like Receptor 
RNA ribonucleic acid 
ROCK rho-associated protein kinase  
S. aureus Staphylococcus aureus 
SCC squamous cell carcinoma 
xxii 
 
Ser or S serine 
Sfn stratifin 
SIGN specific intracellular adhesion molecule-3 grabbing non-integrin  
siRNA small interfering RNA 
ss single stranded 
STAT signal transducer and activator of transcription 
STING stimulator of interferon genes 
TAB TAK-1 associated binding proteins  
TAK1 transforming growth factor-beta activated kinase1 
TBK-1 TANK binding kinase 1  
TGFβ3 transforming growth factor beta3  
Th T helper cell 
THY Todd-Hewitt containing 0.2% yeast extract  
TIR toll interleukin 1 receptor 
TIRAP TIR domain-containing adaptor protein 
TLR toll-like Receptor 
TNF-α tumour necrosis factor alpha 
TPL2 tumour progression locus 2 
TRAF tumour necrosis factor receptor associated factor 
TRAM TRIF-related adaptor molecule 
Treg T regulatory cell 
TRIF TIR domain-containing adaptor-inducing IFN  
TSLP thymic stromal lymphoprotein  
TSS transcription start site 
U units 
UPEC uropathogenic E. coli  
UTI urinary tract infection 
UV ultraviolet 
VWS Van der Woude's syndrome 
WSX-1 cytokine receptor WSX-1 
Introduction 
1 
 
1 Introduction 
 
 
 
 
 
  
Introduction 
2 
 
In mammals, immunity is a multi-layered system that is comprised of barrier defence, innate 
immunity and acquired immunity. Barrier defence provides the first line of protection and acts to 
prevent microbial entry. If this defence is breached, the innate immune system is rapidly activated, 
and acts to contain and/or destroy the invading microorganism. Successful pathogens can overcome 
barrier defence and innate immunity, and in this instance, the acquired immune system is activated 
in a delayed fashion. This is a highly specific response that utilizes both cellular and humoral 
components. Although innate and acquired immunity have been extensively studied in immune 
defence, it is now appreciated that barrier defence plays an active and important role in host 
protection. This project focuses on a specific molecular component of barrier defence (IRF6), and 
the contribution of this component to host responses to pathogen challenge. 
1.1 Barrier defence  
Barrier defence consists of physical, mechanical, chemical and microbiological barriers that prevent 
microorganisms from breaching epithelial tissues. Pathogens can gain access to the body by either 
subverting epithelial cell function or through opportunistic means, for example damaged or 
wounded epithelial tissue, or through vector-mediated entry (Frischknecht 2007, Diamond, Beckloff 
et al. 2009). Physical barriers are provided by epithelial cells themselves, which form tight junctions 
to generate an impenetrable barrier. Mucous membranes also surround the openings of various 
organs such as the lungs, intestines, and the genitourinary tract that are exposed to the external 
environment and microbial challenge (Acheson and Luccioli 2004). These secrete mucus to prevent 
pathogens from coming into physical contact with epithelial cells (Acheson and Luccioli 2004). 
Mechanical defence includes the beating of tiny hairs (cilia), the flushing action of tears and urine, 
and coughing/sneezing, which all directly eject pathogens and other irritants from mucosal surfaces 
(Stannard and O'Callaghan 2006, Diamond, Beckloff et al. 2009, Potempa and Pike 2009).  
Chemical barriers include acidic conditions in the stomach that destroy some pathogens, thus 
preventing them from entering the digestive system, as well as a range of anti-microbial agents 
(such as lysozyme and anti-microbial peptides) present in various body fluids, including sebum, 
phlegm, saliva and tears (Dommett, Zilbauer et al. 2005, Potempa and Pike 2009). Lysozymes are 
hydrolytic enzymes, which are ubiquitously present in animals (Ito, Yoshikawa et al. 1999, Zhao, 
Song et al. 2007, Callewaert and Michiels 2010). They act broadly against a variety of 
microorganisms by cleaving the β-1,4 linked glycosidic bond of peptidoglycan (PGN), which is 
enriched in the cell walls of Gram-positive bacteria (Ito, Yoshikawa et al. 1999, Zhao, Song et al. 
2007).  
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Defensins and cathelicidins are the two main anti-microbial peptide (AMP) families. Defensins are 
cationic peptides characterized by six conserved cysteine residues that form disulfide bridges. They 
are classified into α-defensins, β-defensins and θ-defensins based on the alignment of their disulfide 
bridges, sites of expression and biological activities (Raj and Dentino 2002, Guani-Guerra, Santos-
Mendoza et al. 2010, Tecle, Tripathi et al. 2010). In humans, α-defensins are primarily expressed by 
neutrophils, with disulfide bridging between cysteines 1-6, 2-4 and 3-5 (White, Wimley et al. 1995). 
α-defensins consists of six members. These are the four human neutrophil peptides 1-4, and the two 
epithelial α-defensins 5 and 6, which are expressed in the mucosal layer of the small intestine 
(Quayle, Porter et al. 1998, Ouellette 2004, Tecle, Tripathi et al. 2010). β-defensins are produced by 
epithelial cells of the respiratory, gastrointestinal and genitourinary tracts, as well as by 
keratinocytes in the skin (White, Wimley et al. 1995, Raj and Dentino 2002, Schutte and McCray 
2002, Ganz 2003, Tecle, Tripathi et al. 2010). They contain disulfide bridges between cysteines 1-5, 
2-4 and 3-6 (Guani-Guerra, Santos-Mendoza et al. 2010). Defensins are produced in response to 
pathogen challenge, and have direct anti-microbial effects. They can also have a range of other 
important biological activities, including acting as chemoattractants and stimulators of pro-
inflammatory cytokine production (Guani-Guerra, Santos-Mendoza et al. 2010, Tecle, Tripathi et al. 
2010). Human neutrophil peptides-1-4 (α-defensins) demonstrate antiviral activity in vitro against 
adenovirus, human papilloma virus (HPV) and human immunodeficiency virus-1 (HIV-1) infection 
(Klotman and Chang 2006). β-defensins prevent viral infections through multiple mechanisms such 
as disrupting the viral envelope, inhibiting viral entry to the cell by binding to viral glycoproteins 
and receptors and interfering with the cell-signalling pathways of viral replication (Klotman and 
Chang 2006). β-defensins synergize with other AMPs to act against Gram-negative and Gram-
positive bacteria (Harder, Meyer-Hoffert et al. 2000, Klotman and Chang 2006). Cathelicidins 
contain a highly conserved N-terminal cathelin domain (Zanetti, Gennaro et al. 1995). The human 
cathelicidin gene codes for an inactive precursor protein, human cationic antimicrobial peptide-18, 
which is processed to the active LL-37 peptide in response to appropriate signals (Cowland, 
Johnsen et al. 1995, Frohm, Agerberth et al. 1997). Human cationic antimicrobial peptide-18 is 
produced by several cell types including myeloid cells and epithelial cells of the urinary and 
respiratory tracts and keratinocytes (Cowland, Johnsen et al. 1995, Frohm, Agerberth et al. 1997). 
Cathelicidins exhibit potent antimicrobial effects against Streptococcus pyogenes or Group A 
Streptococcus (GAS) infections in the skin (Dorschner, Pestonjamasp et al. 2001).   
1.2 Pathogen evasion of Barrier defence 
Although some pathogens enter the body through opportunistic means, many others use specific 
virulence mechanisms to breach the epithelium. Several pathogens are able to adhere to, and invade 
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epithelial cells. For example, Uropathogenic Escherichia coli (E. coli) (UPEC), a specific subset of 
extraintestinal pathogenic E. coli causing urinary tract infections (UTI), use fimbrae to bind to 
epithelial cells of the urinary tract (Mulvey, Schilling et al. 2001, Mulvey 2002, Nielubowicz and 
Mobley 2010). They also produce toxins such as cytotoxic necrotizing factor 1, which kills host 
epithelial cells and thus help to breach barrier defence (Amieva, Salama et al. 2002, Chu, Wang et 
al. 2010, Nielubowicz and Mobley 2010). Turn-over or exfoliation is a physiological process of 
intestinal epithelial cells that allows cells to regenerate and eliminate surface bacteria (Frost, Bland 
et al. 1997). However, opportunistic enteric bacteria such as Shigella and Clostridia use this to gain 
entry into the cells via the inter-cellular spaces (Takeuchi 1982, Riegler, Sedivy et al. 1995). 
Salmonella typhimurium utilizes a type III secretion system to inject virulent effector proteins into 
epithelial cells to promote bacterial uptake by macropinocytosis and to paralyze intestinal 
epithelium-mediated inflammatory responses, thereby gaining access to the body (Hansen-Wester 
and Hensel 2001, Zhou and Galan 2001). Gram-positive bacteria such as GAS also utilize numerous 
mechanisms to breach the epithelial barrier. These include M protein, fibronectin-binding proteins, 
hyaluronic acid capsule, extracellular enzymes and toxins, which allow the bacteria to colonize and 
invade cells (LaPenta, Rubens et al. 1994, Molinari and Chhatwal 1999, Cue, Southern et al. 2000). 
These are some of the many mechanisms utilized by bacterial pathogens to successfully gain entry 
into the host. 
Although epithelial cells are sometimes regarded as non-specific components of host defence, it is 
now clear that they contribute more actively. For example, they are able to initiate inflammatory 
responses by virtue of the expression of a range of microbial-sensing pattern recognition receptors 
(Hornef, Normark et al. 2003, Hornef and Bogdan 2005). These sense specific microbial products, 
thus enabling epithelial cells to recognize particular classes of pathogens, and to trigger the most 
appropriate inflammatory response for containment and resolution of the infection.  
1.3 Pattern Recognition Receptors 
Pattern recognition receptors (PRRs) recognize and respond to specific molecular structures on 
microorganisms. Such structures, commonly referred to as pathogen-associated molecular patterns 
(PAMPs), are often essential for survival and/or pathogenicity, and are thus conserved across many 
microbial species (Akira, Uematsu et al. 2006). PRRs can be located at the cell-surface or 
intracellularly, and are predominantly expressed by innate immune cells such as macrophages and 
dendritic cells (DC) (Akira, Uematsu et al. 2006). There are several distinct families of PRRs 
including the Toll-like receptors (TLRs), Nod-like receptors (NLRs), RIG-I-like receptors (RLRs), 
C-type lectin receptors (CLRs) and the PYHIN family (Akira, Uematsu et al. 2006). TLRs are the 
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most comprehensively studied PRRs and are a major focus of this project. TLRs will be discussed 
in detail in this review, while brief overviews will be provided for the other PRR families.  
1.3.1 Toll-like Receptors (TLRs) 
The Toll receptor was first identified in Drosophila as a transmembrane protein that was essential 
for normal dorso-ventral patterning in developing embryos (Anderson, Jurgens et al. 1985). Further 
studies showed that this receptor was also involved in Drosophila host defence through recognition 
of fungal infection and subsequent production of the anti-fungal peptide drosomycin (Lemaitre, 
Nicolas et al. 1996). In 1997, Medzhitov et. al used an expressed sequence tag database to discover 
the hToll protein (now termed TLR4) on the basis of its homology to Drosophila Toll (Medzhitov, 
Preston-Hurlburt et al. 1997). Subsequently, mouse genetic studies showed that a mutation in the 
Tlr4 gene was responsible for the hyporesponsiveness of the C3H/HeJ mouse strain to 
lipopolysaccharide (LPS), a component of the cell wall of Gram-negative bacteria (Poltorak, He et 
al. 1998, Hoshino, Takeuchi et al. 1999). Genetic deletion of Tlr4 subsequently confirmed that this 
receptor was indeed required for LPS responsiveness (Hoshino, Takeuchi et al. 1999). 
Subsequently, a family of these receptors were identified (Rock, Hardiman et al. 1998). TLRs are 
type I transmembrane receptors containing an extracellular leucine-rich repeat (LRR) domain, as 
well as a cytoplasmic domain, which is homologous to the interleukin 1 receptor (IL-1R) 
(Hashimoto, Hudson et al. 1988, Keith and Gay 1990, Gay and Keith 1991). This intracellular 
domain is referred to as the Toll interleukin 1 receptor (TIR) domain. In Drosophila, Toll signalling 
promotes immune responses by activating the transcription factor Dorsal, a homologue of the 
mammalian Rel/NF-κB family (Lemaitre, Nicolas et al. 1996). In mammals, signalling through 
TLRs activates nuclear factor kappaB (NF-κB), which is normally maintained in an inactive form in 
the cytoplasm through interaction with inhibitor of NF-κB (IκB) (Ganchi, Sun et al. 1992, Henkel, 
Zabel et al. 1992, Henkel, Machleidt et al. 1993).  
A total of 13 TLRs have been identified in humans and mice; 10 in humans (TLR1-10) and 12 in 
mice (TLR1-9, 11-13) (Beutler 2004). Each TLR recognizes specific PAMPs (Table 1.1) and 
activates distinct but overlapping signalling pathways through the use of specific combinations of 
adaptor proteins that initiate signalling. This enables the host to respond to distinct classes of 
pathogens to elicit the most appropriate type of immune response to deal with that pathogen class. 
TLR1 can heterodimerize with TLR2 to identify triacyl lipopeptides of bacteria, including 
mycobacteria (Takeuchi, Sato et al. 2002). TLR2 has also been shown to associate with TLR6 to 
detect diacyl lipopeptides of mycoplasma (Takeuchi, Kawai et al. 2001). TLR3 recognizes double-
stranded (ds) RNA from viruses (Alexopoulou, Holt et al. 2001). TLR4 recognizes LPS from Gram-
negative bacteria (above), while TLR5 recognizes flagellin from flagellated bacteria (Hayashi, 
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Smith et al. 2001). TLR7 and TLR8 recognize single-stranded (ss) viral RNA (Heil, Hemmi et al. 
2004, Lund, Alexopoulou et al. 2004) and TLR9 recognizes non-methylated CpG DNA from 
bacteria and DNA viruses (Hemmi, Takeuchi et al. 2000, Bauer, Kirschning et al. 2001, Takeshita, 
Leifer et al. 2001). A role for human TLR10 has not been identified yet, but studies have shown that 
TLR10 is closely related to TLR1 and TLR6 and can recognize bacterial lipopeptides in association 
with TLR2 (Hasan, Chaffois et al. 2005, Guan, Ranoa et al. 2010, Regan, Nally et al. 2013). In 
mice, TLR11 and TLR12 recognize the profilin molecule and uropathogenic bacteria (Zhang, 
Zhang et al. 2004, Lauw, Caffrey et al. 2005, Yarovinsky, Zhang et al. 2005, Koblansky, Jankovic 
et al. 2013, Raetz, Kibardin et al. 2013). TLR13 was recently shown to recognize bacterial RNA 
(Hidmark, von Saint Paul et al. 2012, Oldenburg, Kruger et al. 2012).   
TLR Typical Ligands Species 
TLR1/2 Triacyl lipopeptides Bacteria, including mycobacteria 
TLR2 Lipopeptides Gram-positive bacteria, Mycoplasma 
TLR3 dsRNA Viruses 
TLR4 Lipopolysaccharide (LPS) Gram-negative bacteria 
TLR5 Flagellin Flagellated bacteria 
TLR2/6 Diacyl lipopeptides Mycoplasma 
TLR7 ssRNA, Imidazoquinolines RNA viruses 
TLR8 ssRNA RNA viruses 
TLR9 CpG-DNA Bacteria, including mycobacteria and DNA viruses 
TLR2/10 Lipopeptides Bacteria 
TLR11 Profilin Toxoplasma gondii and uropathogenic bacteria 
TLR12 Profilin  Toxoplasma gondii  
TLR13 Bacterial RNA Bacterial ribosomal RNA 
 
Table 1.1. TLR Recognition of Microbial Components. Specific components of microorganisms 
recognized by different TLRs are indicated. This table is adapted from (Akira 2006). 
1.3.1.1 TLR Localization 
TLRs are localized in different compartments of the cell, depending on their function in detecting 
extracellular versus intracellular pathogens. In phagocytic cells, TLRs that recognize the external 
structure of pathogens (TLRs 1, 2, 4, 5 and 6) are usually located at the cell surface, whereas TLRs 
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that recognize nucleic acids (TLRs 3, 7, 8 and 9) are found intracellularly within endosomal 
compartments (Kawai and Akira 2007). Intracellular localization of these TLRs enables them to 
identify microbial nucleic acids after phagocytosis and pathogen destruction (Barton, Kagan et al. 
2006). Recently, TLR4 has also been shown to be localized in endosomes (Kagan, Su et al. 2008). 
1.3.1.2 TLR Signalling 
TLR signalling is initiated upon the binding of the TLR to its specific ligand (as mentioned in 
Table 1.1). Activated TLRs recruit adaptor proteins, which bind to the TIR domain of the TLRs. 
These adaptor proteins include myeloid differentiation primary response gene 88 (MyD88), 
MyD88-adaptor-like (MAL), TIR domain-containing adaptor-inducing IFN (TRIF) and TRIF-
related adaptor molecule (TRAM) (Medzhitov, Preston-Hurlburt et al. 1998, Fitzgerald, Palsson-
McDermott et al. 2001, Yamamoto, Sato et al. 2002, Fitzgerald, Rowe et al. 2003). These TIR 
domain-containing adaptor proteins, separately or in combination, provide specificity to TLR 
signalling. Based on the adaptor molecule used, TLR signalling can be classified as MyD88-
dependent or TRIF-dependent. TRIF-dependent signalling is discussed in detail in Chapter 4, 
whilst MyD88-dependent signalling is extensively described in Chapter 5. In brief, in response to 
PAMP recognition, all TLRs, except for TLR3, recruit the adaptor protein MyD88, in presence or 
absence of MAL (Figure 1.1) (Takeda and Akira 2004). This recruitment initiates downstream 
signalling via IL-1R-associated kinases (IRAKs) (IRAK4 and IRAK1) and tumour necrosis factor 
associated factor-6 (TRAF6) and subsequently the activation of a mitogen-activated protein kinase 
(MAPK) kinase kinase (MAP3K) called transforming growth factor-beta activated kinase1 (TAK1) 
(Takeda and Akira 2004). TAK1, in turn, activates MAPKs such as extracellular signal-regulated 
kinases (ERK), p38 and c-Jun N-terminal kinases (JNK) (Takeda and Akira 2004). In addition, 
TRAF6 activates inhibitor of kappaB kinase complex (IKK), which comprises of subunits α and β 
(IKKα and IKKβ), as well as NF-κB essential modulator (NEMO)/IKKγ. This leads to the 
phosphorylation and degradation of IκB-α, thus permitting the release and nuclear translocation of 
the transcription factor NF-κB (Takeda and Akira 2004). NF-κB, activator protein-1 (AP-1) and 
other transcription factors then drive inducible expression of target pro-inflammatory genes (Takeda 
and Akira 2004). Whilst TLR 1, 2, 4, 5, 6, 7, 8 and 9 all engage the MyD88 pathway, TLR3 and 
TLR4 utilize the TRIF-dependent pathway (Figure 1.1) (Takeda and Akira 2004). Upon LPS 
recognition, TLR4 initially signals via the MyD88-dependent pathway, however, it is subsequently 
endocytosed and switches to TRIF signalling in early endosomes (Kagan, Su et al. 2008). TRIF 
signalling activates the serine/threonine kinase TANK binding kinase 1 (TBK-1), which 
phosphorylates the transcription factor interferon regulating factor 3 (IRF3) (Takeda and Akira 
2004). IRF3 phosphorylation leads to its nuclear translocation and subsequent activation of type-1 
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interferons (IFN) (Takeda and Akira 2004). IRFs are important transcription factors that are linked 
to both MyD88- and TRIF- dependent TLR signalling. Their roles in TLR signalling are further 
discussed in Section 1.4.  
 
Figure 1.1. MyD88-dependent and -independent TLR4 signalling pathways. Upon stimulation 
with their appropriate ligands, TLR signalling is activated. TLR4 utilizes both MyD88-dependent 
and independent pathways to activate signalling. MyD88-dependent signalling uses MyD88 as an 
adaptor to initiate downstream signalling via IRAK4, IRAK1 and TRAF6. TRAF-6 activates 
TAK1, which in turn activates the p38 and JNK MAPK arms. In addition, TRAF6 activates NF-κB 
by mediating degradation of IκB-α. NF-κB, AP-1 and other transcription factors then drive 
inducible expression of pro-inflammatory target genes. TLR4 also utilizes TRIF and TRAM to 
activate IKK-ε and TBK-1, which in turn activate IRF3. IRF3 is then translocated into the nucleus 
to activate IFN-β transcription. This diagram was modelled on the figure within (Watts 2008). 
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1.3.2 Nod-like receptors (NLRs) 
NLRs are cytosolic pathogen sensors. There are 22 NLRs identified in humans and 34 in mice 
(Ting, Lovering et al. 2008). All NLRs contain a central nucleotide binding or NACHT domain 
which mediates self-oligomerization and activates the NLR signalling pathway (Baccala, Gonzalez-
Quintial et al. 2009). They also contain a C-terminal LRR domain that controls activation and N-
terminal effector domains, such as the caspase recruitment domain (CARD) and pyrin domain, 
which mediates protein-protein interactions to initiate inflammatory responses (Baccala, Gonzalez-
Quintial et al. 2009). Based on their N-terminal effector domain, NLRs are classified into five 
groups, NLRA (containing an acidic transactivation domain), NLRB (containing baculoviral 
inhibitory repeat-like domain), NLRC (containing CARD domain), NLRP (containing pyrin 
domain) and NLRX (containing an unknown domain) (Ting, Lovering et al. 2008). NOD1 and 
NOD2 are well-characterized receptors of the NLRC family. Upon activation, both NOD1 and 
NOD2 recruit an adaptor protein receptor interacting protein (RIP) 2 (Chamaillard, Hashimoto et al. 
2003, Park, Kim et al. 2007). RIP2 in turn activates the IKK complex which causes phosphorylation 
and degradation of IκB and activation of the NF-κB pathway (Abbott, Wilkins et al. 2004, Park, 
Kim et al. 2007). Some NLRP and NLRC family members also form a caspase-1 activating 
inflammasome complex (Poyet, Srinivasula et al. 2001, Martinon, Burns et al. 2002, Tschopp, 
Martinon et al. 2003, Agostini, Martinon et al. 2004, Boyden and Dietrich 2006). Caspase-1 
signalling leads to the maturation of IL-1β and other inflammatory cytokines, and proinflammatory 
cell death or pyroptosis (Suzuki, Franchi et al. 2007). NLR-mediated inflammasome activation 
involves the adaptor molecule called apoptosis-associated speck-like protein containing a CARD 
(ASC) and CARD8 (Suzuki, Franchi et al. 2007, Taniguchi and Sagara 2007). NLR interaction with 
ASC and caspase-1 leads to autoactivation of caspase-1, and the processing of IL-1β, IL-18 and 
other proinflammatory mediators (Johnston, Rahman et al. 2007). 
1.3.3 RIG-I-like receptors (RLRs) 
RLRs are also cytosolic and recognize of microbial or self nucleic acids within the cytoplasm. They 
are RNA helicases that contain a central DExD/H box helicase domain, C-terminal regulatory 
domain and two N-terminal CARD domains (Yoneyama, Kikuchi et al. 2005). The RLR family 
includes three members – Retinoic acid-inducible gene – I (RIG-I), melanoma differentiation-
associated gene 5 (MDA5) and laboratory of genetics and physiology 2 (LGP2) (Parisien, Bamming 
et al. 2009). LGP2 lacks the N-terminal CARD domain and was initially thought to negatively 
regulate RIG-I signalling by binding to its regulatory domain (Parisien, Bamming et al. 2009). 
However, in vivo studies on Lgp-/- mice showed that LGP2 positively mediates RLR responses 
(Satoh, Kato et al. 2010). Following viral infection, RLR signalling is activated. The adaptor for the 
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RLR signalling pathway is IFN-β promoter stimulator 1, which possesses an N-terminal CARD 
domain (Kawai, Takahashi et al. 2005). The binding of IFN-β promoter stimulator 1 leads to the 
activation of IKK-i and TBK-1, which phosphorylates the transcription factors IRF3 and IRF7 
(Kawai, Takahashi et al. 2005). The IRFs induce transcription of type1 IFNs and IFN-inducible 
genes. Inducible expression of type I IFNs and IFN-inducible genes downstream of RLRs enables 
an effective anti-viral response.     
1.3.4 C-type lectin receptors (CLRs)  
CLRs consist of a calcium (Ca2+)-dependent carbohydrate recognition domain, the C-type lectin-
like domain (CTLD), which mediates pathogen recognition (Zelensky and Gready 2005, 
Geijtenbeek and Gringhuis 2009). CLRs recognize and bind to carbohydrates, for example β-
glucans from fungi (Zelensky and Gready 2004). Carbohydrate recognition enhances phagocytosis 
and also promotes inflammatory signalling. CLRs are classified into 17 groups based on their 
molecular structures and phylogeny (Geijtenbeek and Gringhuis 2009). The type I receptors or the 
mannose receptors are transmembrane proteins with an extracellular N-terminal cysteine-rich 
domain, fibronectin type II repeat domain and eight CTLDs and a C-terminal cytoplasmic tail 
(Kerrigan and Brown 2009). The type II receptors are also transmembrane proteins with a single 
extracellular N-terminal CTLD. These receptors include the specific intracellular adhesion 
molecule-3 grabbing non-integrin (SIGN) family members, e.g. DC-SIGN (DC specific) (Kerrigan 
and Brown 2009). The type I and type II receptors recognize mannose residues on the surface of 
pathogens, and this enables phagocytosis and pathogen destruction (Kerrigan and Brown 2009). 
Dectin 1 is a major β-glucan receptor of group V CLRs. It has a single extracellular CTLD and a 
cytoplasmic domain containing an immunoreceptor tyrosine-based activation motif (ITAM) 
(Yokota, Takashima et al. 2001, Brown, Taylor et al. 2002). Dectin 1 can function in the absence of 
Ca2+ (Ariizumi, Shen et al. 2000). Dectin 1 can also recognize the TLR-2 ligand zymosan and can 
cooperate with TLR2 to enhance immune responses (Gantner, Simmons et al. 2003). Upon 
activation, the tyrosine residue of the ITAM domain of Dectin 1 is phosphorylated by Src kinases. 
This leads to the activation of Syk (a tyrosine kinase), which further initiates various cellular 
process such as phagocytosis and generation of reactive oxygen species (Garcia-Garcia and Rosales 
2002, Rogers, Slack et al. 2005, Underhill, Rossnagle et al. 2005, Kerrigan and Brown 2011).   
1.3.5 The PYHIN family 
The PYHIN family contains an N-terminal Pyrin domain and a C-terminal HIN-200 domain 
(Goubau, Rehwinkel et al. 2010). The members of this family have been shown to sense foreign 
double stranded DNA in the cytoplasm and to undergo cell death in response to this signal (Ludlow, 
Johnstone et al. 2005). There are four PYHIN family members identified in humans – interferon-
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inducible protein X (IFIX) or PYHIN1, myeloid cell nuclear differentiation antigen (MNDA), 
absent in melanoma 2 (AIM2) and interferon-inducible protein 16 (IFI16) (Ludlow, Johnstone et al. 
2005, Goubau, Rehwinkel et al. 2010). The latter contains two HIN domains, whilst the other three 
contain a single HIN domain. AIM2 is involved in inflammasome activation. AIM2 recognizes 
cytosolic dsDNA and binds to it through its HIN domain (Hornung, Ablasser et al. 2009). AIM2 
interacts with the ASC adaptor molecule via PYD-PYD interactions (Hornung, Ablasser et al. 
2009). This promotes the assembly of the inflammasome and activation of caspase 1, which triggers 
maturation of the proinflammatory cytokine IL-1β (Hornung, Ablasser et al. 2009). IFI16 was also 
reported to recognize dsDNA and induce IFN-β production via the signalling protein stimulator of 
interferon genes (STING) (Unterholzner, Keating et al. 2010). IFI16 is predominantly present in the 
nucleus, but a small amount of the protein is present in the cytoplasm, which recognizes DNA and 
initiates downstream signalling (Hornung, Ablasser et al. 2009, Unterholzner, Keating et al. 2010). 
Thus, PYHIN family members may be involved in both promoting IFN- production and 
inflammasome activation. 
1.4 Interferon Regulatory Factors (IRFs) 
Several of the PRRs described above (e.g. specific TLRs, RLRs and PYHINs) trigger production of 
type I IFNs, which elicit an anti-viral gene expression program, as well as a potent pro-
inflammatory response. Members of the IRF transcription factor family are required for pathogen-
inducible type I IFN production. There are nine IRF family members (IRF1-9) in mammals (Figure 
1.2), and these primarily regulate transcription of IFNs and IFN-inducible genes (Taniguchi, 
Ogasawara et al. 2001). IRFs possess an amino N-terminal DNA binding domain (DBD), which is 
characterized by a series of five conserved tryptophan residues (Taniguchi, Ogasawara et al. 2001). 
X-ray crystal structures of the IRF1 and IRF2 DBDs has revealed that this module is comprised of 
three α helices flanked on one side by four stranded anti-parallel β-sheets (Fujii, Shimizu et al. 
1999). The tryptophan repeat region forms a helix-turn-helix domain and recognizes the IFN-
stimulated response element sequence (ISRE: 5’-A/GNGAAANNGAAACT-3’) or similar 
sequences such as IRF-binding elements, positive regulatory element (PRE) and IFN consensus 
sequence, all of which possess a conserved core sequence 5’-GAAA-3’(Tanaka, Kawakami et al. 
1993, Fujii, Shimizu et al. 1999).  
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Figure 1.2. Overview of the IRF family. A schematic diagram of IRF family members showing 
the conserved N-terminal DNA binding domain and the IRF-association domain (IAD1 or 2). IRFs 
3, 5, 6 and 7 possess a conserved Ser phosphorylation site (Sato, Hata et al. 1998, Marie, Smith et 
al. 2000, Suhara, Yoneyama et al. 2000, Qin, Liu et al. 2003, Cheng, Brzostek et al. 2006), and 
IRFs 1-9 possess a conserved Lys acetylation site (Caillaud, Prakash et al. 2002). Some IRF family 
members also have repression domain(s). The N-terminal and C-terminal ends of the protein are 
indicated, and the sizes of the different human IRF refseq proteins (in amino acids) are indicated on 
the right. 
 
The C-terminal regions of IRFs contain the IRF-associated domain 1 or 2 (IAD1, IAD2), which 
mediate interactions with other IRF members and other transcription factors and/or co-factors 
(Taniguchi, Ogasawara et al. 2001, Qin, Liu et al. 2003). A crystal structure of IRF3 has shown that 
the IAD bears a high similarity to the MH2 domain of the Smad transcription factor family (Qin, 
Liu et al. 2003, Takahasi, Suzuki et al. 2003). The MH2 domain of the Smads reveals a serine (ser 
or S) residue on its surface, which allows phosphorylation and regulation of the Smad proteins (Qin, 
Lam et al. 1999, Wu, Chen et al. 2000). The IAD is predicted to be the primary site for protein-
protein interactions in IRF family members (Eroshkin and Mushegian 1999, Takahasi, Suzuki et al. 
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2003). IRF3 is constitutively expressed in the cytoplasm of most cells in an inactive form, where the 
IAD is flanked by two autoinhibitory domains (Eroshkin and Mushegian 1999, Takahasi, Suzuki et 
al. 2003). Upon phosphorylation, these autoinhibitory structures are rearranged and protein-protein 
interactions, such as homo and heterodomerization with other IRF family members, as well as 
binding to other transcriptional factors such as signal transducers and activators of transcription 
(STAT) 1 and 2, are facilitated (Eroshkin and Mushegian 1999, Meraro, Hashmueli et al. 1999, 
Lau, Parisien et al. 2000, Takahasi, Suzuki et al. 2003). Phosphorylation also exposes residues 
required for IRF3 DNA-binding and nuclear accumulation (Qin, Liu et al. 2003). IRF3 also contains 
a nuclear export signal (NES), which allows it to shuttle from the nucleus (Qin, Liu et al. 2003). 
IRF3 and IRF7 posttranslational modifications have been studied extensively in the context of TLR 
signalling. Viral challenge triggers phosphorylation of both IRF3 and IRF7 (Lin, Heylbroeck et al. 
1998, Sato, Tanaka et al. 1998, Yoneyama, Suhara et al. 1998, Fitzgerald, McWhirter et al. 2003, 
Honda, Yanai et al. 2005), and the phosphorylation sites on IRF3 have been mapped to Ser385 and 
Ser386 (Suhara, Yoneyama et al. 2000). This enables IRF3 to translocate into the nucleus, associate 
with CREB-binding protein (CBP)/p300 co-activator and activate expression of type I IFN 
(Weaver, Kumar et al. 1998, Yoneyama, Suhara et al. 1998). IRF7 was also phosphorylated on the 
Ser residue conserved with the IRF3 phosphorylation site (Au, Moore et al. 1998, Sato, Hata et al. 
1998, Marie, Smith et al. 2000), and mutation of this Ser residue, in either IRF3 or IRF7, abolished 
IRF activity (Sato, Hata et al. 1998, Marie, Smith et al. 2000, Suhara, Yoneyama et al. 2000). 
Similar studies on IRF5 showed that it was also phosphorylated on the conserved Ser residue by the 
TBK1 kinase leading to dimerization and transcriptional activation (Cheng, Brzostek et al. 2006). 
Whilst Ser phosphorylation is required for IRF activation, lysine (Lys or K) acetylation may 
negatively regulate this family. IRF7 was demonstrated to be acetylated at Lys residue 92 within the 
DBD (Caillaud, Prakash et al. 2002). This Lys residue was important for DNA binding; acetylation 
impaired DNA-binding and IRF7 transcriptional activity (Caillaud, Prakash et al. 2002). 
Interestingly, this Lys site is conserved in all other IRF family members (Caillaud, Prakash et al. 
2002). 
The IRF family has been primarily studied for its role in TLR signalling, in particular regulating 
inducible type I IFN production (Ozato, Tailor et al. 2007). However, this family also functions in 
reproduction and development (Riego, Perez et al. 1995, Bazer, Spencer et al. 1997, Ozato, Tailor et 
al. 2007), tumour suppression, apoptosis and embryonic development (Tanaka, Kawakami et al. 
1993, Kondo, Schutte et al. 2002, Tamura and Ozato 2002, Tsujimura, Nagamura-Inoue et al. 
2002). Specific IRF family members have well-established functions in development of immune 
cell lineages. IRF8 plays an important role in development of immune cells including macrophages, 
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monocytes, DCs, natural killer (NK) cells, CD4+ and CD8+ T cells (Tamura and Ozato 2002, 
Turcotte, Gauthier et al. 2005, Greeneltch, Schneider et al. 2007, Huang, Zhu et al. 2008). IRF8 
knockout mice showed impaired myeloid cell differentiation, and also developed a syndrome 
similar to human chronic or acute myelogenous leukemia (Holtschke, Lohler et al. 1996). 
Macrophages, monocytes, DCs and T cells from these mice also showed functional abnormalities, 
with resistance to apoptosis and hypersensitivity to cytokines (Huang, Zhu et al. 2008). These 
defects indicate the importance of IRF8 in myelopoiesis. Similarly, IRF4 plays a role in B-cell and 
T-cell maturation (Mittrucker, Matsuyama et al. 1997). Mice lacking IRF4 showed normal B-cells 
and T-cells initially, however, they progressively develop enlarged spleen and lymph nodes, 
impaired T-cells responses, decreased serum immunoglobulin concentrations and deficient 
cytotoxic and antitumour responses (Mittrucker, Matsuyama et al. 1997).  
1.4.1 IRFs in TLR Signalling 
The IRFs impart signalling specificity to individual TLR pathways. IRF1, IRF3, IRF7 and IRF8 
have all been linked to TLR3, TLR4, TLR7 and TLR9 signalling (Ozato, Tailor et al. 2007). TLR4 
utilizes TRIF and TRAM to activate IRF3 and the IFN pathway (Fitzgerald, Rowe et al. 2003), 
whereas TLR3 utilizes TRIF, but not TRAM, to activate IRF3 (Fitzgerald, Rowe et al. 2003). 
Importantly, the activation of IRF3 is unique to TLR3 and TLR4 signalling, amongst the various 
TLRs (Doyle, Vaidya et al. 2002). IRF3 is constitutively expressed in most cell types (Au, Moore et 
al. 1995). In response to TLR3 or TLR4 agonists, IRF3 undergoes phosphorylation at the Ser385 
and Ser386 sites in the C-terminal region, dimerizes, translocates to the nucleus and activates IFN-β 
transcription (Weaver, Kumar et al. 1998, Yoneyama, Suhara et al. 1998, Marie, Smith et al. 2000, 
Suhara, Yoneyama et al. 2000). IRF3 is critical for innate immunity signalling upon viral challenge. 
Irf3-/- mice were shown to be more susceptible to viral infections and virus-mediated IFN-β 
production was impaired in these mice (Sato, Suemori et al. 2000). Other IRF family members are 
involved in other TLR signalling arms. For example, MyD88-dependent signalling activates IRF5 
in macrophages (Takaoka, Yanai et al. 2005). IRF5 interacts with MyD88 and TRAF6 upon LPS or 
CpG DNA stimulation and translocates to the nucleus to activate gene expression (Takaoka, Yanai 
et al. 2005). In TLR7 signalling, IRAK-1 and TRAF6 interacts with and activates IRF5 
(Schoenemeyer, Barnes et al. 2005). IRF8 is also involved in TLR signalling. Studies on 
macrophages from Irf8-/- mice showed reduced ERK and JNK activation upon LPS +/- IFN-γ 
stimulation, and this activation was rescued upon retroviral transduction of IRF8 (Zhao, Kong et al. 
2006). IRF8 was also demonstrated to interact with TRAF6 and enhance TRAF6 ubiquitination 
(Zhao, Kong et al. 2006). How this might occur is unclear, but one possibility is that the association 
with IRF8 somehow promotes TRAF6 autoubiquitination (Zhao, Kong et al. 2006). This study 
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suggests that IRF8 mediates responses to some TLR ligands. Apart from IFN- transcription, IRFs 
are also involved in regulating expression of some chemokines, such as Chemokine (C-C motif) 
ligand (CCL) 5 (CCL5) (Lin, Heylbroeck et al. 1999, Genin, Algarte et al. 2000, Melchjorsen and 
Paludan 2003), as well as the IL-12 family of cytokines that control differentiation of T cell sub-sets 
(Bettelli and Kuchroo 2005). The IL-12 cytokine is composed of two sub-units, p35 and p40, and is 
also produced by some epithelial cells in response to pathogen challenge (Snijders, Hilkens et al. 
1996, Walter, Kajiwara et al. 2001). The p40 subunit also combines with p19 to form the cytokine 
IL-23 (Oppmann, Lesley et al. 2000). IRF1 and IRF8 have been shown to regulate IL-12p40 gene 
expression and play crucial roles in T helper cell type 1 immune responses (Figure 1.3) (Taki, Sato 
et al. 1997, Masumi, Tamaoki et al. 2002). IRF1, IRF5 and IRF7 all activated the IL-12p35 
promoter activity, whereas IRF3 repressed this response (Figure 1.3) (Dahlberg, Auble et al. 2006). 
 
 
 
Figure 1.3. IRFs impart specificity to TLR signalling. (A) The IRFs impart signalling specificity 
to individual TLR pathways. TLR3 and TLR4 utilize the TRIF adaptor to activate IRF3, while 
TLRs 4, 7, 8, and 9 utilize the MyD88 adaptor to activate IRF5 and IRF-7 to trigger gene 
expression. (B) IRFs impart cell-type specific TLR signalling. MyD88-dependent TLR signalling 
activates IRF1 in cDCs, IRF7 in pDCs, and IRF5 in macrophages. (C) Different IRFs regulate 
expression of different sub-units of the IL-12 cytokine family. For example, transcription of the IL-
12p35 sub-unit is driven by IRF1/5/7, while transcription of the IL-12p40 sub-unit is driven by 
IRF1 or IRF8.  
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In addition to being responsible for differences in gene expression programs triggered by distinct 
TLR agonists, IRF family members also contribute to cell type-specific responses to individual 
TLR ligands. One well-characterized example is TLR9 signalling in DCs. Based on their surface 
markers, DCs can be categorized into several populations, including plasmacytoid DCs (pDCs) and 
conventional DCs (cDCs). These cells also vary in their responses to pathogen challenge. In pDCs, 
IRF7 is constitutively expressed and is recruited in a MyD88-dependent fashion to promote type I 
IFN production upon CpG stimulation (Honda, Yanai et al. 2005). MyD88-dependent signalling in 
pDCs recruits IRAK4, IRAK1 and TRAF6 (Honda, Yanai et al. 2005). The IRAK1-IRAK4-TRAF6 
complex binds to IRF7 and TRAF6 polyubiquitinates IRF7 (Honda, Yanai et al. 2004, Kawai, Sato 
et al. 2004, Uematsu, Sato et al. 2005). IRAK-1 phosphorylates IRF7 at the multiple Ser sites near 
its C-terminal end, which enables nuclear translocation and activation of type 1 IFN genes 
(Uematsu, Sato et al. 2005). However, in cDCs, IRF1, rather than IRF7, promotes MyD88-
dependent type I IFN (Negishi, Fujita et al. 2006, Schmitz, Heit et al. 2007). In these cells, IRF1 
binds directly to MyD88 upon TLR activation and induces expression of IFN-β, IL-12p35 and other 
inflammatory genes (Negishi, Fujita et al. 2006, Schmitz, Heit et al. 2007). These responses were 
lost in cDCs from Irf1-/- mice (Negishi, Fujita et al. 2006, Schmitz, Heit et al. 2007). Thus, the 
expression of individual IRF family members can determine how a specific cell type responds to 
TLR ligands and/or pathogen challenge (Figure 1.3).  
1.4.2 Major Target of IRFs 
Several target genes for IRFs have been identified, however the major IRF targets in the context of 
TLR signalling and inflammatory processes are IFN-β, members of the IL-12 cytokine family and 
some chemokines, e.g. CCL5. The biological roles of these specific cytokines and chemokines are 
briefly discussed below. 
1.4.2.1 IFN-β  
Interferon was first described as “interfering agent” that interfered with viral replication (Isaacs and 
Lindenmann 1957). Type I IFNs are expressed in most cell types and play an important role in host 
defence. IFN-β is a type 1 IFN and acts via the IFNA receptor (Platanias 2005). IFN-β is mainly 
produced in response to viruses and dsRNA (Platanias 2005). Although IFN-β expression, upon 
appropriate stimulation, is produced by all cell-types, a major source of IFN-β production is a sub-
population of DCs, pDCs (Colonna, Krug et al. 2002, Coccia, Severa et al. 2004). 
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1.4.2.2 Members of the IL-12 cytokine family 
The IL-12 family of cytokines is comprised of four members that heterodimerize for their biological 
functions. They are formed by a unique combination of alpha and beta subunits and have diverse 
roles in innate and acquired immunity. The beta subunits are p40 and Epstein-Barr virus induced 
gene (EBI) 3, while the alpha subunits are p35, p19 and p28 (Vignali and Kuchroo 2012). IL-12 is 
formed by the heterodimerization of the p40 and p35 subunits, while IL-23 is formed by the 
heterodimerization of the p40 and p19 subunits. Both of these cytokines instruct T helper (Th) cell 
development (Vignali and Kuchroo 2012). IL-27, a heterodimer of EBI3 and p28, and IL-35, a 
heterodimer of EBI3 and p35, are the other two known members of this cytokine family and have a 
more immunosuppressive role (Vignali and Kuchroo 2012). 
1.4.2.2.1 IL-12 
IL-12 promotes IFN-γ production by T-cells and NK cells and facilitates the development and 
differentiation of T cells to Th 1 cells (Nakamura, Okamura et al. 1989, Hsieh, Macatonia et al. 
1993, Manetti, Parronchi et al. 1993, Trinchieri 1993). Upon infection, IL-12 also regulates the 
expansion and recruitment of CD8+ T cells (Pearce and Shen 2007). IL-12 is produced by various 
cell types, for example macrophages, dendritic cells and B cells, after PAMP recognition 
(Trinchieri, Wysocka et al. 1992, Hsieh, Macatonia et al. 1993, Macatonia, Hosken et al. 1995, 
Gately, Renzetti et al. 1998). IL-12-triggered IFN-γ production induces pro-inflammatory cytokines 
that are important for clearing intracellular pathogens (Langrish, McKenzie et al. 2004). The IL-12 
receptor (IL-12R) comprises of two sub-units, IL-12Rβ1 and IL-12Rβ2 (Chua, Chizzonite et al. 
1994, Presky, Yang et al. 1996). Upon binding to the receptor, the Janus kinase (JAK) /STAT 
pathway is activated. IL-12R activates the STAT4 transcription factor to enable transcriptional 
activation of target genes (Bacon, Petricoin et al. 1995, Jacobson, Szabo et al. 1995, Kaplan, Sun et 
al. 1996). IL-12R is expressed mainly by NK cells and activated Th1 cells, but was also shown to 
be expressed by DCs in vitro (Desai, Quinn et al. 1992, Grohmann, Belladonna et al. 1998). 
Dysregulated production of IL-12 is associated with various inflammatory conditions, including 
Crohn’s disease and multiple sclerosis (Nicoletti, Patti et al. 1996, Balashov, Smith et al. 1997, 
Monteleone, Biancone et al. 1997, Parronchi, Romagnani et al. 1997, Gee, Guzzo et al. 2009).  
1.4.2.2.2 IL-23 
IL-23 was discovered in 2000, when Oppmann et. al. showed the p40 can covalently attach to a new 
subunit, p19, through disulphide bonding (Oppmann, Lesley et al. 2000). IL-23 is produced by 
macrophages and dendritic cells in response to PAMPs and has similar, but distinct functions to IL-
12 (Langrish, McKenzie et al. 2004). IL-23 is recognised by IL-12Rβ1 and the IL-23R receptors, 
which is expressed by T-cells, NK cells, monocytes, DCs and activated macrophages (Parham, 
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Chirica et al. 2002). Downstream signalling through this receptor also results in activation of the 
JAK/STAT signalling pathway (Parham, Chirica et al. 2002). IL-23 is important for the 
development, maintenance and function of Th17 cells, since p19-/- mice have impaired Th17 
responses, despite having normal IFN-γ production (Happel, Zheng et al. 2003, Murphy, Langrish 
et al. 2003, Ghilardi, Kljavin et al. 2004, Schulz, Kohler et al. 2008, Riol-Blanco, Lazarevic et al. 
2010). In contrast, p35-/- mice have more Th17 cells (Murphy, Langrish et al. 2003). Th17 cells 
produce IL-17 and IL-22, cytokines that are important for clearing extracellular pathogens but also 
drive autoimmune diseases (Happel, Zheng et al. 2003, van de Veerdonk, Gresnigt et al. 2009, 
Waite and Skokos 2012). Excessive production of IL-23/IL-17 in skin drives dysregulated 
inflammation and leads to psoriasis (Lee, Trepicchio et al. 2004, Tonel, Conrad et al. 2010, 
Mudigonda, Mudigonda et al. 2012). Anti-IL-23 or anti-IL-17 therapies have thus been developed 
for the treatment of psoriasis (Krueger, Langley et al. 2007, Leonardi, Kimball et al. 2008, Kurzeja, 
Rudnicka et al. 2011). 
1.4.2.2.3 IL-27 
IL-27 was identified by Pflanz et. al. as a heterodimeric cytokine composed of EBI3 and p28 
subunits, which was structurally homologous to IL-12 subunits p40 and p35 (Pflanz, Timans et al. 
2002). It is mainly produced by macrophages and DCs in response to TLR agonists (Pflanz, Timans 
et al. 2002). IL-27 signals through its receptor IL-27R, which is composed of the cytokine receptor 
WSX-1 and glycoprotein-130 (gp130) (Pflanz, Timans et al. 2002, Pflanz, Hibbert et al. 2004). The 
latter is a component of the IL-6 receptor family and is thus shared by this family of cytokines (IL-
6, IL-11 etc) (Taga and Kishimoto 1997). IL-27 receptor signalling also activates the JAK/STAT 
pathway in T cells and promotes Th1 cell development, therefore, IL-27 was initially thought to be 
a pro-inflammatory cytokine (Pflanz, Timans et al. 2002, Hibbert, Pflanz et al. 2003, Lucas, 
Ghilardi et al. 2003, Takeda, Hamano et al. 2003, Stumhofer and Hunter 2008). However, 
subsequent studies in vivo revealed that IL-27 limited T cell-mediated inflammation and inhibited 
Th1, Th2, and Th17 responses (Hamano, Himeno et al. 2003, Villarino, Hibbert et al. 2003, 
Stumhofer and Hunter 2008). IL-27 was also shown to activate T-cells to produce the anti-
inflammatory cytokine IL-10 (Awasthi, Carrier et al. 2007, Fitzgerald, Zhang et al. 2007, 
Stumhofer, Silver et al. 2007).  
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1.4.2.2.4 IL-35 
IL-35, a heterodimer of the EBI3 and p35 subunits, is an immunosuppressive cytokine (Devergne, 
Birkenbach et al. 1997). IL-35 is mainly produced by Treg cells and is also important for their 
development (Collison, Workman et al. 2007). Very little is known about IL-35 function, however 
one study showed that IL-35 inhibits T cell proliferation by inducing cell cycle arrest at the G1 
phase (Collison, Workman et al. 2007, Collison, Chaturvedi et al. 2010, Chaturvedi, Collison et al. 
2011). 
1.4.2.3 CCL5 
CCL5, also known as regulated on activation, normal T cell expressed and secreted (RANTES), is a 
member of the CC chemokine family (Lapteva and Huang 2010). CCL5 is a potent chemotractant 
of T cells, but also attracts DCs, NK cells, eosinophils, basophils and mast cells to sites of 
inflammation (Stanford and Issekutz 2003, Grayson and Holtzman 2006). CCL5 is produced by 
various cells including macrophages, platelets, eosinophils, fibroblasts, epithelial cells, endothelial 
cells and endometrial cells (Grayson and Holtzman 2006). CCL5 mediates its inflammatory 
responses through the C-C motif receptor 5 (CCR5) (Blanpain, Buser et al. 2001). CCL5 has been 
implicated to have a role in various biological processes including control of certain pathogens, for 
example HIV, and enhanced inflammation in inflammatory conditions, such as atherosclerosis, and 
cancer (Cocchi, DeVico et al. 1995, Levy 2009, Lapteva and Huang 2010, Katsounas, Schlaak et al. 
2011). CCL5 is also essential for costimulation of T cells, and Ccl5-/- mice show defective T cell 
proliferation and inflammatory responses (e.g. IFN-γ, IL-2) following antigen stimulation (Taub, 
Turcovski-Corrales et al. 1996, Makino, Cook et al. 2002). 
1.5 Interferon Regulatory Factor 6 
One IRF family member that has not been studied in the context of TLR signalling is IRF6. The 
IRF6 gene is 19kb in size and encodes a 467 amino acid (aa) transcription factor. As with other 
family members, IRF6 has a highly conserved N-terminal DBD with the five conserved tryptophan 
residues (aa 13-113), and a less conserved C-terminal domain (aa 226-394) (Figure 1.2). IRF6 has 
89% homology (aa sequence similarity) with IRF5, which has been shown to activate IFN 
transcription upon viral infection (Barnes, Moore et al. 2001, Barnes, Field et al. 2003, Takaoka, 
Tamura et al. 2008), participate in TLR4-mediated MyD88 signalling (Ouyang, Negishi et al. 2007) 
and suppress tumour formation by regulating the cell cycle and promoting apoptosis (Barnes, 
Kellum et al. 2003). IRF6 function has primarily been studied in the context of developmental 
pathways. 
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1.5.1 Developmental functions of IRF6 
IRF6 has an important role in development in humans and in mice. It is primarily expressed by 
epithelial cells of various tissues in mouse, chicken, zebrafish and Xenopus laevis embryos (Ben, 
Jabs et al. 2005, Ingraham, Kinoshita et al. 2006, Knight, Schutte et al. 2006, Richardson, Dixon et 
al. 2006, Sabel, d'Alencon et al. 2009). In mice, enriched IRF6 expression was seen in the 
developing secondary palate and adult skin (Kondo, Schutte et al. 2002). IRF6 expression was also 
present in the medial edges of the paired palatal shelves, palatal rugae, tooth germs, thyroglossal 
duct, external genitalia, hair follicles and skin throughout the body (Kondo, Schutte et al. 2002). 
Consistent with these expression patterns, genetic variations in IRF6 are associated with various 
degrees of cleft lip, cleft palate, undifferentiated skin and syndactyly in humans (Kondo, Schutte et 
al. 2002, Zucchero, Cooper et al. 2004, Blanton, Cortez et al. 2005, Ghassibe, Bayet et al. 2005, 
Scapoli, Palmieri et al. 2005, Srichomthong, Siriwan et al. 2005, Park, McIntosh et al. 2007, 
Jugessur, Shi et al. 2009). Van der Woude syndrome (VWS) is the most common form of 
syndromic orofacial clefting and is characterized by lip pits, cleft lips, cleft palate and hypodontia. 
Popliteal pterygium syndrome (PPS) has orofacial features similar to VWS with the addition of 
webbed skin of legs, genital hypoplasia, oral synychia, adhesions between the eyelids and 
syndactyly. Both of these syndromes are autosomal dominant. The loci for VWS and PPS were 
mapped to human chromosome 1q32-q41 (Murray, Nishimura et al. 1990, Sander, Schmelzle et al. 
1994, Schutte, Basart et al. 1999), and IRF6 was subsequently identified as the defective gene in 
these syndromes (Koillinen, Wong et al. 2001). The first identified mutation in IRF6 was a 
nonsense mutation in one affected twin of monozygotic twins (Kondo, Schutte et al. 2002). The 
parents and the other twin had no defect and did not show any mutation in IRF6 (Kondo, Schutte et 
al. 2002). The mutation in the affected twin occurred in exon 4 of IRF6. This results in the 
generation of a stop codon at residue 92 (instead of glutamic acid); consequently the encoded 
protein is truncated and non-functional (Kondo, Schutte et al. 2002). Subsequently, 45 unrelated 
patients with VWS and 13 patients with PPS were found to have a mutation in IRF6 (Kondo, 
Schutte et al. 2002). Mutations in the gene are frequently observed in the DBD or the IAD1 (Kondo, 
Schutte et al. 2002, Little, Rorick et al. 2009).  
In normal palate formation, the paired palatal shelves extend from the maxilla towards each other 
and fuse. The medial edge epithelial (MEE) lining of the palatal shelves is lost following the fusion 
and the surrounding mesenchyme migrates and fuses to the palatal cleft (Knight, Schutte et al. 
2006). IRF6 is expressed in the medial edge epithelium and the levels of IRF6 expression showed a 
rapid increase prior to the fusion events (Knight, Schutte et al. 2006). The elimination of the MEE 
may involve multiple cellular processes including apoptosis, migration and/or epithelial-to-
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mesenchyme transition (Martinez-Alvarez, Tudela et al. 2000, Cuervo, Valencia et al. 2002). How 
IRF6 mutations result in improper fusion events is still unclear at this stage. Studies on mice 
deficient in transforming growth factor beta3 (TGFβ3), which also exhibits cleft palate, have 
revealed decreased IRF6 expression in the MEE of these mice (Kaartinen, Voncken et al. 1995, 
Proetzel, Pawlowski et al. 1995). This suggests that IRF6 may have a role in the elimination of the 
MEE lining through one or more of the above mentioned cellular processes. Mutations in the Notch 
ligand Jagged2 also exhibits craniofacial and limb defects, similar to IRF6 (Jiang, Lan et al. 1998, 
Richardson, Dixon et al. 2009). This suggests that IRF6 may collaborate with Notch signalling 
during oral periderm differentiation and palatal fusion events (Richardson, Dixon et al. 2009). 
Consistent with the genetic defects in humans, IRF6 null mice show severe abnormalities in skin, 
limb and craniofacial development and die shortly after birth (Ingraham, Kinoshita et al. 2006, 
Richardson, Dixon et al. 2006). IRF6 null mice also have dysregulated keratinocyte development 
(Ingraham, Kinoshita et al. 2006, Richardson, Dixon et al. 2006). In mice, four stratified layers of 
epidermis are formed during development. These layers, from innermost to outer, are basal, 
spinous, granular and cornified. Mice deficient in IRF6 did not have a normal stratified epidermis 
and showed a thicker epidermis compared to wild-type mice (Ingraham, Kinoshita et al. 2006, 
Richardson, Dixon et al. 2006). The basal layer was normal, but the spinous layer was expanded, 
and the outer granular and cornified layers were absent (Ingraham, Kinoshita et al. 2006, 
Richardson, Dixon et al. 2006). The suprabasal keratinocytes in these mice proliferated and failed to 
terminally differentiate into the different layers of the epidermis (Ingraham, Kinoshita et al. 2006, 
Richardson, Dixon et al. 2006). IRF6 null mice displayed ectopic expression of keratin 14 (K14) in 
the spinous layer. This suggests that IRF6 may negatively regulate K14 expression (Ingraham, 
Kinoshita et al. 2006, Richardson, Dixon et al. 2006). Notch1 activation has also been shown to 
induce IRF6 in mouse and human keratinocytes and squamous cell carcinoma (SCC) cell-lines. 
Conditional deletion of Notch1 and Notch2 in keratinocytes in mice resulted in a significant 
reduction in IRF6 expression in the epidermis. Previous studies demonstrated that two transcription 
factors of the POU domain family Skin-1a and Tuberculin skin test reactivity 1 have a role in K14 
repression (Sugihara, Kudryavtseva et al. 2001). Also, Skin-1a was shown to interact with CBP, and 
this interaction may act to silence K14 expression (Sugihara, Kudryavtseva et al. 2001). IRF1, IRF3 
and IRF7 can interact with CBP and/or p300 (Yoneyama, Suhara et al. 1998, Yang, Lin et al. 2003, 
Dornan, Eckert et al. 2004), so it is possible that IRF6 may be involved in K14 repression via 
interactions with the CBP/p300 coactivator complex. Alternatively, Skin-1a and Tuberculin skin 
test reactivity 1 may be direct target genes of IRF6. Apart from Irf6-/- mice, Ikkα-/- and stratifin-/- 
(Sfn) mice display similar phenotypes in the developing epithelium (Takeda, Takeuchi et al. 1999, 
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Li, Lu et al. 2005). The expression of IKKα and Sfn in IRF6 mutant mice appeared normal and 
IRF6 expression was not affected in IKKα or Sfn mutant mice (Ingraham, Kinoshita et al. 2006, 
Richardson, Dixon et al. 2006). However, double heterozygous mutants of IRF6/Sfn showed 
similar, but less severe, defects as IRF6 homozygous mice, suggesting that IRF6 and Sfn interact 
genetically to regulate keratinocyte and epidermal development (Richardson, Dixon et al. 2006). In 
total, the above studies identify IRF6 as an important regulator of keratinocyte proliferation and 
differentiation during mouse embryogenesis. 
1.5.2 IRF6 Regulation 
Despite its well-established role in the development of the epidermis, the cellular and molecular 
mechanisms by which IRF6 functions are poorly understood. IRF6 possesses a multi-species 
conserved enhancer sequence 9.7 kb upstream of its transcription start site (MCS9.7). MCS9.7 is 
expressed during early mouse cranio-facial development stages and also in suprabasal layers and 
differentiated keratinocytes (Rahimov, Marazita et al. 2008). This enhancer region also contains 
conserved binding sites for p63, Notch and transcription factor activating enhancer binding protein-
2 (Rahimov, Marazita et al. 2008, Thomason, Zhou et al. 2010, Restivo, Nguyen et al. 2011). There 
are 3 potential binding sites for p63 in the IRF6 locus; one in the MCS9.7 enhancer, one upstream 
of the transcription start site and one within the first intron (Thomason, Zhou et al. 2010). In 
addition, within the MCS9.7 enhancer region, there are three ISRE sites, which results in a positive 
feedback loop for the regulation of IRF6 transcription (Moretti, Marinari et al. 2010, Thomason, 
Zhou et al. 2010). During palatal development, Pbx proteins regulate the expression of Wnt9b and 
Wnt3, which in turn regulate p63. p63 then binds to MCS9.7 to regulate Irf6 expression and proper 
palatal development (Ferretti, Li et al. 2011).  
The only biochemically-verified protein that IRF6 has been shown to interact with is mammary 
serine protease inhibitor (maspin) (Bailey, Khalkhali-Ellis et al. 2005). Maspin is a member of the 
serpin family of serine protease inhibitors, which is expressed in normal mammary epithelial cells 
(Zou, Anisowicz et al. 1994). Maspin inhibits tumour invasion and metastasis in breast cancer cells 
(Zou, Anisowicz et al. 1994, Bailey, Khalkhali-Ellis et al. 2006), and indeed its expression is 
reduced during tumour development (Sheng, Carey et al. 1996). Further, targeted maspin 
overexpression in mice resulted in reduced development of mammary lobular-alveolar structures 
due to increased apoptosis and disrupted cell differentiation (Zhang, Magit et al. 1999). 
Interestingly, IRF6 was also expressed in normal mammary epithelial cells and, similar to maspin, 
this expression was lost during tumour progression (Bailey, Khalkhali-Ellis et al. 2005). Analysis of 
deletion mutants showed that IRF6 directly binds to maspin via the IAD (Bailey, Khalkhali-Ellis et 
al. 2005). This interaction is likely regulated by IRF6 phosphorylation, since IRF6-maspin 
Introduction 
23 
 
interactions were significantly reduced in cells treated with lambda-phosphatases (Bailey, 
Khalkhali-Ellis et al. 2005). Subsequent studies on IRF6 in breast development revealed that IRF6 
controls breast epithelium differentiation by promoting cell cycle arrest (Bailey, Abbott et al. 2008). 
IRF6 exists in a non-phosphorylated state in non-proliferating cells, but was rapidly phosphorylated 
as cells entered the cell cycle (Bailey, Abbott et al. 2008). IRF6 phosphorylation decreased its 
stability leading to degradation (Bailey, Abbott et al. 2008). This may allow the cell to progress 
from the Go phase to enter the G1 phase of the cell cycle (Bailey, Abbott et al. 2008). This suggests 
that IRF6 has a role in regulating proliferation and differentiation of mammary epithelial cells, and 
presumably the interaction with maspin is involved in this process (Bailey, Abbott et al. 2008). 
In SCC, IRF6 down-regulation, due to methylation of a CpG dinucleotide island located in the 
promoter, was linked to invasiveness and differentiation status. Using siRNA gene knockdown in 
keratinocytes, as well as a ChIP-seq approach, this study identified IRF6 target genes on a genome 
wide scale (Botti et al, 2011). These findings should aid in understanding of IRF6 functions in 
keratinocytes. In summary, IRF6 has an essential role in epithelial development and IRF6 loss of 
function can lead to developmental defects and tumour development. However, the molecular 
mechanisms by which IRF6 functions are only just beginning to be elucidated. 
1.6 TLRs in Epithelial cells 
TLRs are expressed predominantly on cell types that are likely to be the first to encounter microbial 
challenge. Thus, phagocytic cells such as macrophages, neutrophils and DCs express the broadest 
repertoire of TLRs, although expression is not only restricted to these cell types (Zarember and 
Godowski 2002). Given the emerging role of epithelial cells in inducible responses to pathogen 
challenge, it is not surprising that these cells are also reported to express various TLRs (Hippenstiel, 
Opitz et al. 2006, Gribar, Anand et al. 2008). Table 1.2 shows the expression patterns of various 
human and mouse TLRs in epithelial cells of the intestine, airway, kidneys, bladder and skin. 
Responses of epithelial cell-lines to various TLR ligands have also been studied to address which 
TLR receptors are functionally significant in these cells. In intestinal epithelial cell lines (IEC) like 
HT-29 and T84, LPS activated NF-κB and triggered the release of pro-inflammatory cytokines, 
suggesting that these cells express a functional TLR4 signalling complex (Otte, Cario et al. 2004). 
TLR9 was also shown to be functional in IECs. TLR9 expression was increased and IL-8 was 
secreted when these cells were exposed to DNA from S. enterica serovar Dublin (Ewaschuk, 
Backer et al. 2007). In the human keratinocyte cell line HaCaT, LPS induced expression of CD14 
and TLR4 (Kollisch, Kalali et al. 2005). Treatment with Candida albicans, as well as heat killed 
Mycobacterium tuberculosis triggered nuclear translocation on NF-κB and Interleukin 8 (IL-8) 
production in primary human keratinocytes (Pivarcsi, Bodai et al. 2003). Both primary human 
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keratinocytes and HaCaT cells secreted the chemokine IL-8 in response to the TLR3 ligand 
Poly(IC), the TLR2 ligand Tripalmitoyl-S-glycerylcysteine (Pam3Cys) and the TLR5 ligand 
flagellin (Kollisch, Kalali et al. 2005). Several groups have shown that airway epithelial cells 
express all TLRs at the mRNA and/or protein levels and can initiate inflammatory responses upon 
exposure to PAMPs. Airway epithelial cells responded to LPS, as well as invading pathogens such 
as Streptococcus pneumonia, by producing IL-8 via TLR4 and TLR2 (Armstrong, Medford et al. 
2004, Schmeck, Huber et al. 2006). Similar studies performed on mouse primary urinary tract 
epithelial cells have demonstrated that UPEC and LPS can activate NF-κB signalling and induce 
pro-inflammatory responses in a TLR4-dependent manner (Tsuboi, Yoshikai et al. 2002, Chassin, 
Goujon et al. 2006). The above studies suggest that at least some types of epithelial cells express 
functional PRRs and are actively involved in host defense mechanisms. Other than host defence, 
there is growing evidence that epithelial-expressed TLRs may also contribute to the development of 
dysregulated mucosal inflammation (Gribar, Anand et al. 2008).  
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TLR Intestinal Epithelium Pulmonary 
Epithelium 
Urothelium Skin References 
 Small 
Intestine 
Large 
Intestine 
Airway Renal 
Epithelium 
Ureter and Bladder 
Epithelium 
Epidermis and 
Keratinocytes 
 
TLR1 RNAh RNAh RNAh,m RNAm N.D. RNAh (Rock, Hardiman et al. 1998, Becker, Diamond et al. 2000, 
Tsuboi, Yoshikai et al. 2002, Melmed, Thomas et al. 2003, 
Muir, Soong et al. 2004, Otte, Cario et al. 2004, Greene, 
Carroll et al. 2005, Kollisch, Kalali et al. 2005, Zhang, 
Louboutin et al. 2005, Schmeck, Huber et al. 2006) 
TLR2 RNAh RNAh,m RNAh,m RNAm RNAm RNAh (Becker, Diamond et al. 2000, Cario, Rosenberg et al. 2000, 
Backhed, Soderhall et al. 2001, Naik, Kelly et al. 2001, 
Tsuboi, Yoshikai et al. 2002, Wolfs, Buurman et al. 2002, 
Melmed, Thomas et al. 2003, Pivarcsi, Bodai et al. 2003, 
Muir, Soong et al. 2004, Otte, Cario et al. 2004, Greene, 
Carroll et al. 2005, Hauber, Tulic et al. 2005, Kollisch, 
Kalali et al. 2005, Zhang, Louboutin et al. 2005, Ortega-
Cava, Ishihara et al. 2006, Schmeck, Huber et al. 2006, 
Shigeoka, Holscher et al. 2007, Szebeni, Veres et al. 2007) 
 Proteinh Proteinh Proteinh,m Proteinh,m  Proteinh 
TLR3 Proteinh RNAh RNAh,m RNAm RNAm RNAh (Becker, Diamond et al. 2000, Cario and Podolsky 2000, 
Cario, Rosenberg et al. 2000, Backhed, Soderhall et al. 
2001, Tsuboi, Yoshikai et al. 2002, Muir, Soong et al. 2004, 
Otte, Cario et al. 2004, Greene, Carroll et al. 2005, Kollisch, 
Kalali et al. 2005, Begon, Michel et al. 2007, Szebeni, 
Veres et al. 2007) 
  Proteinh Proteinh,m   Proteinh 
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TLR4 RNAh,m RNAh,m RNAh,m RNAm RNAh,m RNAh (Becker, Diamond et al. 2000, Cario and Podolsky 2000, 
Cario, Rosenberg et al. 2000, Backhed, Soderhall et al. 
2001, Hornef, Frisan et al. 2002, Tsuboi, Yoshikai et al. 
2002, Wolfs, Buurman et al. 2002, Ortega-Cava, Ishihara et 
al. 2003, Pivarcsi, Bodai et al. 2003, Bambou, Giraud et al. 
2004, Muir, Soong et al. 2004, Otte, Cario et al. 2004, 
Samuelsson, Hang et al. 2004, Greene, Carroll et al. 2005, 
Hauber, Tulic et al. 2005, Kollisch, Kalali et al. 2005, 
Jilling, Simon et al. 2006, Neal, Leaphart et al. 2006, 
Ortega-Cava, Ishihara et al. 2006, Leaphart, Cavallo et al. 
2007, Szebeni, Veres et al. 2007) 
 Proteinh,m Proteinh,m Proteinh,m Proteinh,m Proteinh,m Proteinh 
TLR5 Proteinh,m RNAh RNAh,m RNAm RNAm RNAh (Becker, Diamond et al. 2000, Backhed, Soderhall et al. 
2001, Bambou, Giraud et al. 2004, Muir, Soong et al. 2004, 
Otte, Cario et al. 2004, Greene, Carroll et al. 2005, Kollisch, 
Kalali et al. 2005, Zhang, Louboutin et al. 2005, Ortega-
Cava, Ishihara et al. 2006, Begon, Michel et al. 2007) 
  Proteinh Proteinh,m   Proteinh 
TLR6 N.D. RNAh RNAh,m RNAm N.D. RNAh (Becker, Diamond et al. 2000, Tsuboi, Yoshikai et al. 2002, 
Melmed, Thomas et al. 2003, Muir, Soong et al. 2004, Otte, 
Cario et al. 2004, Greene, Carroll et al. 2005, Kollisch, 
Kalali et al. 2005, Zhang, Louboutin et al. 2005) 
TLR7 RNA RNAh RNAh,m Absentm N.D. RNAh 
Proteinh 
(Du, Poltorak et al. 2000, Muir, Soong et al. 2004, Otte, 
Cario et al. 2004, Kollisch, Kalali et al. 2005, Pawar, Patole 
et al. 2006, Li, Sohn et al. 2013) 
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TLR8 Absent RNAh RNAh,m Absent N.D. Absenth (Du, Poltorak et al. 2000, Muir, Soong et al. 2004, Otte, 
Cario et al. 2004, Droemann, Albrecht et al. 2005, Kollisch, 
Kalali et al. 2005, Anders and Schlondorff 2007)    Protein
h,m    
TLR9 Proteinh,m RNAh RNAh,m Absentm N.D. RNAh 
Proteinh 
(Tsuboi, Yoshikai et al. 2002, Anders, Vielhauer et al. 2004, 
Muir, Soong et al. 2004, Otte, Cario et al. 2004, Rumio, 
Besusso et al. 2004, Greene, Carroll et al. 2005, Kollisch, 
Kalali et al. 2005, Pedersen, Andresen et al. 2005, Begon, 
Michel et al. 2007, Ewaschuk, Backer et al. 2007, Lebre, 
van der Aar et al. 2007) 
TLR10 N.D. Absenth RNAh,m N.D. N.D. RNAh (Chuang and Ulevitch 2001, Muir, Soong et al. 2004, Otte, 
Cario et al. 2004, Kollisch, Kalali et al. 2005) 
TLR11 N.D. N.D. RNAm RNAm RNAm N.D. (Tsuboi, Yoshikai et al. 2002, Muir, Soong et al. 2004, 
Zhang, Zhang et al. 2004) 
 
Table 1.2. The expression of various human (h) and mouse (m) TLRs in epithelial cells from different anatomical locations. This information is 
based on existing literature in which mRNA levels were quantified using qPCR, and protein levels were detected using Western blotting. N.D. = not 
determined. 
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1.6.1 TLR localization in epithelial cells 
Although epithelial cells can express TLRs, distinct subcellular localizations have often been 
reported. For example, in airway epithelium, TLR4 and TLR5 were expressed at the basolateral 
surface, whereas TLR2 was expressed at the apical surface of these cells (Hertz, Wu et al. 2003, 
Adamo, Sokol et al. 2004, Muir, Soong et al. 2004). In primary bronchial epithelial cells, TLR4 was 
localized to the intracellular compartment of the cell (Guillot, Medjane et al. 2004), whilst TLR9 
was expressed at the cell surface in these cells (Greene, Carroll et al. 2005). This contrasts with the 
localization of these TLRs in macrophages and DC, and suggests that there may be distinct 
regulation and function of TLRs in epithelial cells versus phagocytes. In keratinocytes, TLR1, 
TLR2 and TLR5 expression was found in the basal cells, whilst TLR4 was expressed in the 
epidermis of the skin (Kawai, Shimura et al. 2002, Baker, Ovigne et al. 2003, Pivarcsi, Bodai et al. 
2003). In IECs, TLR3, TLR4 and TLR5 expression was found on the basolateral surface, while 
TLR2 and TLR9 were expressed in both the apical and basolateral surfaces (Chabot, Wagner et al. 
2006). These differences in localization of the TLRs suggest that epithelial cells may have a unique 
way of interacting with pathogens and triggering immune responses.  
TLRs are also differentially localized in specific cell types of the intestinal epithelium. In normal 
human colon tissue, TLR2 and TLR4 expression was predominantly localized to the crypt epithelial 
cells (Cario, Rosenberg et al. 2000, Furrie, Macfarlane et al. 2005). This crypt cell expression of 
TLR4 has also been reported in mice (Ortega-Cava, Ishihara et al. 2003). In mice, TLR2, 4 and 5 
have been shown to be localized on the follicle-associated epithelium and the intestinal epithelium 
(Chabot, Wagner et al. 2006). TLR2 and TLR9 expression were found on the apical and basolateral 
pole of the follicle-associated epithelium, but only on the apical surface in intestinal epithelium 
(Chabot, Wagner et al. 2006). TLR4 was localized internally in the Golgi-apparatus of the 
epithelium (Hornef, Frisan et al. 2002). The differential localization of TLR4 in IEC may enable it 
to differentiate between non-pathogenic luminal bacteria and pathogenic bacteria. Thus, there 
appears to be a very specialized pattern of TLR expression within both the tissue and the epithelial 
cells. This may be important for host defence and for preventing unwanted responses against non-
pathogenic microorganisms. However, it is also worth noting that there are often concerns about the 
specificity of several antibodies used to detect various TLRs, so this must also be considered when 
assessing the literature on TLR localization within epithelial cells and specific tissues. 
1.6.2 TLR responsiveness of keratinocytes 
Human skin is constantly exposed to microbes, and is therefore equipped to detect pathogens, and 
to prevent their entry and multiplication. Skin cells such as keratinocytes have been reported to 
Introduction 
29 
 
express TLRs and produce inflammatory cytokines in response to PAMPs. Table1.3 summarizes 
the TLR responses that have been reported in keratinocytes. 
TLR Agonist/Pathogen Inflammatory Response References 
TLR Agonist 
TLR1/2 Pam3Cys, PGN NF-κB nuclear translocation   
IL-8, CCL20, CCL2, MMP9, 
iNOS, β-defensin 2 
(Kawai, Shimura et al. 2002, 
Mempel, Voelcker et al. 2003, 
Niebuhr, Baumert et al. 2010)  
TLR2/6 Lipoteichoic acid (LTA), 
Zymosan 
NF-κB nuclear translocation   
IL-8, iNOS, β-defensin 2 
(Kawai, Shimura et al. 2002, 
Mempel, Voelcker et al. 2003) 
TLR3 Polyinosinic-polycytidylic 
acid (Poly(IC)) 
IRF3 nuclear translocation   
IFN-α, IFN-β, IL-8, CCL27, 
Chemokine (C-X-C motif) 
ligand (CXCL)9, CXCL10 
(Kollisch, Kalali et al. 2005, 
Miller, Sorensen et al. 2005, Dai, 
Sayama et al. 2006, Lebre, van 
der Aar et al. 2007) 
TLR4 LPS NF-κB nuclear translocation  
IL-8, IL-1α, IL-1β 
(Song, Park et al. 2002, Kollisch, 
Kalali et al. 2005) 
TLR5 Flagellin IL-8, Tumour necrosis factor 
alpha (TNF-α), thymic 
stromal lymphoprotein 
(TSLP), β-defensins 2 and 3 
(Kollisch, Kalali et al. 2005, 
Lebre, van der Aar et al. 2007) 
TLR7 Imiquimod IL-6, IL-8, TNF-α, IL-1β, 
IL-12, IL-23, IL-17, IFN-γ 
(Kono, Kondo et al. 1994, 
Kollisch, Kalali et al. 2005, 
Olaru and Jensen 2010, Li, Sohn 
et al. 2013) 
TLR9 CpG DNA type 1 IFN, IL-8, β-defensins (Miller, Sorensen et al. 2005, 
Lebre, van der Aar et al. 2007) 
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Pathogen 
TLR2 
and 2/6 
Staphylococcus aureus (S. 
aureus) 
TNF-α, IL-8, TSLP, β-
defensins 
(Mempel, Voelcker et al. 2003, 
Midorikawa, Ouhara et al. 2003, 
Sumikawa, Asada et al. 2006, 
Aufiero, Guo et al. 2007, Kisich, 
Howell et al. 2007, Vu, Baba et 
al. 2010, Ommori, Ouji et al. 
2013) 
TLR2 GAS IL-1α, IL-1β, IL-6, IL-8 (Wang, Ruiz et al. 1997) 
TLR9 Herpes simplex virus (HSV) type-1 IFN, TNF-α, CCL5, 
colony simulating factors, IL-
3, defensins 
(Schnipper, Levin et al. 1984, 
Melchjorsen and Paludan 2003, 
Shao, Zhang et al. 2010) 
TLR2 
and 4 
Candida albicans NF-κB nuclear translocation  
IL-8, TNF-α, IL-1β, IL-6, 
IFN-γ 
(Pivarcsi, Bodai et al. 2003, 
Wollina, Kunkel et al. 2004, 
Eyerich, Wagener et al. 2011) 
Skin Inflammatory Disorders 
TLR1-5, 
7 and 9 
Psoriasis IL-23, IL-17, IFN-γ 
NF-κB activation 
Th17 development and 
responses 
(Baker, Ovigne et al. 2003, Lee, 
Trepicchio et al. 2004, Miller, 
Sorensen et al. 2005, Piskin, 
Sylva-Steenland et al. 2006, 
Begon, Michel et al. 2007, 
Wilson, Boniface et al. 2007, 
Manel, Unutmaz et al. 2008) 
TLR2 
and 9 
Atopic dermatitis (AD) TNF-α, CCL5, IL-1α, IFN-γ (Pastore, Corinti et al. 1998, 
Giustizieri, Mascia et al. 2001, 
Kaburagi, Shimada et al. 2001) 
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Danger-Associated Molecular Patterns (DAMPs) 
TLR3 UV-damage (U1 non-coding 
RNA) 
IL-1β, TNF-α, IL-6 (Skiba, Neill et al. 2005, Lai, Di 
Nardo et al. 2009, Bernard, 
Cowing-Zitron et al. 2012) 
TLR3 Wound/Injury (dsRNA from 
necrotic cells) 
TNF-α, IL-6 (Lai, Di Nardo et al. 2009, Lin, 
Fang et al. 2011) 
 
Table 1.3. TLR responses in keratinocytes. Based on existing literature, the responses of 
keratinocytes to various TLR agonists, common skin pathogens, in skin inflammatory disorders and 
DAMPs are listed in this table.  
 
1.7 Project Aims and Hypothesis 
Despite the strong homology of IRF6 with IRF5, an important regulator of TLR responses, only one 
study has addressed possible IRF6 functions in TLR pathways. Mammary epithelial cells expressed 
TLR3 at the mRNA level, and the TLR3 ligand poly(IC) was reported to trigger IRF6 translocation 
into the nucleus (Bailey, Abbott et al. 2008, Bailey and Hendrix 2008). IRF6 expression analyses in 
mouse and chick embryos indicates that IRF6 is mainly expressed in epithelial cells (Ben, Jabs et al. 
2005, Ingraham, Kinoshita et al. 2006, Knight, Schutte et al. 2006, Richardson, Dixon et al. 2006), 
a finding that is consistent with the phenotypes revealed by IRF6 loss of function in both mice and 
humans (Kondo, Schutte et al. 2002, Zucchero, Cooper et al. 2004, Blanton, Cortez et al. 2005, 
Ghassibe, Bayet et al. 2005, Scapoli, Palmieri et al. 2005, Srichomthong, Siriwan et al. 2005, 
Ingraham, Kinoshita et al. 2006, Richardson, Dixon et al. 2006, Park, McIntosh et al. 2007, 
Jugessur, Shi et al. 2009). In summary, the existing literature suggests that IRF6 is expressed in 
epithelial cells, particularly in the skin. This places this IRF family member as a possible 
component of danger recognition pathways in these cells, but this has not been examined to date. 
This project therefore aimed to investigate the role of IRF6 in barrier defence.  
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1.7.1 Hypothesis 
IRF6 contributes to barrier defence by acting as a key component of pattern recognition receptor 
signalling in epithelial cells. 
1.7.2 Research Aims 
This project aimed to elucidate the role of IRF6 in epithelial cell-mediated inflammatory responses 
through the following aims: 
Aim 1: To characterize IRF6 expression in human epithelial cell populations from distinct 
anatomical locations.  
Aim 2: To investigate the role of IRF6 in poly(IC)-regulated gene expression in keratinocytes. 
Aim 3: To investigate the role of IRF6 in MyD88-dependent TLR signalling in keratinocytes.  
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2 Materials and Methods 
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2.1 Materials 
2.1.1 General Reagents 
The Rho-associated protein kinase (ROCK) inhibitor Y27632 was sourced from either Sigma-
Aldrich (St Louis, MO, USA) or Reagents Direct (Encinitas, CA, USA), and was used at a final 
concentration of 5 µM. Calcium chloride (Merck, Darmstadt, Germany) was dissolved in 
DNase/RNase free water at a concentration of 1 M, autoclaved prior to use and diluted in tissue 
culture media to a final concentration of 2 mM. Human recombinant IFN-γ (R&D Systems, 
Minneapolis, MN, USA) was stored at a concentration of 2.5 µg/ml at -200C and diluted in tissue 
culture media to a final concentration of 2.5 ng/ml. Phorbol 12-myristate 13-acetate (PMA) (Sigma-
Aldrich) was solubilised in dimethyl sulfoxide (DMSO) at a concentration of 10 µg/ml, stored at -
800C and was diluted in tissue culture media to a final concentration of 30 ng/ml. 
2.1.2 Primers 
Primers used for quantitative PCR (qPCR) analysis were designed using Primer3 public software 
(http://www.basic.nwu.edu/biotools/Primer3.html). If possible, at least one of the primer pairs was 
designed to span exon-exon junctions to avoid amplification of any contaminating genomic DNA. 
Primer pairs were selected to amplify a product of 80-150 bp and to have melting temperatures 
(Tm) of 60-640C. Absence of predicted secondary structures and primer dimers was confirmed 
using Oligo 6.8 software (Molecular Biology Insights, Cascade, CO, USA). Primer concentrations 
(100-400 nM) were first optimized, prior to use for subsequent quantitative analyses. The 
amplification of a single product by each primer pair was confirmed by the dissociation curve of 
each qPCR. Primer pairs used for qPCR are listed in Table 2.1.   
Primer Forward (5’-3’) Reverse (5’-3’) 
Product 
Size (bp) 
Exons 
targetted 
hIRF6 TAGCGATCTCATTGCCCA CACTACTGGAATGACCTGAAC 139 5-6 
hIRF3 CGTGATGGTCAAGGTTGTGC AGAGTGGGTGGCTGTTGGAA 119 6-7 
hIRF8 CCAGCCAGTTCTTCCGAGAG CCGGAAACTCTTCCCCAAAG 96 6-7 
hHPRT TCAGGCAGTATAATCCAAAGATGGT AGTCTGGCTTATATCCAACACTTCG 84 4-5 
hIFN-β CAGTCCTGGAAGAAAAACTGGAGA TTGGCCTTCAGGTAATGCAGAA 109 1 
hIL-8 GGAGAAGTTTTTGAAGAGGGCTGA TGCTTGAAGTTTCACTGGCATCTT 93 3-4 
hIL-
12p35 
GCTCCAGAAGGCCAGACAAA GCCTCCACTGTGCTGGTTTT 99 2-3 
hIL-
12p40 
GATGCCGTTCACAAGCTCAAGT GACCTCCACCTGCCGAGAAT 126 4-5 
hIL-
23p19 
GGACTCAGGGACAACAGTCAGTTC GAGAAGGCTCCCCTGTGAAAA 103 2-3 
Materials and Methods 
35 
 
hCCL5 CTCCAACCCAGCAGTCGTCTT CCAAAGAGTTGATGTACTCCCGAAC 95 2-3 
hCCL20 GCGAATCAGAAGCAGCAAGC GCCGTGTGAAGCCCACAATA 90 1-2 
hEBI3 CATGGCTCCCTACGTGCTC GGGCTTGATGATGTGCTCTGT 94 3-4 
hIL-
27p28 
GCTTTGCGGAATCTCACCTG GGTGGAGATGAAGCAGAGACG 134 2-3 
hIVL GGTCCCATCAAAGCAAGAGG CTGCTCCTGTGGCTCCTTCT 94 1 
hTLR1 CACCAAGTTGTCAGCGATGTG CAAATGCAGGAACGGGCTAA 147 1 
hTLR2 TGGTGTCTGGCATGTGCTGT CCAGGCCCACATCATTTTCA 104 1 
hTLR3 
GCTCTGGAAACACGCAAACC CTCGTCAAAGCCGTTGGACT 
97 3 
hTLR4 
GAGCCCTGCGTGGAGGT TGGTTGAGAAGGGGAGGTTGT 
91 1-2 
hTLR5 
TGTTTCTGGAAATGGCTGGAC CATGATGTGGTGGGCAAGAA 
100 1 
hTLR6 
GTCCCTGGCAAGAGCATTGT AATGGCACCACTCACTCTGGA 
106 1 
hTLR7 
ACATCTCCCCAGCGTCCTTT TTTTTGACCCCAGTGGAATAGG 
90 2 
hTLR8 
AGCTGCGCTACCACCTTGAA TGCTCTGCATGAGGTTGTCG 
108 2 
hTLR9 
ACTTCTTCCAAGGCCTGAGC GGCCAGGTAATTGTCACGGA 
134 2 
hTLR10 
TTGACCCTGGCAAAAGCATTA TGGCACCACTCATTCTGGAC 
106 1 
Table 2.1. List of Primers used for qPCR. 
2.1.3 Plasmids 
The IRF6 expression constructs, the IFN-β promoter-luciferase construct, pIFN-β-luc (Sato, 
Suemori et al. 2000) and the pEF (empty vector) plasmids were kindly provided by A/Prof. Glen 
Scholz (Bio21, University of Melbourne). The human IL-23p19 promoter luciferase construct, pIL-
23p19-luc was PCR cloned from genomic DNA, as described in Section 2.2.11. The renilla reporter 
plasmid pRL-SV40, as well as the pGL2-Basic (pGL2-B) and the pGL2-Control (pGL2-C) 
luciferase constructs were from Promega. 
2.1.4 Antibodies 
The antibodies used in these studies are listed in Table 2.2. 
Antibody Specificity Antibody 
Type  
Application Dilution Concentration          
(µg/ml) 
MW of Antigen 
detected (kDa) 
Source 
Primary Antibodies 
Rabbit α-
IRF6 
Human Polyclonal WB 
IF 
IHC 
1/1000 
1/250 
1/1200 
0.6 
2.4 
0.5 
60 Cell Signaling 
Technology, 
Danvers, MA, 
USA 
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Rabbit α-
GAPDH 
Human/ 
mouse 
Polyclonal WB 1/2500 0.1 37 Trevigen, 
Gaithersburg, 
MD, USA 
Mouse α-
Lamin A/C 
Human/ 
mouse 
Monoclonal 
(4C11) 
WB 1/2500 1 74 (Lamin A) 
63 (Lamin C) 
Cell Signaling 
Technology 
Mouse α-
IL-23p19 
Human Monoclonal 
(727753) 
WB 1/500 1 20 R&D Systems 
Secondary Antibodies 
Goat α-
rabbit IgG-
HRP 
Rabbit IgG - WB 1/2500 0.4 - Cell Signaling 
Technology 
Horse α-
mouse IgG-
HRP 
Mouse IgG - WB 1/2500 0.4 - Cell Signaling 
Technology 
Goat α-
rabbit IgG-
Alexa488 
Rabbit IgG - IF 1/400 5 - Molecular 
Probes, 
Eugene, OR, 
USA 
Chicken α-
rabbit IgG-
Alexa647 
Rabbit IgG - IF 1/400 5 - Molecular 
Probes 
Goat α-
rabbit IgG-
Biotin 
Rabbit IgG - IHC 1/200 4 - Santa Cruz 
Biotechnology, 
Santa Cruz, 
CA, USA 
Table 2.2. List of Antibodies used in this thesis. WB = Western Blotting; IF = 
Immunoflourescence microscopy; IHC = Immunohistochemistry. 
2.1.5 TLR agonists 
The details and preparation of stock solutions of TLR ligands as follows: Poly(IC) (TLR3 agonist, 
Invivogen, San Diego, CA, USA), a synthetic dsRNA analogue, was solubilized in sterile water at 1 
mg/ml; zymosan (TLR2/Dectin 1 agonist, Sigma-Aldrich), purified from Saccharomyces cerevisiae 
cell wall, was dissolved in sterile phosphate buffered saline (PBS) at 100 mg/ml; flagellin (TLR5 
agonist, Invivogen) is a recombinant flagellin from Salmonella typhimurium and was reconstituted 
in sterile water at 10 µg/ml; Pam3Cys (TLR1/2 agonist, Calbiochem, Darmstadt, Germany), a 
bacterial lipoprotein analogue, was solubilised in sterile water at 10 µg/ml; CpG 2006 (TLR9 
agonist, Geneworks, Adelaide, SA, Australia), a synthetic oligonucleotide containing unmethylated 
CpG dinucleotides, was solubilized in sterile water at 5 µM; LPS (TLR4 agonist, Sigma-Aldrich), 
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purified from Salmonella enterica serotype Minnesota, was prepared in culture medium at 10 
µg/ml; imiquimod (R837) (TLR7 agonist, Invivogen), an imidazoquinoline amine analogue to 
guanosine, was solubilized in sterile water at 1 mg/ml and Pam2CGDPKHPKSF (FSL-1) (TLR2/6 
agonist, Invivogen), a synthetic lipoprotein derived from Mycoplasma salivarium cell wall, was 
solubilized in sterile water at 10 mg/ml. All stock solutions were stored at -200C. 
TLR agonists were diluted in media to achieve a final concentration as follows: Poly(IC) - 30 
µg/ml, zymosan - 100 µg/ml, flagellin - 10 ng/ml, Pam3Cys - 15 ng/ml, CpG 2006 - 0.3 µM, LPS - 
100 ng/ml, Imiquimod (R837) - 25 µg/ml and FSL-1 - 100 ng/ml.  
2.1.6 siRNAs 
The siRNAs used in gene silencing studies are as follows: IRF6(1) (Invitrogen, Carlsbad, CA, USA, 
Stealth) (Sense: CAG GCA CCU AUA CAG CCC UUC UAU A; Antisense: UAU AGA AGG 
GCU GUA UAG GUG CCU G), IRF6(2) (Invitrogen, Pre-made stealth) siRNA Id: HSS105511 
IRF6, IRF3 (Invitrogen Stealth)  (Sense: GAG AAU ACU GUG GAC CUG CAC AUU U; 
Antisense: AAA UGU GCA GGU CCA CAG UAU UCU C) and SLC39A8 (Invitrogen Stealth) 
(Sense: GCC AUC AAU GGU GUG ACA UTT; Antisense: AUG UCA CAC CAU UGA UGG 
CTT). 
 
Figure 2.1. A schematic diagram indicating IRF6 siRNA targeting sites. This figure is a 
schematic diagram of the human IRF6 mRNA showing the different exons and the intron region 
(grey line). The untranslated regions of the mRNA are indicated in green, while the translated 
regions are indicated in pink. The target sites for the two siRNAs used are indicated by arrows (in 
exons 7 and 8). 
2.2 Methods 
2.2.1 Cell lines and culture conditions 
2.2.1.1 A498 
A498 is a human kidney epithelial cell-line and was kindly provided by Dr. Makrina 
Totsika (University of Queensland). These cells were originally isolated from a patient 
with renal carcinoma (Giard, Aaronson et al. 1973). A-498 cells were cultured in 
Advanced Dulbecco’s Modified Eagle Medium (DMEM) (Life technologies, Carlsbad, 
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CA, USA) with 10% foetal bovine serum (FBS) (Invitrogen), 2 mM L-glutamine 
(Invitrogen), 1.5 g/l Sodium bicarbonate (Invitrogen), 20 units(U)/ml Penicillin and 20 
µg/ml Streptomycin. For freezing down cells, 10% DMSO was added to complete 
growth media. 
2.2.1.2 BEAS-2B 
BEAS-2B is a human lung/bronchial epithelial cell-line, which was obtained from the 
American Tissue Culture Collection (ATCC, Manassas, VA, USA) (CRL-9609). These 
cells were isolated from normal human bronchial epithelium and were virally 
transformed to immortalise them (Albright, Jones et al. 1990). BEAS-2B cells were 
cultured in DMEM-F12 (Ham’s F12) media (Invitrogen), supplemented with 10% FBS, 
20 U/ml Penicillin and 20 µg/ml Streptomycin. For freezing down the cells, 10% DMSO 
was added to complete growth media. 
2.2.1.3 CaCo-2 
CaCo-2 is a human colon epithelial cell-line, which was kindly provided by Dr. Makrina 
Totsika (University of Queensland). These cells were isolated from a patient of 
colorectal adenocarcinoma. Media used for routine culture of CaCo-2 cells was identical 
to that used for A498 cells. 
2.2.1.4 HaCaT 
HaCaT are a human keratinocyte cell-line and were kindly provided by Dr. Timothy 
Barnett (University of Queensland). These cells were isolated from normal adult skin 
and were immortalised as a result of a spontaneous transformation in vitro (Boukamp, 
Petrussevska et al. 1988). HaCaT cells were cultured in DMEM (Invitrogen) with 10% 
FBS, 20 U/ml Penicillin and 20 mg/ml Streptomycin. For freezing down the cells, 10% 
DMSO was added to complete growth media. 
2.2.1.5 Human Embryonic Kidney (HEK) 293 and HEK293-TLR3 cells 
The HEK293 cell-line was derived from human embryonic kidney (Graham, Smiley et 
al. 1977) and was obtained from ATCC (CRL-1573) . HEK293-TLR3 cells are stably 
transfected with human TLR3, thus conferring responsiveness to TLR3 agonists 
(Yamamoto, Sato et al. 2002). Both HEK293 and HEK293-TLR3 cells were cultured as 
described for HaCaT cells. 
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2.2.1.6 HeLa 
HeLa is a human cervical epithelial cell-line, which was kindly provided by Dr. Makrina 
Totsika (University of Queensland). These cells were isolated from a patient’s 
adenocarcinoma (Jones, McKusick et al. 1971). HeLa cells were cultured in RPMI 
(Invitrogen) with 10% FBS, 2 mM L-Glutamine, 0.1 mM MEM non-essential amino 
acids (Invitrogen), 1 mM Sodium pyruvate (Invitrogen), 50 mM HEPES buffer 
(Invitrogen), 20 U/ml Penicillin and 20 mg/ml Streptomycin. For freezing down HeLa 
cells, 10% DMSO was added to complete growth media. 
2.2.1.7 MCF-7 
MCF-7 is a human mammary epithelial cell-line, derived from a metastatic site from a 
patient with breast adenocarcinoma (Soule, Vazguez et al. 1973). These cells were 
obtained from ATCC (HTB-22). MCF-7 cells were cultured in Minimum Essential 
Medium (MEM) (Invitrogen) with 10% FBS, 0.01 mg/ml Bovine Insulin, 2 mM L-
Glutamine, 20 U/ml Penicillin and 20 mg/ml Streptomycin. For freezing down the cells, 
10% DMSO was added to complete growth media. 
2.2.1.8 RAW264.7 and RAW-ELAM 
RAW264.7 is a mouse macrophage-like cell-line, which was obtained from ATCC (TIB-
71). These cells were originally derived from tumours of mice after Abelson leukaemia 
virus infection (Raschke, Baird et al. 1978) and exhibit macrophage-like characteristics 
such as phagocytosis, and also robustly respond to stimulation with PAMPs. RAW-
ELAM cells are RAW264 mouse macrophages stably transfected with a construct  in 
which the endothelial leucocyte adhesion molecule (ELAM) promoter drives NF-B-
dependent expression of green fluorescent protein (GFP) upon activation (Stacey, Young 
et al. 2003). RAW264.7 cells were cultured in RPMI with 5% FBS, 2 mM L-glutamine, 
20 U/ml Penicillin and 20 mg/ml Streptomycin. For freezing down the cells, freezing 
media contained 50% FBS, 40% complete growth media and 10% DMSO. 
2.2.1.9 T24 
T24 is a human bladder epithelial cell-line that was kindly provided by Dr. Makrina 
Totsika (University of Queensland). These cells were isolated from a patient with 
transitional cell carcinoma (Bubenik, Baresova et al. 1973). T24 cells were cultured in 
McCoy’s 5a media (Invitrogen) containing 10% FBS, 20 U/ml Penicillin and 20 mg/ml 
Streptomycin. For freezing down the cells, 10% DMSO was added to complete growth 
media. 
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2.2.1.10 THP-1 
THP-1 is a human monocytic cell-line, originally derived from the peripheral blood of a 
patient with acute monocytic leukemia (Tsuchiya, Yamabe et al. 1980). These cells can 
be differentiated to a macrophage-like phenotype by culturing for 48 h with PMA 
(Tsuchiya, Yamabe et al. 1980). These cells were obtained from ATCC (TIB-202). THP-
1 cells were cultured in RPMI with 10% FBS, 2 mM L-Glutamine, 1 mM Sodium 
pyruvate, 10 mM HEPES buffer, 50 μM β-mercaptoethanol, 20 U/ml Penicillin and 20 
mg/ml Streptomycin. THP-1 cells were differentiated into macrophages using PMA (30 
ng/ml) for 48 h. Undifferentiated cells were frozen down using freezing media, which 
consisted of 50% FBS, 40% complete growth media and 10% DMSO. 
2.2.2 Primary Cells 
2.2.2.1 Primary human keratinocytes 
All work using primary human cells was carried out with the approval of The University 
of Queensland Medical Research Ethics Committee (Project number H339). Primary 
epidermal keratinocytes were isolated from neonatal foreskin samples (samples were 
collected from Russell Medical Centre, Brisbane, Queensland). In brief, samples were 
rinsed in 70% ethanol, and then rinsed in PBS. Excess fat tissue was then excised from 
the skin and the skin was incubated overnight at 40C in Dispase II (1 mg/ml) (Roche, 
Basel, Switzerland) plus antibiotics (20 U/ml penicillin, 20 µg/ml streptomycin and 10 
µg/ml gentamicin). The epidermis layer was peeled off and separated from the dermis. 
The epidermal cells were isolated by incubating in 0.25% trypsin (Invitrogen) for 5 
minutes (min) and then cultured in a proliferating state. Primary keratinocytes were 
maintained in an undifferentiated state in Defined Keratinocyte serum-free media, 
supplemented with 50 µg/ml bovine pituitary extract and 5 µg/ml epidermal growth 
factor, 20 U/ml penicillin, 20 µg/ml streptomycin and 10 µg/ml gentamicin (Life 
technologies). For all experiments, unless stated otherwise, untreated cells were used at 
low passage numbers (up to 7 passages) to minimise differentiation of cells. To maintain 
cells in a proliferating state, 5 µM Y27632 (ROCK inhibitor) was included in culture 
media. To differentiate primary keratinocytes, 2 mM calcium chloride was added for up 
to 72 h. Undifferentiated cells were frozen down using freezing media, which consisted 
of complete growth media and 10% FBS and 10% DMSO. 
2.2.2.2 Primary human monocyte derived macrophages (HMDM) 
Human monocyte-derived macrophages (HMDM) were isolated from buffy coats 
obtained from the Australian Red Cross Blood Service. Generation of HMDMs was 
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performed by Dr. Nilesh Bokil (Institute for Molecular Bioscience, University of 
Queensland). In brief, monocytes were isolated by MACS using CD14+ magnetic beads 
(Miltenyi Biotech, Bergisch Gladbach, Germany), as previously described (Schroder, 
Irvine et al. 2012). Monocytes were differentiated into macrophages by using 1 X 104 
U/ml recombinant human CSF-1 (Chiron, Emeryville, CA, USA). HMDMs were 
maintained in Iscove’s modified Dulbecco’s medium (Life Technologies) with 20 U/ml 
penicillin, 20 µg/ml streptomycin and 2 mM L-glutamine.  
2.2.3 Storage of cells 
Cells and cell-lines at a low passage number were stored in liquid nitrogen. Cells at 70-80% 
confluence were harvested (as described below, Section 2.2.4), pelleted by centrifugation at 500 g 
for 5 min and resuspended in specific freezing media, described above. Cells were aliquoted into 
cryo-vials, after which they were frozen slowly in isopropanol using cryo-freezing containers 
placed at -800C, and then transferred into liquid nitrogen. Cryo-vials of cells were rapidly defrosted 
in a 370C water bath and resuspended in 10 ml of warmed complete growth media. Cells were then 
pelleted by centrifugation at 500 g for 5 min, after which they were resuspended in fresh complete 
growth media and cultured, as described above.  
2.2.4 Sub-culturing techniques 
All cells and cell-lines, except for RAW264.7, RAW-ELAM, THP-1 and HMDMs, were sub-
cultured using trypsinization. Briefly, culture media was aspirated out and cells were washed with 
PBS. Cells were incubated in 0.25% trypsin (Invitrogen) for 1-5 min at 370C. In the case of primary 
keratinocytes, a trypsin substitute Tryple Express (1 X) (Invitrogen) was used. Trypsin was 
deactivated using 10% FBS containing media and cells were pelleted down by centrifuging at 500 g 
for 5 min. RAW264.7, RAW-ELAM and HMDM cells were harvested using 18-gauge blunt end 
needle to dislodge adherent cells, whilst THP-1 cells are non-adherent. Cells were then pelleted 
down by centrifuging at 500 g for 5 m. Supernatant was discarded and cells were resuspended in 
fresh media and cultured in 370C incubator with 5% CO2.  
2.2.5 PAMP stimulation 
For stimulation of epithelial cells with defined PAMPs, cells were plated out one day (d) before 
treatment. Cells were stimulated with the PAMPs listed above (Section 2.1.4) by diluting them in 
the media to achieve the final concentration indicated. Control cells were left unstimulated. For 
kinetic analyses within individual experiments, culture supernatants and/or cell lysates were 
harvested from independent replicate wells. That is, a different well of cells was used for each 
specific time point.  
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2.2.6 RNA extraction and reverse transcriptase PCR 
Cells were scraped off plates using a cell-scraper and lysed in RNA lysis buffer (Buffer RLT plus 
0.1 M β-mercaptoethanol, Qiagen, Valencia, CA, USA) followed by homogenization using a 21-
gauge needle. RNA was then extracted according to the manufacturer’s protocol (QIAGEN RNA 
mini kit). RNA derived from the cell-lines A-549, AGS, HT29, MKN28 and T84 were kindly 
provided by A/Prof. Glen Scholz (Bio21, University of Melbourne). Absorbance of RNA samples 
were measured at 260 nm using a ND1000 Nanodrop (Biolab, Auckland, New Zealand) and the 
values were converted into concentration (µg/ml) using the equation: A260 reading of 1.0 is 
equivalent of 40 µg/ml RNA. cDNAs were synthesised from 1 μg of extracted RNA using 500 ng 
oligo dT (Geneworks), 1 X First-strand buffer (Invitrogen), 1 µl 0.1 M DTT (Invitrogen), 1 µl 3.75 
µM dNTPs (Invitrogen) and 0.25 µl Superscript III reverse transcriptase (Invitrogen). cDNA 
synthesis was performed by incubating at 42˚C for 30 min. The synthesized cDNA was diluted 10 
times in RNase-free water and subsequently used for qPCR. 
2.2.7 Real-time PCR (qPCR) 
All qPCR reactions were performed using SYBR Green PCR Master Mix (Applied BioSystems, 
Foster City, CA, USA) and the Applied Biosystems 7900HT RT-PCR or ViiA7 systems. A 10 µl 
reaction mix was prepared with 1 X SYBR Green PCR Master Mix (5 µl), 100-400 nM primers 
(forward and reverse) and 2 µl of diluted cDNA. All cDNA samples were run in triplicate in 384-
well plate (Invitrogen). Primers designed to amplify specific genes are listed above (Table 2.1), and 
mRNA levels for specific genes were quantified relative to expression of the house-keeping gene 
hypoxanthine-guanine phosphoribosyltransferase (HPRT). That is, data were expressed relative to 
HPRT using the ∆Ct method. The following equation, which is recommended by Applied 
Biosystems, was used to calculate relative gene expression:  
gene/hprt = 2- ; where Ct = geneCt – hprtCt (the difference in cycle thresholds) 
SD = 2- - 2-x ; where x = Ct + SQRT(SDgene2 + SDhprt2) 
2.2.8 Western blotting 
For analysis of protein expression by immunoblotting, cells were lysed using RIPA lysis buffer (50 
mM Tris-HCl pH7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton-X 100, 1% Sodium deoxycholate, 
0.1% SDS) containing 1 X complete protease inhibitor cocktail (Roche) and 1 X phosphatase 
inhibitor (1 mM sodium vanadate, 1 mM sodium pyrophosphate, 1 mM sodium molybdate, 10 mM 
sodium fluoride). Cell lysates were collected using a cell-scraper and were passed through a 21-
gauge needle to homogenize the lysates. Protein concentrations were determined using Bradford’s 
protein assay (Bio-rad, Hercules, CA, USA) or BCA assay (Pierce, Rockford, IL, USA), according 
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to the manufacturer’s protocol. Immunoblotting was performed by loading 10 μg of protein lysate 
on a pre-cast 4-20% gradient SDS-PAGE gel (Bio-rad). The separated proteins were transferred 
onto methanol-activated polyvinylidene diflouride (PVDF) membranes and were blocked using 
Blotto which contained 5% Skim milk powder in Tris-buffered saline with Tween 20. Membranes 
were then probed for specific antigens (IRF6, GAPDH, Lamin A/C or IL-23p19) as per the details 
in Table 2.2. Horseradish peroxidase (HRP) conjugated α-Rabbit or α-mouse antibody (Cell 
Signaling Technology) was used as secondary antibody, as per the details in Table 2.2. Immobilon 
Western Chemiluminescent HRP substrate (Millipore, Billerica, MA, USA) was used for 
immunodetection.  
2.2.9 Gene silencing 
The listed siRNAs (Section 2.1.6) were diluted in Opti-MEM reduced serum media (Life 
Technologies) to the final concentration of 200 pM, after which they were transfected into primary 
keratinocytes (300,000 cells/well of a 12-well plate (Nunc, Thermo Scientific, MA, USA)) using 
Lipofectamine 2000 reagent 5 µl/transfection (Life technologies) and the reverse transfection 
method, as described by the manufacturer. Cells were harvested or were stimulated for the indicated 
timepoints 72 h post-transfection, after which RNA and proteins were extracted and qPCR and 
immunoblotting were performed (as described in Section 2.2.7 and 2.2.8). 
2.2.10 Enzyme-linked Immunosorbent Assays (ELISA) 
Supernatants were collected from cells treated with different TLR ligands. IL-8 cytokine levels 
were quantified using a human IL-8 ELISA kit (BD Biosciences, San Jose, CA, USA), according to 
the manufacturer’s protocol (capture antibody used at 2 µg/ml; detection antibody used at 2 µg/ml). 
For IL-23p19 ELISA, a human IL-23p19 monoclonal antibody (R&D Systems) was used as capture 
antibody (1 µg/ml) and a biotinylated α-human IL-23p19 (Bio Legend, San Diego, CA, USA) was 
used as detection antibody (0.5 µg/ml). Immuno 96-well micro plates (Nunc) were coated overnight 
with the capture antibody. Recombinant human IL-8 or IL-23 (R&D Systems) standards and 
samples (50 µl/well) were then added and ELISA plates were incubated for 2 h at 37˚C. After 
washing, the biotinylated detection antibody was added for 1 h, followed by further washing and a 
30 min incubation with Streptavidin-HRP conjugate (1 µg/ml). 3,3′,5,5′-Tetramethylbenzidine 
(TMB) substrate (Sigma-Aldrich) (100 µl/well) was then added to detect HRP activity, and 2 mM 
sulphuric acid (100 µl/well) was added to stop the reaction. Absorbance was read on a plate reader 
at 450 nm, and cytokine levels were determined from the standard curves. The estimated detection 
limit for the IL-8 ELISA was 80 pg/ml, while for the IL-23p19 ELISA it was 300 pg/ml. 
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2.2.11 PCR Cloning 
The region immediately upstream of the transcription start site (TSS) of the human IL-23p19 
promoter was cloned from genomic DNA from primary keratinocytes into the pGL2B-luciferase 
construct (Promega, Madison, WI, USA) using the primer pairs, IL-23p19 F (5’-CA CCC GGG 
ACT GTG AGG CCT GAA ATG-3’) and IL-23p19 R (5’-GC AAG CTT CTT TTT GCC TTC 
TTC TCA AAT CTG GC-3’). These primer pairs were designed such that the TSS and a putative 
upstream IRF binding site (-815 to +1 bp) were present in the amplified PCR product. XmaI and 
HindIII restriction sites were also engineered within the primer sequences, as part of the cloning 
strategy. The 815 bp PCR product was digested with the XmaI and HindIII restriction enzymes 
(New England BioLabs, Ipswich, MA, USA) , after which it was ligated into the promoterless 
luciferase reporter construct pGL2-B, which had previously been digested with XmaI and HindIII 
(Figure 2.2). Ligations were carried out using T4 DNA ligase (New England BioLabs) using a 
molar ratio of 1:3 (vector to insert). 10 µl ligation reaction was prepared using 1 X T4 DNA ligase 
buffer (New England BioLabs), 1 µl T4 DNA ligase and 8 µl of digested vector and insert and 
incubated at 160C overnight. Ligated plasmids were then transformed and purified as described 
below (Section 2.2.12). 
 
Figure 2.2. Plasmid map of pIL-23p19-luc. Plasmid map of pIL-23p19-luc was adapted from the 
pGL2-B map provided by Promega (https://au.promega.com/). The IL-23p19 promoter is marked in 
grey (inserted using the restriction sites indicated), and the putative IRF and NF-κB binding sites 
are indicated. The luciferase gene is indicated in green, and the other sites on the plasmid are 
highlighted in yellow.  
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2.2.12 Plasmid purification 
The above ligations were transformed into Top10 (Invitrogen) or XL-1Blue competent E. coli cells. 
XL-1Blue E. coli cells were prepared by growing bacteria in super optimal broth media at room 
temperature until they reach an absorbance (A600) of 0.6. Following this, the cells were centrifuged 
at 2500 g for 10 min at 40C and resuspended in transformation broth (40C) (10 mM PIPES, 55 mM 
MnCl2, 15 mM CaCl2, 250 mM KCl, pH 6.7) and centrifuged again at 2500 g for 10 min at 4
0C. 
Cells were then resuspended in transformation broth with 7% DMSO and snap-frozen in liquid 
nitrogen and subsequently stored in -800C. Mini-preps were performed on transformed bacteria 
using the alkaline lysis method. Cells were pelleted and resuspended in 250 µl resuspension buffer 
P1 (Qiagen) followed by lysis in 250 µl lysis buffer P2 (Qiagen). DNA was precipitated using 150 
µl cold 3 M sodium acetate (pH 5.2) and 150 µl chloroform and centrifuged at 14000 g for 5 min. 
The upper layer (containing DNA) was carefully removed and purified by sequential 100% and 
70% ethanol washes. The DNA was resuspended in 30 µl of DNase/RNase-free water and 
subsequently analysed by restriction enzyme digestion and DNA sequencing. Maxi-preps of the 
sequence-verified pIL-23p19 plasmid, and all other plasmids (Section 2.1.3), were prepared using 
QIAGEN Maxi-prep Kits (Qiagen), according to the manufacturer’s protocol.  
2.2.13 Transient transfection analysis and reporter gene assays 
HEK293 cells or HEK293-TLR3 cells were transfected with 100 ng of the indicated firefly 
luciferase reporter plasmid, as well as 10 ng of the SV-40 renilla plasmid. An IRF6 expression 
plasmid was added to required cells in various concentrations. The total concentration of plasmid 
DNA was kept constant at 2 μg in all transfections, using empty pEF vector. Cells were seeded 
overnight, and transient transfections were performed on the following d using 10 µl lipofectamine 
2000 reagent (Invitrogen) and 2 μg plasmids (as described above) in 1 ml serum-free DMEM for 6 
h, after which the medium was replaced with complete growth medium for 15 h. The cells were 
then stimulated with 30 μg/ml Poly(IC) for 8 h, then lysed using Passive lysis buffer (Promega Dual 
Luciferase Kit). Firefly and renilla luciferase activity were then measured using the VICTOR 
system (PerkinElmer, Waltham, MA, USA), as well as the Promega Dual Luciferase Kit (Promega), 
according to the manufacturer’s protocol. The firefly luciferase reading was normalized to the 
renilla luciferase reading to correct for differences in transfection efficiency between different 
transfections.  
RAW264.7 cells were transfected with 5 μg of the indicated firefly luciferase reporter, as well as 5 
μg of the IRF6 expression plasmid or empty vector, in 300 μl media in 0.4 cm cuvettes using a Bio-
Rad Gene Pulser XCell Electroporator (260 V, 1000 μF). After electroporation, cells were washed 
in PBS and plated out in 6-well plates (Nunc) and incubated for 20 h, after which cells were 
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stimulated with 30 μg/ml poly(IC) for 8 h or were left unstimulated. Cells were harvested using the 
Roche luciferase lysis buffer (Roche) and luciferase activity was measured using a MicroBeta trilux 
luminometer (PerkinElmer) and Roche Luciferase Reporter Gene Assay kits (Roche), as per the 
manufacturer’s protocol. Total protein concentrations in lysates were determined using BCA assay 
(Pierce), as described earlier. Luciferase readings were normalised to total protein.  
2.2.14 Nuclear and Cytoplasmic fractionation 
HaCaT cells were plated out overnight in 10 cm tissue culture dishes (Nunc) and were stimulated on 
the following d with 30 μg/ml Poly(IC) over a time-course. Cells were detached using 0.25% 
Trypsin (Invitrogen), and were washed thrice with PBS. Cells were re-suspended in Hypotonic 
Wash Buffer (HWB) (10 mM HEPES pH 7.4, 1.5 mM MgCl2, 10 mM KCl) containing 1 X 
complete protease inhibitor cocktail (Roche), 1 X phosphatase inhibitor (1 mM sodium 
pyrophosphate, 1 mM sodium molybdate, 10 mM sodium fluoride), 1 mM sodium vanadate 
(Sigma-Aldrich) and 1 mM phenylmethylsulfonyl fluoride (Sigma-Aldrich) to cause cell swelling, 
after which they were lysed using 0.1% NP-40. Lysed cells were then centrifuged at 500 g for 5 min 
and supernatants (cytoplasmic extracts) were collected, aliquoted and stored at -80˚C. The nuclei 
were then washed with HWB buffer, after which the nuclear proteins were extracted by hypertonic 
lysis of nuclear membrane using nuclear extraction buffer (NEB) (20 mM HEPES pH 7.8, 1.5 mM 
MgCl2, 0.42 M NaCl, 20% glycerol, 0.2 mM EDTA) containing 1 X complete protease inhibitor 
cocktail (Roche), 1 X phosphatase inhibitor (1 mM sodium pyrophosphate, 1 mM sodium 
molybdate, 10 mM sodium fluoride), 1 mM sodium vanadate (Sigma-Aldrich) and 1 mM 
phenylmethylsulfonyl fluoride (Sigma-Aldrich), aliquoted and stored at -80˚C. Protein 
concentrations in nuclear and cytoplasmic extracts were determined using Bradford’s protein assay 
(Bio-rad) as per the manufacturer’s protocol. Extracts were subjected to immunoblotting, as 
described above. 
2.2.15 Immunofluoresence microscopy 
Primary keratinocytes were plated out in 24-well plates containing circular coverslips overnight, 
after which they were stimulated with 30 μg/ml poly(IC) or 100 ng/ml FSL-1 for 4 h, or were left 
untreated. Cells were fixed using 4% paraformaldehyde for 15 min, before incubating in blocking 
buffer (5% FBS, 1% Triton-X100 in PBS). Immunofluorescence staining was performed using a 
rabbit anti-IRF6 antibody (1 in 250 dilution in blocking buffer), followed by a goat anti-rabbit 
Alexa-647-conjugated (Invitrogen) secondary antibody. Cells were also stained with 4', 6-
diamidino-2-phenylindole (DAPI) (1 µg/ml, Sigma-Aldrich) and 6.6 mg/ml phalloidin (Alexa-594, 
Invitrogen). Coverslips were mounted on glass slides using mounting media (Dako, Glostrup, 
Denmark) and sealed using nail polish. Images were captured at 100X using an oil immersion 
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objective and a Carl Zeiss Meta Inverted LSM 510 microscope (Carl Zeiss, Jena, Germany). Levels 
of cytoplasmic and nuclear IRF6 in control and stimulated cells were quantified using ImageJ 1.45s 
software (National Institutes of Health, Bethesda, MD, USA). Samples were blinded by Mr. Daniel 
Hohenhaus (Institute for Molecular Bioscience, University of Queensland), prior to quantification. 
2.2.16 Flow Cytometry 
RAW-ELAM cells were cultured in complete growth media (Section 2.2.1.8) overnight (1 X 106 
cells/well of a 6-well plate), after which they were stimulated with zymosan, Pam3Cys or LPS as 
per Section 2.15 for 6 h. Cells were then washed and harvested in PBS and fixed in 2% 
paraformaldehyde for 5 min at room temperature. Following this, cells were centrifuged at 500 g for 
5 min and resuspended in PBS. Cells were passed through a 40 µm cell strainer (BD Biosciences) to 
separate out clumps and GFP levels (mean fluorescence intensity) was calculated using FACS 
CantoII flow cytometer (BD Biosciences). Data collected were analysed using FlowJo 9.4.4 
software (Tree Star, Ashland, OR, USA). 
2.2.17 Immunohistochemistry (IHC) 
IHC was performed on 7 μm sections from wounded adult mouse skin tissue (kindly provided by 
A/Prof Kiarash Khosrotehrani, University of Queensland). The sections were de-waxed using 
xylene and were rehydrated in a gradient of ethanol (100, 95, 80 and 70%). Antigen retrieval was 
also performed using the boiling method; slides were boiled in sodium citrate buffer (10 mM Tri-
sodium citrate, 0.05% Tween 20, pH 9.0) for 10 min, after which they were incubated at room 
temperature for 30 min to enable them to cool down. Hydrogen peroxide (0.3%) (Sigma-Aldrich) 
treatment was used to quench endogenous peroxidase activity. Slides were blocked in 2% heat-
inactivated FBS in PBS for 1 h. The primary antibody (anti-IRF6) was diluted 1:1200 times (Table 
2.2) in the blocking solution. Approximately 200 μl of antibody was added to each section, and 
tissues were incubated overnight at 40C. A secondary biotinylated α-rabbit antibody was diluted in 
blocking solution, as per the details in Table 2.2, and added to the sections for 1 h, followed by 
incubation with ABC Reagent (Vector laboratories, Burlingame, CA, USA) for 30 min. The DAB-
Plus Substrate kit (Vector Laboratories) was used to visualize reactions. The slides were then 
dehydrated using gradient of ethanol (70, 80 and 100%) and mounted using a xylene-based 
mounting media (United Biosciences, Carindale, QLD, Australia).  
2.2.18 Pathogen infection assays 
Primary keratinocytes were cultured in antibiotic-free media for at least 2 passages, prior to their 
use in infection assays. Cells were plated out one d prior to infection. On the following d, cells were 
challenged with GAS strain JRS4 at multiplicity of infection of 30. JRS4 (Nakagawa, Amano et al. 
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2004) were grown in Todd-Hewitt containing 0.2% yeast extract (THY) medium at 37°C by Dr. 
Timothy Barnett (University of Queensland). Following infections, all media was replaced with 
media containing 100 µg/ml gentamycin to kill all extra-cellular bacteria. To assess intracellular 
bacterial loads, cell lysates were harvested at 4 and 8 h post-infection using 0.25% trypsin and 
0.025% Triton-X100. These were plated out onto THY agar plates. Plates were incubated overnight 
at 37˚C and intracellular bacterial loads of JRS4 were calculated. 
2.2.19 Data presentation and statistical analyses 
Where data were combined from 3 or more independent experiments, statistical analysis was 
performed using Prism6 software (Graphpad, San Diego, CA, USA). Error bars and statistical tests 
used for individual datasets are listed within the relevant figure legends. p-values of 0.05 or less 
were considered as statistically significant. In some figures, data from individual experiments 
(usually representative of multiple experiments) are provided. In these cases, statistical analysis was 
not performed, but error bars from replicates within individual experiments are included to provide 
an indication of the variance within those individual experiments. 
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3 IRF6 expression and TLR responses in epithelial cell populations 
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3.1 Introduction 
Developmental studies in mouse, chicken, zebrafish and Xenopus laevis embryos have revealed that 
IRF6 is primarily expressed by epithelial cells of various tissues (Ben, Jabs et al. 2005, Ingraham, 
Kinoshita et al. 2006, Knight, Schutte et al. 2006, Richardson, Dixon et al. 2006). In mice, Irf6 
expression was reported in the epithelial cells of the developing palate like medial edges of the 
paired palatal shelves, palatal rugae, tooth germs, thyroglossal duct, and also in the external 
genitalia, hair follicles and skin throughout the body (Kondo, Schutte et al. 2002). Either an 
inactivating mutation in Irf6 (Richardson, Dixon et al. 2006) or global knock-out of the gene 
(Ingraham, Kinoshita et al. 2006) is also associated with abnormalities in skin, limb and craniofacial 
development in the mouse (Ingraham, Kinoshita et al. 2006, Richardson, Dixon et al. 2006). 
Keratinocytes from these mice are also hyperproliferative and fail to terminally differentiate 
(Ingraham, Kinoshita et al. 2006, Richardson, Dixon et al. 2006). In line with these studies, genetic 
variations in IRF6 are associated with various degrees of cleft lip, cleft palate, undifferentiated skin 
and syndactyly in humans (Kondo, Schutte et al. 2002, Zucchero, Cooper et al. 2004, Blanton, 
Cortez et al. 2005, Ghassibe, Bayet et al. 2005, Scapoli, Palmieri et al. 2005, Srichomthong, 
Siriwan et al. 2005, Park, McIntosh et al. 2007, Jugessur, Shi et al. 2009). However, a detailed 
analysis of IRF6 expression in various human epithelial cell types has not been performed.  
As discussed in Chapter 1, several studies have shown that some epithelial cell types possess 
functional TLRs and initiate inflammatory responses upon pathogen invasion. IRFs are important 
components within TLR signalling pathways, and IRF1, IRF3 and IRF7 have been linked to TLR3, 
TLR4, TLR7 and TLR9 signalling (Taniguchi, Ogasawara et al. 2001, Moynagh 2005, Tamura, 
Yanai et al. 2008). IRFs have also been shown to impart cell-type specificity within TLR signalling 
(Taniguchi, Ogasawara et al. 2001, Moynagh 2005, Tamura, Yanai et al. 2008). IRF6 has not been 
studied in the context of innate immunity and TLR signalling. Given that it is primarily expressed in 
the epithelial cells in mouse, chicken and zebrafish and that IRFs impart cell-type specificity in 
TLR signalling, the central hypothesis of this thesis was that IRF6 is an epithelial cell-specific 
regulator of TLR signalling. Thus, the first aim of this chapter was to characterize IRF6 expression 
patterns in a panel of human epithelial cell lines. Once this information was determined, 
responsiveness to a panel of TLR agonists was examined, with a focus on regulated expression of 
well-characterized IRF target genes. 
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3.2 Results 
3.2.1 Human keratinocytes express high levels of IRF6 mRNA and protein 
For characterization of IRF6 expression patterns, a panel of human epithelial cell lines from diverse 
anatomical locations was examined. For comparison, gene expression was also analyzed in human 
monocytic cells (THP-1 cells) and macrophage-like cells (PMA-differentiated THP-1 cells), which 
are known to express other IRF family members (Honda and Taniguchi 2006). IRF6 mRNA 
expression, relative to the housekeeping gene HPRT, was analyzed by qPCR. Figure 3.1A shows 
IRF6 expression in different epithelial cell lines and the two myeloid cell line populations. IRF6 
mRNA expression was particularly elevated in keratinocytes (HaCaT), and was also expressed by 
bladder (T24), colon (CaCo-2, HT29, T84), stomach (AGS, MKN28) and breast epithelial cell lines 
(MCF-7) (Figure 3.1A). IRF6 mRNA was not detected in kidney (A498, HEK293), respiratory 
(A549, BEAS-2B), cervical (HeLa) epithelial cell lines, or in the myeloid line THP-1 (Figure 
3.1A). Hence, IRF6 was highly expressed in certain epithelial cells, but was not detected in the 
myeloid cell-lines. As controls, IRF3 and IRF8 mRNA levels were also assessed in these cell lines. 
IRF3 is a ubiquitously expressed member of the IRF family (Au, Moore et al. 1995), while IRF8 
expression is restricted to myeloid cell populations (Tamura and Ozato 2002). As expected, IRF3 
mRNA was expressed in all the cell types examined, consistent with its presumed ubiquitous 
expression (Figure 3.1A). Nonetheless, the levels were somewhat lower in HEK293 cells, HeLa 
and T84 cells, as compared to the other epithelial cells examined. Also as expected, IRF8 mRNA 
expression was largely restricted to the myeloid cell types (THP-1 and PMA-differentiated THP-1 
cells), although AGS, CaCo-2 and T84 stomach epithelial cells also expressed low levels of this 
transcription factor. However, the expression in the myeloid cell lines was ~10 fold higher than in 
these cells (Figure 3.1A). Thus, IRF family members show distinct cellular expression profiles, 
with IRF6 being expressed by certain epithelial cell populations, but not myeloid cells.  
The initial analysis of human epithelial cell lines indicated that IRF6 mRNA was highly expressed 
by keratinocytes (HaCaT cells). Thus, primary human keratinocytes were next analysed to further 
validate these findings. For comparison, IRF6 mRNA levels were also quantified in primary human 
monocytes and monocyte-derived macrophages. Consistent with the cell line data, IRF6 mRNA was 
highly expressed in primary keratinocytes but was not detected in primary monocytes or 
macrophages (Figure 3.1B). Again, IRF3 mRNA was present in all cell populations and IRF8 
mRNA was restricted to primary monocytes and macrophages (Figure 3.1B). These data from 
primary cells are thus consistent with the cell line data. 
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Figure 3.1. Human keratinocytes express high levels of IRF6. mRNA levels of IRF6, IRF3 and 
IRF8, relative to HPRT, were examined by qPCR in a panel of (A) epithelial cell-lines and (B) 
primary cells. Data represents mean ± SEM of 3 independent experiments, ** p < 0.01, *** p ≤ 
0.001, ****p≤ 0.0001 (compared to all other cell populations) (one-way analysis of variance 
(ANOVA), followed by Tukey’s test), ND indicates that no signal for the indicated gene was 
detected after 35 PCR cycles in the sample. (C) Whole cell lysates from the indicated cell lines 
were subjected to SDS PAGE and immunoblotting for IRF6 and GAPDH. Data are representative 
of 3 independent experiments. 
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To determine whether IRF6 protein expression mirrored mRNA expression, immunoblotting was 
next performed. IRF6 was robustly expressed by primary keratinocytes and the keratinocyte cell-
line HaCaT, but was absent in T24, CaCo-2 and HEK293 cells (Figure 3.1C). These data are 
generally consistent with the mRNA expression profiles as both primary keratinocytes and HaCaT 
expressed high levels of IRF6 mRNA and protein, whereas HEK293 cells did not. However, the 
mRNA and protein expression data were not always consistent, since T24 and CaCo-2 cells 
expressed some IRF6 mRNA but did not express detectable levels of IRF6 protein. Thus, consistent 
with previous studies in mouse and other species (Ingraham, Kinoshita et al. 2006, Richardson, 
Dixon et al. 2006), IRF6 expression is enriched in keratinocytes in humans.  
3.2.2 The TLR3 agonist poly(IC) triggers IL-8 production from human keratinocytes  
Given the above findings, responses of epithelial cells that express IRF6 protein (primary 
keratinocytes, HaCaT cells) to agonists of different TLRs were next assessed. One previous study 
reported that primary keratinocytes and HaCaT cells responded to agonists of TLR3, TLR5 and 
TLR1/2 by secreting IL-8 (Kollisch, Kalali et al. 2005). Keratinocytes have also been reported to 
respond to the TLR3 ligand Poly(IC) with activation and nuclear translocation of IRF3 and 
production of IFN-α and IFN-β (Dai, Sayama et al. 2006, Lebre, van der Aar et al. 2007). To 
corroborate TLR responsiveness of keratinocytes, a systematic comparison of human keratinocyte 
responses to different TLR agonists was performed. IL-8/CXCL8 was first examined, since this 
neutrophil-attracting CXC chemokine is secreted by epithelial cells in response to a wide range of 
stimuli (Eckmann, Kagnoff et al. 1993, Schulte, Wattiau et al. 1996, Kollisch, Kalali et al. 2005, 
Olaru and Jensen 2010). Primary keratinocytes and HaCaT cells were stimulated with agonists of 
TLR3 (poly(IC)), TLR2/Dectin 1 (zymosan), TLR5 (flagellin), TLR1/2 (Pam3Cys), TLR9 (CpG 
DNA) and TLR4 (LPS), after which cell supernatants were collected at 4, 8 and 24 h post 
stimulation, and secreted IL-8 levels were measured by ELISA. The TLR3 ligand poly(IC) 
triggered robust IL-8 production in both primary keratinocytes and HaCaT cells (Figure 3.2). IL-8 
induction was maximal at 24 h post stimulation in primary keratinocytes, while it peaked at 8 hours 
post stimulation in HaCaT cells. However, neither of these cell populations responded to the other 
PAMPs examined, at least in terms of IL-8 secretion. These data suggest that the primary functional 
TLR receptor in keratinocytes appears to be TLR3, although agonists for all TLRs were not 
examined. Furthermore, it should be noted that cytoplasmic poly(IC) can also activate RIG-I and 
MDA-5 (Kato, Takeuchi et al. 2008), although treatment with extracellular poly(IC) as performed 
here preferentially activates endosomal TLR3 (Alexopoulou, Holt et al. 2001). 
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Figure 3.2. The TLR3 agonist poly(IC) triggers IL-8 production from human keratinocytes. 
Secreted IL-8 levels released from (A) primary keratinocytes and (B) HaCaT cells after stimulation 
with poly(C) (30 μg/ml), zymosan (100 µg/ml), flagellin (10 ng/ml), Pam3Cys (15 ng/ml), CpG 
2006 (0.3 µM), LPS (100 ng/ml) were quantified using ELISA. Data represents mean ± SD of 
experimental triplicates and is representative of 3 independent experiments.  
 
3.2.3 Poly(IC) upregulates the expression of a sub-set of TLR target genes in primary 
human keratinocytes 
IRF family members typically promote TLR-inducible expression of IFN-β and members of the IL-
12 cytokine family (Honda and Taniguchi 2006). I therefore next examined TLR-regulated mRNA 
expression of IFN-β, as well as the IL-12 family (IL-12p40, IL-12p35, IL-23p19, EBI3 and IL-
27p28) in IRF6-expressing human keratinocytes. IL-8 mRNA was also monitored, given that 
poly(IC) triggered robust IL-8 secretion in these cells (Figure 3.2). The chemokines 
CCL5/RANTES and CCL20 were also examined because several studies have demonstrated that 
IRF family members activate CCL5 gene expression (Lin, Heylbroeck et al. 1999, Genin, Algarte et 
al. 2000, Melchjorsen and Paludan 2003), and because CCL20 has a well-documented role in 
promoting leukocyte recruitment to epithelial tissues (Williams 2006, Ito, Carson et al. 2011). 
Primary keratinocytes responded to Poly(IC) stimulation with robust up-regulation of mRNAs for 
IFN-β (>10,000 fold), IL-8 (>1,000 fold), IL-23p19 (>40 fold), EBI3 (>100 fold), CCL5 (>10,000 
fold) and CCL20 (>60 fold) (Figure 3.3). IL-12p35 mRNA was also very modestly increased (~4 
fold). Maximal responses for these genes were apparent at 24 h post stimulation, except for IFN-β, 
which peaked at the earliest time point examined (4 h post stimulation). Apart from polyIC, the 
TLR5 ligand flagellin caused a much less pronounced upregulation of IL-8 (~100 fold) and CCL20 
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mRNAs (~30 fold) at 4 h post-stimulation. For the TLR target genes examined, these cells were not 
particularly responsive to the other TLR agonists included in this analysis.  
 
Figure 3.3. Poly(IC) triggers robust gene expression changes in primary keratinocytes. 
Primary keratinocytes were stimulated with the indicated TLR ligands (concentrations used were 
identical to that used in Figure 3.2). Total RNA was collected at the indicated time points and 
mRNA levels of potential IRF6 target genes (A) IL-8, (B) IFN-β, (C) CCL5, (D) CCL20, (E) IL-
23p19, (F) EBI3, (G) IL-12p40, (H) IL-12p35 and (I) IL-27p28 were quantified, relative to HPRT, 
using qPCR. Data represents mean ± SEM from 3 independent experiments, * p ≤ 0.05, ** p < 0.01, 
*** p ≤ 0.001, **** p ≤ 0.0001 as compared to unstimulated control (two-way ANOVA, followed 
by Tukey’s test).  
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3.2.4 HaCaT cells behave similarly to primary keratinocytes in responsiveness to different 
TLR agonists 
The above data indicated that poly(IC) upregulated the mRNA expression of a panel of IRF 
candidate genes in primary human keratinocytes. To determine if similar results were apparent in 
the human keratinocyte cell-line HaCaT, a similar analysis was performed. Similar results were 
indeed apparent, with poly(IC) upregulating mRNA expression of IFN-β (65.3 fold), IL-8 (54.8 
fold), IL-23p19 (63.7 fold), EBI3 (80 fold), CCL5 (680 fold) and CCL20 (1400 fold) (Figure 3.4). 
Maximal responses for these genes were apparent at 8 h post-stimulation, except for IFN-β and 
EBI3, which peaked at 4 h and 24 h post-stimulation, respectively. Apart from poly(IC), most of the 
other TLR ligands had only modest effects on inflammatory gene expression in HaCaT cells. CpG 
DNA and LPS both caused a delayed increase in IL-12p35 and IL-12p40 expression (Figure 3.4G-
H), but these responses were very weak. Similarly, zymosan only very modestly increased IFN-β 
(Figure 3.4B) and IL-12p35 mRNA levels (Figure 3.4H). Thus, consistent with the primary 
keratinocyte data, HaCaT cells responded robustly to poly(IC), whereas agonists for other TLRs 
had only modest effects, if any (Figure 3.4).  
3.2.5 Poly(IC)-inducible IL-23p19 mRNA expression does not occur in IRF6-deficient T24 
cells 
Since T24 cells did not express detectable IRF6 protein (Figure 3.1C), I next assessed whether 
there were any obvious differences in TLR responsiveness of these cells. As with primary 
keratinocytes and HaCaT cells, poly(IC) robustly upregulated IFN-β (>3000 fold), CCL5 (25 fold), 
CCL20 (250 fold), EBI3 (50 fold) and IL-8 (16.7 fold) mRNA expression in T24 cells (Figure 3.5). 
In contrast, IL-23p19 mRNA was not regulated by this stimulus in these cells. The upregulation of 
IL-12p35 mRNA by poly(IC) (12 fold) was also somewhat stronger than was apparent for primary 
keratinocytes and HaCaT cells. T24 cells did not robustly respond to other TLR agonists examined, 
except for flagellin, Pam3Cys and CpG DNA which induced EBI3 expression very modestly at 24 
h. In summary, like keratinocytes, T24 cells primarily responded to poly(IC), but the inducible IL-
23p19 response was absent from these cells. Thus, T24 cells can also be used as a cellular system to 
overexpress IRF6 and determine the effects on potential IRF6 target genes. 
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Figure 3.4. HaCaT cells respond to the TLR3 agonist poly(IC). HaCaT cells were stimulated 
with the indicated TLR ligands (concentrations used were identical to that used in Figure 3.2). 
Total RNA was collected at the indicated time points and mRNA levels of potential IRF6 target 
genes (A) IL-8 (B) IFN-β, (C) CCL5, (D) CCL20, (E) IL-23p19, (F) EBI3, (G) IL-12p40, (H) IL-
12p35 and (I) IL-27p28 were quantified, relative to HPRT, using qPCR. Data represents mean ± 
SEM from 3 independent experiments, * p ≤ 0.05, ** p < 0.01, *** p ≤ 0.001, **** p ≤ 0.0001 as 
compared to unstimulated controls (two-way ANOVA, followed by Tukey’s test).  
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Figure 3.5. T24 cells respond to poly(IC), but do not induce IL-23p19 mRNA expression upon 
poly(IC) stimulation. T24 cells were stimulated with various TLR ligands (concentrations used 
were identical to that used in Figure 3.2). Total RNA was collected at indicated timepoints and 
mRNA levels of potential IRF6 target genes (A) IL-8, (B) IFN-β, (C) CCL5, (D) CCL20, (E) IL-
23p19,  (F) EBI3, (G) IL-12p40, (H) IL-12p35 and (I) IL-27p28 were quantified, relative to HPRT, 
using qPCR. Data represents mean ± SEM from 3 independent experiments, ** p < 0.01, *** p ≤ 
0.001, **** p ≤ 0.0001 as compared to unstimulated controls (two-way ANOVA, followed by 
Tukey’s test). 
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3.2.6 Confirmation of activity of TLR agonists on RAW-ELAM cells 
For the three cell types examined, poly(IC) triggered robust responses, whereas, in some of the cell 
types, very weak responses for some genes were also apparent when flagellin, LPS or CpG DNA 
were used as stimuli. To ensure that the other TLR agonists (Pam3Cys, zymosan) were indeed 
active at the concentrations used, the effects of these PAMPs were examined using a control cell 
line. Since RAW-ELAM cells respond to activation signals with NF-B-dependent expression of 
green fluorescent protein (GFP) (Stacey, Young et al. 2003), these cells provide a convenient read-
out for screening TLR agonist activity. Hence, RAW-ELAM cells were stimulated with Pam3Cys 
or zymosan, as well as LPS as a positive control, and inducible GFP expression was monitored 
using flow cytometry analysis. All three stimuli upregulated GFP expression in these cells (Figure 
3.6A-D). This therefore confirms that both Pam3Cys and zymosan were active at the concentrations 
used in the epithelial cell experiments. Overall, these data imply that poly(IC) was the only stimulus 
triggering robust regulated gene expression in human keratinocytes. 
 
Figure 3.6. Zymosan, Pam3Cys and LPS were active on RAW-ELAM cells. RAW-ELAM cells 
were stimulated with zymosan (100 μg/ml), Pam3Cys (15 ng/ml) or LPS (100 ng/ml), or were left 
unstimulated for 8 h. Mean fluorescence intensity of GFP was analysed using flow cytometry. 
Unstimulated control cells were gated in order to determine % cells responding to a particular 
stimulus. The red histogram (A-C) shows untreated cells and the blue overlay shows (A) zymosan, 
(B) Pam3Cys or (C) LPS stimulated cells. (D) Data represents the mean fluorescence intensity of 
unstimulated and stimulated cells. Data was collected from > 5000 events for each sample and 
represents a single experiment.  
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3.2.7 IRF6 expression during keratinocyte differentiation 
In contrast to my findings, some studies have reported that certain MyD88-triggering TLR agonists 
do activate keratinocytes, with IL-8 secretion being observed (Pivarcsi, Bodai et al. 2003, Kollisch, 
Kalali et al. 2005, Lebre, van der Aar et al. 2007, Miller and Modlin 2007, Niebuhr, Baumert et al. 
2010). It was therefore considered that cellular differentiation status could be an important variable 
modifying TLR responsiveness. Furthermore, IRF6 is known to play a critical role in keratinocyte 
differentiation (Richardson, Dixon et al. 2006, Restivo, Nguyen et al. 2011, Biggs, Rhea et al. 
2012), and so it is possible that the role(s) of IRF6 in TLR responses is impacted by the 
differentiation state. Therefore, this variable was next examined. IRF6 expression was first 
examined in proliferating and differentiated primary keratinocytes. The Rho-kinase inhibitor, 
Y27632, has been shown to increase keratinocyte proliferation and prevent cells from terminally 
differentiating (Terunuma, Limgala et al. 2010). Therefore, Y27632 was included in primary 
keratinocyte cultures to maintain them in an undifferentiated state. It is well established in the 
literature that Ca2+ influx into keratinocytes promotes differentiation, for example by promoting 
phospholipase C–γ1-mediated transcription of keratinocyte differentiation markers such as 
involucrin (IVL) (Hennings, Holbrook et al. 1980, Hennings, Michael et al. 1980, Boyce and Ham 
1983, Watt 1983, Shipley and Pittelkow 1987, Ng, Su et al. 1996). Hence, extracellular Ca2+ was 
used to trigger keratinocyte differentiation.  
Keratinocytes were cultured in media containing Y27632 (5 μM) or Ca2+ (2 mM CaCl2), or were 
left untreated for 24 h. RNA was harvested and qPCR was performed to measure gene expression of 
IRF6. IVL, which is a known marker for keratinocyte differentiation (Watt 1983, Murphy, Flynn et 
al. 1984), was used as a control gene to monitor the differentiation of the cells. IRF6 mRNA 
expression was found to be significantly higher in Ca2+-treated keratinocytes when compared to 
Y27632-treated or untreated keratinocytes (Figure 3.7A). As expected, IVL mRNA expression was 
high in Ca2+ treated cells, as compared to Y27632 or untreated cells (Figure 3.7B). Hence, IRF6 
mRNA expression was higher in differentiated cells when compared to proliferating cells, as 
anticipated. To determine whether this effect was also apparent at the protein level, IRF6 protein 
levels were examined in undifferentiated and differentiated keratinocytes using western blotting. 
Consistent with the gene expression data, IRF6 protein was high in differentiated cells when 
compared to proliferating cells, which expressed low levels of IRF6 protein (Figure 3.7C). IRF6 
expression was also detected in untreated cells, however the level of expression was less when 
compared to the differentiated cells.  
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Figure 3.7. IRF6 expression in primary keratinocytes during differentiation. Levels of (A) 
IRF6 and (B) IVL mRNAs (relative to HPRT) in proliferating (Y27632-treated; 5 µM for 24 h) and 
differentiated (Ca2+-treated; 2 mM for 24 h) primary keratinocytes were determined by qPCR. Data 
represents mean ± SEM of 3 independent experiments, * p < 0.05, ** p < 0.01 (compared to 
untreated control) (one-way ANOVA, followed by Tukey’s test). (C) Whole cell lysates from 
proliferating and differentiated keratinocytes were subjected to SDS PAGE, and immunoblotting for 
IRF6 and GAPDH was performed. Data are representative of 3 independent experiments. 
 
3.2.8 Differentiation status of primary human keratinocytes does not affect TLR mRNA 
expression 
As expected, IRF6 mRNA and protein expression was regulated during keratinocyte differentiation. 
I next used qPCR to determine whether mRNA expression of any of the TLRs was similarly 
regulated. Figure 3.8 shows that TLR expression was comparable across all three cell populations 
examined. This indicates that any differences that may exist in the ability of these cells to respond 
to TLR agonists is unlikely to result from regulated TLR expression. In contrast, differential IRF6 
expression does have the potential to influence TLR responsiveness.  
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Figure 3.8. TLR mRNA expression is not regulated during primary human keratinocyte 
differentiation. mRNA levels of TLR1 – TLR10 (relative to HPRT) in proliferating (Y27632-
treated; 5 µM for 24 h) and differentiated (Ca2+-treated; 2 mM for 24 h) were assessed by qPCR. 
Data represents mean ± range of 2 independent experiments.  
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3.2.9 Differentiation status of primary human keratinocytes does not greatly influence 
poly(IC)-responsiveness 
To determine if keratinocyte differentiation affects responses to the TLR3 agonist poly(IC), 
inducible IL-8 production from undifferentiated and differentiated cells was measured by ELISA. 
As previously observed (Figure 3.2), poly(IC) strongly upregulated IL-8 production from these 
cells, with a maximal response observed at 24 hours post-stimulation. However, there was no 
significant difference observed in the levels of IL-8 secreted in undifferentiated versus 
differentiated cells, although differentiated cells showed marginally higher IL-8 levels (Figure 3.9). 
This suggests that, at least for IL-8 release, differentiation status of keratinocytes does not influence 
poly(IC)/TLR3 responsiveness. In similar experiments, the effects of differentiation status on 
MyD88-dependent responses were also assessed (see Chapter 5.2.3). 
 
Figure 3.9. Differentiation status does not affect poly(IC)-inducible IL-8 production from 
primary keratinocytes. IL-8 chemokine levels released from proliferating (Y27632-treated; 5 µM 
for 24 h) and differentiated (Ca2+-treated; 2 mM for 24 h) primary keratinocytes stimulated with 
poly(IC) (30 μg/ml) were quantified using ELISA. Data represents mean ± SEM of 3 independent 
experiments. 
 
3.3 Summary and discussion of Chapter 3 
3.3.1 IRF6 expression is enriched in keratinocytes 
In humans, IRF6 expression has been reported in oral, epidermal and mammary epithelial cells 
(Zucchero, Cooper et al. 2003, Zucchero, Cooper et al. 2004, Bailey, Margaryan et al. 2009, 
Richardson, Dixon et al. 2009, Botti, Spallone et al. 2011, Restivo, Nguyen et al. 2011). However, a 
detailed expression analysis of IRF6 mRNA and protein in a panel of epithelial cells had not 
previously been performed. This analysis was undertaken because of the diversity of anatomical 
locations and functions of epithelial tissues. The finding that IRF6 was expressed at particularly 
elevated levels in keratinocytes is consistent with findings from mouse models (Ingraham, 
Kinoshita et al. 2006, Richardson, Dixon et al. 2006), as well as phenotypic effects of IRF6 
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deficiency in humans (Kondo, Schutte et al. 2002, Botti, Spallone et al. 2011, Restivo, Nguyen et 
al. 2011). Consistent with prior expectation, IRF3 mRNA was ubiquitously expressed in all cell 
types examined, whilst IRF8 mRNA was largely restricted to myeloid cells (THP-1 and PMA-
differentiated THP-1). The low level of IRF8 mRNA expression in AGS, CaCo-2 and T84 
stomach/colon epithelial cells is consistent with its reported constitutive expression in human colon 
carcinoma cells (Yang, Thangaraju et al. 2007, McGough, Yang et al. 2008). 
One interesting observation from this analysis was that IRF6 mRNA expression did not always 
track with IRF6 protein expression. Although primary keratinocytes and HaCaT cells both 
expressed high levels of this transcription factor at the mRNA and protein level, T24 and CaCo-2 
cells expressed IRF6 mRNA, whereas protein expression was not detectable by immunoblotting. 
Previous studies have shown that loss of IRF6 expression results in more invasive and progressive 
SCCs (Botti, Spallone et al. 2011). Cell proliferation leads to IRF6 phosphorylation, and 
subsequently to cause its proteosomal degradation (Bailey, Abbott et al. 2008), which may 
contribute to the loss of IRF6 expression in progressive tumours (Botti, Spallone et al. 2011). 
Hence, it is conceivable that loss of IRF6 protein expression may contribute to transformation 
and/or metastatic potential of other epithelial cancer cells, such as T24 and/or CaCo-2 cells. 
3.3.2 Human keratinocytes are responsive to the TLR3 agonist poly(IC) 
Since human keratinocytes were shown to express high levels of IRF6, these cells were used as a 
system to investigate possible IRF6 functions in TLR responses. HaCaT are a spontaneously 
immortalised human adult skin cells that has characteristics of normal basal keratinocytes 
(Boukamp, Petrussevska et al. 1988). Thus, they are widely used as a cell line model of 
keratinocytes (Schurer, Kohne et al. 1993, Lehmann 1997, Altenburger and Kissel 1999, Boukamp 
2005, Deyrieux and Wilson 2007, Wiegand, Abel et al. 2009, Ridd, Dhir et al. 2010, Magcwebeba, 
Riedel et al. 2012, McNeilly, Woods et al. 2012), and were also used in my experiments in addition 
to primary keratinocytes. Initial characterization showed that both primary keratinocytes and 
HaCaT cells were primarily responsive to the TLR3 agonist poly(IC); IFN-β, IL-23p19, IL-8, CCL5 
and CCL20 mRNAs were all robustly up-regulated. As previously noted, several studies have 
demonstrated that the cytoplasmic RNA sensors RIG-I and MDA-5 also respond to intracellular 
poly(IC) (Kato, Takeuchi et al. 2008). However, since extracellular poly(IC) was added to cells, 
rather than being transfected in, it is unlikely that these receptors are responsible for the effects 
observed in this study. Nonetheless, future experiments should carefully address the requirement for 
TLR3 versus the cytoplasmic RNA sensors in mediating poly(IC)-inducible gene expression in 
keratinocytes. 
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A limited number of previous studies have examined TLR responsiveness in human keratinocytes. 
Keratinocytes have been shown to produce IL-8 upon poly(IC), Pam3Cys, flagellin, zymosan, LPS 
and CpG-DNA stimulation (Kollisch, Kalali et al. 2005, Lebre, van der Aar et al. 2007, Miller and 
Modlin 2007). Kollisch et al compared the responses of both primary keratinocytes and HaCaT to 
various TLR ligands and found that these cells responded to the TLR3 ligand poly(IC), the TLR1/2 
ligand Pam3Cys and the TLR5 ligand flagellin with inducible IL-8 production (Kollisch, Kalali et 
al. 2005). Several other studies have looked at responses of different TLR ligands in keratinocytes. 
TLR5 ligand flagellin stimulation induced TNF-α, TSLP and β-defensins 2 and 3 expression in 
primary keratinocytes (Baker, Ovigne et al. 2003, Miller, Sorensen et al. 2005, Lebre, van der Aar 
et al. 2007, Le, Takai et al. 2011, Xie, Takai et al. 2012), while in my experiments it was mostly 
inactive. TLR2 activation, by LTA or PGN, activated NF-κB dependent IL-8 and inducible nitric 
oxide synthase (Pivarcsi, Bodai et al. 2003). Pam3Cys (TLR1/2 ligand) stimulation induced the 
secretion of CCL20, CCL2, matrix metallopeptidase 9 and IL-8 in primary kerationocytes (Niebuhr, 
Baumert et al. 2010). Primary keratinocytes and HaCaT cells were also shown to be responsive to 
TLR2/Dectin 1 ligand zymosan by inducing IL-8 and CCL20 production (Pivarcsi, Koreck et al. 
2004). The TLR4 ligand LPS has also been shown to activate keratinocytes to release pro-
inflammatory cytokines like IL-8, IL-1α, IL-1β, TNF-α, CCL2 and CCL20, and to upregulate 
expression of intercellular adhesion molecule 1 (Song, Park et al. 2002, Kollisch, Kalali et al. 2005, 
Lebre, van der Aar et al. 2007). Stimulation of keratinocytes with CpG DNA also induced IL-8, 
CCL2, CCL20, CXCL9 and CXCL10 (Kollisch, Kalali et al. 2005, Miller, Sorensen et al. 2005, 
Lebre, van der Aar et al. 2007). In summary, various studies have reported that keratinocytes were 
responsive to many MyD88-dependent TLR agonists.  
However, most of these agonists did not have any pronounced effects on expression of any genes in 
keratinocytes in my experiments. Although the activities of these TLR agonists were confirmed in 
another cell-based assay (RAW-ELAM cells), it is possible that macrophages have enhanced 
sensitivity to these stimuli as compared to keratinocytes. Thus, it would have been useful to 
examine keratinocyte responses across concentration ranges for various TLR ligands, including 
Pam3Cys and zymosan. The outputs examined in these studies (IFN-, IL-12 family members, 
specific chemokines) largely reflected the focus on the identification of potential IRF6 target genes. 
Thus, it is possible that keratinocytes do respond to some of the other TLR ligands examined, but 
with different genes responding. This would seem unlikely given that some of the genes (e.g. IL-8, 
CCL20) are generically upregulated by most TLR agonists; nonetheless, this possibility cannot be 
formally excluded. 
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Some differences in responses of primary keratinocytes versus HaCaT cells were noted. Primary 
keratinocytes showed the most pronounced upregulation of IL-8, CCL5, IL-23p19 and EBI3 
mRNAs at 24 hours post stimulation, whereas in HaCaT cells maximal responses occurred at 8 
hours post-stimulation (with the exception of EBI3). Primary keratinocytes also showed a delayed 
upregulation of IL-12p35 at 24 hours, whilst this response was not observed in HaCaT cells. 
However, both cell populations showed robust upregulation of IFN-β at 4 hours post-stimulation. 
Interestingly, certain differences in primary keratinocytes and HaCaT cell responses to TLR ligands 
have been reported previously. The levels of poly(IC)-inducible IL-8 and CCL20 were found to be 
much higher in primary keratinocytes, when compared to HaCaT cells (Olaru and Jensen 2010). 
Primary keratinocytes and HaCaT cells also respond differently to various stress signals and 
microbial agents (Bari, Bacsa et al. 2011). Ultraviolet (UV) radiation induced stress caused robust 
upregulation of TNF-α production in primary keratinocytes, while it was very mildly produced by 
HaCaT cells (Bari, Bacsa et al. 2011, Muthusamy and Piva 2013). In contrary, UV-exposure and 
IL-1α treatment in conjunction, showed a greater increase in TNF-α production in HaCaT cells, 
while only modestly having an effect on primary keratinocytes (Muthusamy and Piva 2013). 
Nonetheless, in general TLR responsiveness was quite similar between these two cell populations. 
Since T24 cells did not express detectable IRF6 protein, TLR responsiveness was examined in these 
cells to screen for possible differences that might be attributable to this transcription factor. T24 cell 
TLR responses were actually quite similar to keratinocytes; these cells also primarily responded to 
poly(IC) with upregulation of IL-8, IFN-β and IL-12p35 mRNAs. In contrast, poly(IC) did not 
upregulate IL-23p19 mRNA expression in these cells, in contrast to the findings with keratinocytes. 
Hence, the possible involvement of IRF6 in regulating poly(IC)-inducible expression of this gene 
was subsequently investigated (Chapter 4).  
Interestingly, poly(IC) selectively regulated IL-23p19 and EBI3 mRNAs in keratinocytes, without 
any pronounced effect on other IL-12 family members (IL-12p35 was the only family member 
regulated, but the effect was very modest by comparison). The IL-12 family of cytokines have α 
and β sub-units that heterodimerize to form functional cytokines (Gee, Guzzo et al. 2009). Although 
IL-23p19 and EBI3 are α and β sub-units of this family, they have not previously been reported to 
form a functional heterodimer. Previously, EBI3 and IL-27p28 heterodimer, IL-27, were found to 
be co-expressed in macrophages and macrophage derived cells of granulomas (Larousserie, Pflanz 
et al. 2004), and subsequently studies identified it to have an immunosuppressive function in T cell 
activation (Stumhofer and Hunter 2008). Therefore, it is possible that IL-23p19 and EBI3, being 
induced in keratinocytes simultaneously, forms a functional heterodimer, and this is discussed 
further in Chapter 4 and Chapter 6. One previous study in IEC, using both in vivo and in vitro 
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systems, showed that pro-inflammatory mediators like IL-1α or TNF-α up-regulated the expression 
of IL-12p35, IL-23p19 and EBI3 (Maaser, Egan et al. 2004). EBI3 forms a non-covalently bound 
heterodimer with IL-12p35, however, the function of this cytokine is not well-characterized. This 
study also showed the IL-12p35 and EBI3 mRNA induction were not co-ordinately regulated, 
suggesting that IL-35 may not be the primary cytokine of the IL-12 family secreted by these cells 
(Maaser, Egan et al. 2004). However, they also found the IL-23p19 is secreted by these cells and its 
regulation paralleled that of EBI3 (Maaser, Egan et al. 2004). IL-23p19 expression, in the absence 
of IL-12p40, was also expressed in TNF-α activated endothelial cells, certain Th1- and Th2- 
polarised T cells and also in rheumatoid arthritis synovial fibroblasts (Brentano, Ospelt et al. 2009). 
This is in line with what I found in keratinocytes, where IL-23p19 and EBI3 were robustly 
upregulated in response to poly(IC), whilst IL-12p35 was modestly upregulated when compared to 
the other two family members.  
3.3.3 The differentiation status of keratinocytes does not affect TLR3 responsiveness 
A previous study in HaCaT cells showed that TLR2 and TLR4 mRNA was upregulated during 
keratinocyte differentiation (Pivarcsi, Koreck et al. 2004). Cell surface expression of TLR2 and 
TLR4 also increased. Another study showed that differentiation of keratinocytes permitted 
inducible expression of beta-defensin 2 and 3 in response to Staphylococcus epidermidis (Lai, 
Cogen et al. 2010). Finally, the keratinocyte growth and differentiation factor TGF-α upregulated 
the expression of TLR5 and TLR9 in primary keratinocytes, and enhanced the production of IL-8 
and beta-defensins in response to agonists of these receptors (Miller, Sorensen et al. 2005). 
Although I observed that IRF6 was upregulated during primary human keratinocyte differentiation, 
which is consistent with previous studies (Richardson, Dixon et al. 2006), I did not observe any 
effect of differentiation on TLR1-10 mRNA expression or responsiveness to poly(IC). This result 
contradicts the previous study in HaCaT cells that reported differences in TLR2 and TLR4 mRNA 
levels between undifferentiated and differentiated keratinocytes (Pivarcsi, Koreck et al. 2004). This 
may be because HaCaT cell lines are immortalized keratinocytes obtained from adult skin, whilst 
the differentiation studies in this chapter were performed using primary keratinocytes from neonatal 
skin. A previous study comparing foetal, neonatal and adult skin did reveal significant differences 
in TLR expression and responsiveness, with elevated TLR mRNA in neonatal keratinocytes as 
compared to those from adult skin (Iram, Mildner et al. 2012). This could therefore be one factor to 
consider, however, basal cells in both foetal and adult skin were reported to have similar expression 
of the TLRs. Given that I only examined expression of TLRs at the mRNA level, as well as 
poly(IC)-regulated IL-8 production, my data cannot discount the possibility that keratinocyte 
differentiation does impact certain TLR responses; this was further investigated within Chapter 5. 
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In the next chapter (Chapter 4), I pursued the possible involvement of IRF6 in regulating 
expression of TLR3-target genes, particularly IL-23p19. 
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4 IRF6 involvement in poly(IC)-regulated gene expression in keratinocytes 
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4.1 Introduction 
In the previous chapter (Chapter 3), I demonstrated that human keratinocytes express high levels of 
IRF6 and primarily respond to the TLR3 agonist poly(IC). In the TLR3 pathway, TRIF interacts 
directly with the TIR domain of TLR3 and mediates signalling (Yamamoto, Sato et al. 2003). Upon 
activation, the TRIF pathway leads to the activation of the serine/threonine kinase TBK-1, which in 
turn phosphorylates the transcription factor IRF3 (Fitzgerald, McWhirter et al. 2003, Fitzgerald, 
Rowe et al. 2003, Oshiumi, Matsumoto et al. 2003, Sato, Sugiyama et al. 2003). Activation of IRF3 
induces production of type I IFN (Au, Moore et al. 1995, Schafer, Lin et al. 1998). IFN-β, in 
particular, signals in an autocrine fashion to activate the transcription factors STAT1 and STAT2, 
which leads to activation of type I IFN target genes (Li, Leung et al. 1996, Su and David 2000). 
Type I IFN target genes mediate anti-viral responses, which are typically required for responses to 
pathogens activating TLR3 (Doyle, Vaidya et al. 2002, Doyle, O'Connell et al. 2003). Hence, IRF3 
mediates essential gene expression programs for host defence against pathogens. TRIF signalling is 
also able to activate NF-κB via TRAF6 (Jiang, Mak et al. 2004, Cusson-Hermance, Khurana et al. 
2005, Sasai, Oshiumi et al. 2005). The C-terminal domain of TRIF contains a receptor-interacting 
protein homotypic interaction motif. This motif is essential for interactions between TRIF and RIP1 
(Meylan, Burns et al. 2004, Kaiser and Offermann 2005). The RIP family is involved in NF-κB 
activation and in the absence of RIP1, TLR3- and TLR4-mediated NF-κB activation is impaired 
(Meylan, Burns et al. 2004). RIP1 undergoes K63-linked polyubiquitination and interacts with 
TRAF6 and TAK1, which results in NF-κB signalling (Ea, Deng et al. 2006, Li, Kobayashi et al. 
2006). Although IRF3 is the primary transcription factor driving IFN-β responses in TLR3 
signalling, other IRFs such as IRF1, IRF5 and IRF7 have also been shown to activate IFN-β and 
other IRF target genes (Barnes, Richards et al. 2004, Honda, Yanai et al. 2004, Kawai, Sato et al. 
2004, Honda, Ohba et al. 2005, Schoenemeyer, Barnes et al. 2005, Takaoka, Yanai et al. 2005). 
Importantly, NF-κB co-operates with IRF3 and IRF7 to enhance type I IFN production and anti-
viral responses (Maniatis, Falvo et al. 1998, Wathelet, Lin et al. 1998, Fitzgerald, Rowe et al. 2003).  
IRFs also regulate transcription of some chemokines and the members of the IL-12 family of 
cytokines (as discussed in Chapter 1) (Honda and Taniguchi 2006). IL-12 family sub-units 
heterodimerize to form functional cytokines, and these play key roles in skewing adaptive immune 
responses (Trinchieri 2003, Vignali and Kuchroo 2012). In this chapter, I investigated the role of 
IRF6 in TLR3 signalling. Particular emphasis was placed on IFN-β as a target gene, given that it is 
a well-characterized target gene for many IRFs. Since circumstantial evidence in Chapter 3 pointed 
to a potential role for IRF6 in regulating poly(IC)-inducible IL-23p19 expression, this gene was also 
a focus of the studies described within. 
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4.2 Results 
4.2.1 IRF6 activates the IFN-β promoter  
In the previous chapter, it was established that keratinocytes express high levels of IRF6, that these 
cells were robustly responsive to the TLR3 ligand, poly(IC), and that this stimulus strongly 
upregulated IFN-β expression. Since other IRFs are known to activate the IFN-β promoter, the 
effect of IRF6 on activity of this promoter was initially examined. The PREs of the IFN-β promoter 
(GAGAAGTGAAAGT) contain well-characterized IRF binding sites (Schafer, Lin et al. 1998, 
Merika and Thanos 2001, Escalante, Nistal-Villan et al. 2007). Figure 4.1A shows a schematic 
representation of the IFN-β promoter, including the PREs. 
HEK293 cells, which did not express IRF6 mRNA or protein (Figure 3.1A and C), were used to 
examine regulation of the human IFN-β promoter by IRF6. pGL2C, which contains the SV-40 
promoter driving luciferase expression, was used as a specificity control. Cells were also co-
transfected with a SV-40 driven Renilla plasmid to normalize transfection efficiency between 
samples. Co-transfection experiments showed that IRF6 activated the IFN-β promoter in a dose-
dependent manner. The maximal amount of IRF6 expression plasmid used increased luciferase 
activity ~30 fold (Figure 4.1B). The effect was selective, since IRF6 co-transfection did not 
increase the activity of the pGL2C promoter.  
4.2.2 IRF6 expression enhances poly(IC)-mediated IFN-β promoter activity 
In keratinocytes, the TLR3 ligand Poly(IC) strongly upregulated IFN-β mRNA expression (Figures 
3.3B and 3.4B). Therefore, the effect of poly(IC) and IRF6 on IFN-β promoter activity was 
examined in HEK293 cells ectopically expressing TLR3 (Matsumoto, Kikkawa et al. 2002). In 
HEK293-TLR3 cells, Poly(IC) strongly activated the IFN-β promoter (~30 fold), and this response 
was further enhanced (~75 fold) in cells co-transfected with IRF6 (Figure 4.2A and B), however, 
this increase was not statistically significant for the sample size. As expected, poly(IC) did not 
activate the IFN-β promoter in parental HEK-293 cells. These data imply that IRF6 may contribute 
to TLR3-mediated activation of IFN-β expression in keratinocytes. Somewhat surprisingly, IRF6 
alone had a more modest effect in activating the IFN-β promoter in HEK293-TLR3 (~3 fold), as 
compared to the effect observed in HEK293 cells (~5 fold) within the same experiments. 
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Figure 4.1. IRF6 activates the IFN-β promoter in HEK293 cells. (A) Schematic representation 
of the human IFN- promoter, with key regulatory elements indicated. The IFN-β promoter 
contains four PREs: PREI, PRE II, PRE III and PRE IV. IRF3 or IRF7 bind to PRE I and III regions 
of the promoter (Munshi, Yie et al. 1999). (B) HEK293 cells were transfected with 100 ng pGL2C 
or IFN--luc, as well as the indicated amounts of IRF6 expression plasmid. The total DNA 
concentration was kept constant in each transfection by making up all transfections to a total of 2 µg 
with empty vector, and 10 ng Renilla-luciferase vector was included to control for transfection 
efficiency. After 24 h, lysates were prepared, and luciferase activity, relative to the internal Renilla 
luciferase reporter control, was quantified. Data represents mean ± SD of 3 independent 
experiments, **** p < 0.0001 (compared to IFN-β promoter alone) (one-way ANOVA, followed by 
Tukey’s test). 
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Figure 4.2. IRF6 expression enhances poly(IC)-mediated activation of the IFN-β promoter 
activity. HEK293 or HEK293-TLR3 cells were transfected with 100 ng IFN--luc, and 200 ng of 
IRF6 expression plasmid. The total DNA concentration was kept constant in each transfection by 
making up all transfections to a total of 2 µg with empty vector, and 10 ng Renilla-luciferase vector 
was included to control for transfection efficiency. After 24 h, cells were stimulated with poly(IC) 
(30 µg/ml) for 8 h. Lysates were prepared, and luciferase activity, relative to the internal Renilla 
luciferase reporter control, was quantified. Data in (A) is presented relative to poly(IC)-treated cells 
and represents mean ± SEM of 3 independent experiments. Data in (B) is a representative 
experiment showing raw data, and represents mean ± range of experimental replicates.  
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4.2.3 IRF6 knockdown selectively impairs TLR3-induced IL-23p19 expression in primary 
keratinocytes 
Although the above transient transfection analysis suggests a role for IRF6 in poly(IC)-inducible 
IFN-β mRNA expression, such approaches are highly artificial. Therefore, more direct evidence 
was sought. For this purpose, siRNA-mediated gene silencing was employed. Since keratinocytes 
also express IRF3, and IRF3 drives TLR3-inducible IFN-β in many cell types (Doyle, Vaidya et al. 
2002, Sato, Sugiyama et al. 2003, Sasai, Matsumoto et al. 2006), IRF3 expression was also silenced 
in these cells. IRF6 knock-down reduced basal IRF6 mRNA (Figure 4.3A) and protein expression 
(Figure 4.3B), whilst IRF3 knock-down reduced basal IRF3 mRNA expression (Figure 4.3C). In 
contrast to the conclusions reached from promoter-reporter analysis, silencing of IRF6 expression in 
primary human keratinocytes did not reduce poly(IC)-inducible IFN-β expression. In fact, there was 
a trend for increased expression. However, knock-down of IRF3 diminished this response 
substantially (Figure 4.3D). Knockdown of IRF6, but not IRF3, in these cells resulted in a 2-fold 
reduction in poly(IC)-inducible IL-23p19 mRNA expression in these cells (Figure 4.3E). This 
effect was confirmed using two different siRNAs against IRF6 (Figure 4.4A-D). In contrast, IRF6 
knockdown had no selective effect, as compared to IRF3 knockdown, on inducible EBI3, CCL5, IL-
8 or CCL20 mRNA levels, although there was a trend for reduced CCL20 mRNA expression 
(Figure 4.3F-H and J). Finally, treatment with poly(IC) modestly increased (~ 2 fold) IRF6 mRNA 
expression itself, and this response was also reduced by the IRF6 siRNA (Figure 4.3I), as would be 
predicted. Collectively, these data indicate that IRF3 drives poly(IC)-inducible IFN-β expression in 
human keratinocytes, and suggest that IRF6 may actually act as a negative regulator of this 
response. In contrast, IRF6 specifically promotes poly(IC)-inducible IL-23p19 mRNA expression, 
thus implicating this transcription factor in a sub-set of TLR3 responses in keratinocytes.  
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Figure 4.3. IRF6 knockdown selectively impairs TLR3-inducible IL-23p19 mRNA expression 
in primary keratinocytes. IRF6 and IRF3 expression in primary human keratinocytes were 
knocked down by reverse transfection using siRNA (200 pM). After 72 h, cells were stimulated 
with poly(IC) (30 µg/ml) for 4 h or were left unstimulated, after which total cellular RNA and 
whole cell lysates were generated. Basal levels of IRF6 mRNA (A) and IRF6 protein (B), as well as 
(C) IRF3 mRNA were determined by qPCR or immunoblotting. Poly(IC)-inducible levels of 
mRNAs for (D) IFN-β, (E) IL-23p19, (F) EBI3, (G) CCL5, (H) CCL20, (I) IRF6 and (J) IL-8 were 
quantified by qPCR. mRNA levels were quantified relative to HPRT and GAPDH was used as a 
protein loading control to ensure equal loading. Data represents mean ± SEM from 3 independent 
experiments, * p < 0.05 as compared to other siRNA-treated cells (two-way ANOVA, followed by 
Tukey’s test). For (D) to (I), data are displayed relative to the poly(IC)-stimulated control. 
Immunoblotting data in (B) is representative of 2 independent experiments.  
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Figure 4.4. Effects of IRF6 knock-down on inducible gene expression in human keratinocytes 
are apparent with independent siRNAs. IRF6 expression in primary human keratinocytes was 
knocked down by reverse transfection using two different siRNAs (200 pM). After 72 h, cells were 
stimulated with poly(IC) (30 µg/ml) for 4 h or were left unstimulated. Total RNA was collected and 
basal mRNA expression of (A) IRF6 and (B) IRF3, as well as inducible mRNA expression of (C) 
IFN-β and (D) IL-23p19 was quantified, relative to HPRT, by qPCR. Data represents mean ± SD of 
experimental triplicates and is representative of 2 independent experiments.  
 
4.2.4 IRF6 over-expression in T24 cells enhances poly(IC)-inducible IL-23p19 expression  
Since gene silencing with independent IRF6 siRNAs identified IL-23p19 as a likely IRF6 target 
gene in TLR3 signalling, further experimental evidence to support this conclusion was sought. 
Thus, IRF6 was over-expressed in T24 (bladder epithelial) cells, since these cells do not express 
IRF6 protein and did not upregulate IL-23p19 mRNA in response to poly(IC) (Figures 3.1C and 
3.5E). As expected, ectopic expression of IRF6 resulted in elevated expression of IRF6 mRNA 
(Figure 4.5A). Poly(IC) treatment further enhanced IRF6 mRNA levels in cells transfected with the 
IRF6 expression plasmid (Figure 4.5A), consistent with the previously observed upregulation of 
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IRF6 by poly(IC) in keratinocytes (Figure 4.3I). Whereas ectopic expression of IRF6 did not affect 
poly(IC)-inducible IFN-β mRNA expression (Figure 4.5B), inducible IL-23p19 mRNA expression 
was increased ~ 2 fold (Figure 4.5C), Poly(IC) induced IRF6 expression was also increased in cells 
overexpressing IRF6. Interestingly, T24 cells transfected with empty vector did respond to poly(IC) 
with inducible IL-23p19 mRNA expression (~ 20 fold), which is in contrast to findings with 
untransfected T24 cells (Figure 3.5E). It is possible that transfection alone somehow affects T24 
cell function to permit an inducible IL-23p19 response. Collectively, these data support the 
conclusion that IL-23p19 is a target gene of IRF6 in TLR3 signalling.   
 
 
Figure 4.5. IRF6 over-expression in T24 cells confers poly(IC)-inducible IL-23p19 mRNA 
expression. T24 cells were transfected with either an IRF6 expression plasmid (200 ng) or an 
empty vector control (200 ng). After 24 h, cells were stimulated for 24 h with poly(IC) (30 µg/ml) 
or were left unstimulated. mRNA levels of (A) IRF6, (B) IFN-β and (C) IL-23p19 were quantified, 
relative to HPRT, using qPCR. Data (relative to vector control) represents mean ± range of two 
independent experiments.  
 
4.2.5 IRF6 enhances IL-23p19 promoter activity upon poly(IC) stimulation   
Both gene silencing and overexpression approaches suggested that IRF6 contributes to poly(IC)-
inducible transcription of IL-23p19. To determine whether IRF6 can activate the human IL-23p19 
promoter, gene reporter assays were performed. Figure 4.6A shows a schematic representation of 
the IL-23p19 promoter highlighting the candidate IRF6 binding sites (ISREs). The human IL-23p19 
promoter region containing the potential IRF binding sites was cloned into a luciferase reporter 
vector. In brief, -815 bp to +1 bp (transcription start site) region of the promoter was amplified from 
human genomic DNA using primers with flanking restriction sites and cloned into XmaI and 
HindIII cut pGL2-B vector.   
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Initially, HEK293-TLR3 cells, which did not express IRF6 mRNA or protein (Figure 3.1A and C), 
were transfected with the IL-23p19 promoter-luciferase reporter construct with or without an IRF6 
expression plasmid. An SV40 promoter-luciferase construct (pGL2C) was used as a control. Cells 
were also transfected with an SV40 promoter driven Renilla vector to normalize transfection 
efficiency. The IL-23p19 promoter was highly active in HEK293-TLR3 cells (~ 10 fold greater 
luciferase activity than pGL2C, itself a very strong promoter) (Figure 4.6B). However, 
overexpression of IRF6 did not further affect the activity of the IL-23p19 promoter. Moreover, 
treatment with poly(IC) did not increase the activity of the IL-23p19 promoter; in fact, poly(IC) 
reduced the activity of the promoter in cells that had been co-transfected with an IRF6 expression 
plasmid.  
 
Figure 4.6. IRF6 enhances poly(IC)-inducible activity of the IL-23p19 promoter in RAW264.7 
cells. (A) Schematic representation of the human IL-23p19 promoter, with key regulatory elements 
indicated. The IL-23p19 promoter contains a putative IRF3 and IRF7 binding site containing the 
ISRE sequence (Al-Salleeh and Petro 2008). (B) HEK293-TLR3 cells were transfected with 100 ng 
pGL2C or IL-23p19-luc, as well as 200 ng of IRF6 expression plasmid. Total DNA concentrations 
were kept constant by making up all transfections to a total of 2 µg with empty vector, and 10 ng 
Renilla-luciferase vector was included to control for transfection efficiency. After 24 h, cells were 
stimulated with poly(IC) for 8 h. Lysates were prepared, and luciferase activity, relative to the 
internal Renilla luciferase reporter control, was quantified. Data represents mean ± range of 
experimental replicates from a single experiment. (C) RAW264.7 cell-lines were transfected with 5 
μg pGL2C or IL-23p19-luc and 5 μg IRF6 plasmid or empty vector for 21 h, and then stimulated 
with poly(IC) for 8 h. Lysates were prepared and luciferase activity was quantified, relative to total 
proteins. Data represents mean ± range of two independent experiments.  
IRF6 involvement in poly(IC)-regulated gene expression in keratinocytes 
79 
 
The very high constitutive activity of this promoter in HEK293-TLR3 cells is inconsistent with the 
very low basal expression of the IL-23p19 gene in the same cells. This suggested that there may be 
some transcription factor in HEK293 cells driving high levels of luciferase expression in the context 
of transiently transfected plasmid, which would likely mask any effect of IRF6 in promoting 
poly(IC)-inducible IL-23p19 promoter expression. For this reason, an alternative cellular system 
was sought; the RAW264.7 mouse macrophage-like cell-line was thus used as a non-epithelial cell 
line. These cells were chosen because they are easily transfectable, and being a macrophage-like 
cell they respond to a range of TLR ligands. Similar experiments were performed using RAW264.7 
cells; the IL-23p19 or pGL2C promoter reporter constructs were transfected with or without IRF6 
and were subsequently stimulated with poly(IC). Again, the IL-23p19 promoter was active in these 
cells, but in this case, the activity was comparable to that observed with pGL2C (Figure 4.6C). 
IRF6 co-transfection did not affect the basal activity of the IL-23p19 promoter, however, the 
poly(IC) response was enhanced in cells transfected with IRF6 (~ 6 fold), as compared to those 
transfected with empty vector (~ 2 fold). This effect was specific for the IL-23p19 promoter, since 
the activity of pGL2C was unaffected by IRF6 co-transfection and/or poly(IC) stimulation. These 
data therefore suggest that IRF6 activates the IL-23p19 promoter in response to the TLR3 ligand 
poly(IC). 
4.2.6 Poly(IC) stimulation may promote IRF6 nuclear translocation 
Since previous experimental evidence supported a role for IRF6 in promoting poly(IC)-inducible 
IL-23p19 mRNA expression, the next aim was to determine whether poly(IC) triggers IRF6 
translocation into the nucleus. Thus, primary keratinocytes were stimulated with poly(IC) over a 
time-course or were left untreated, after which immunofluorescence microscopy was performed to 
detect IRF6 expression. The cells were also stained with DAPI (nuclear) and Phalloidin (actin) to 
visualize cell morphology. In initial experiments, IRF6 was predominantly localized to the nucleus, 
with some staining in the cytoplasm (Figure 4.7A). There also appeared to be some enrichment at 
the plasma membrane. Upon poly(IC) stimulation, IRF6 was still expressed in both nucleus and 
cytoplasm, but the cytoplasmic IRF6 pool appeared to be reduced as compared to unstimulated cells 
(Figure 4.7B). Although this was suggestive of nuclear translocation, this observed effect did not 
occur in subsequent experiments. Moreover, the high nuclear expression of IRF6 in primary 
keratinocytes made it difficult to use this approach to monitor nuclear translocation.  
Although HaCaT cells also expressed both nuclear and cytoplasmic IRF6, the cytoplasmic pool 
appeared to be more pronounced than was observed in primary keratinocytes (Figure 4.7C). Thus, 
these cells were used for subsequent experiments, which involved cell fractionation to examine 
IRF6 nuclear translocation. HaCaT cells were stimulated with poly(IC) over a time course, after 
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which nuclear and cytoplasmic fractions were extracted. Western blotting was performed on the 
extracts to monitor IRF6 localization. Levels of GAPDH (cytoplasmic protein) and LaminA/C 
(nuclear protein) were also quantified by immunoblotting to confirm the purity of extracts, and to 
ensure equal protein loading. Consistent with microscopy data (Figure 4.7C), IRF6 was 
predominantly expressed in the cytoplasm in these cells, with some expression in the nucleus 
(Figure 4.7D). IRF6 expression in the cytoplasm increased at 4 and 8 h post-stimulation. At 6 h 
post-stimulation, IRF6 levels in the nucleus increased. One interpretation of these data is that 
poly(IC) increased IRF6 protein expression, with concomitant nuclear translocation at 6 h post-
stimulation.  
 
Figure 4.7. Poly(IC) stimulation may promote IRF6 nuclear translocation. IRF6 localization 
was determined in (A) unstimulated and (B) poly(IC)-stimulated primary keratinocytes using 
immunofluorescence microscopy, as well as in unstimulated HaCaT cells (C). The arrows indicate 
cytoplasmic staining and the arrowheads indicate nuclear staining of IRF6. (D) HaCaT cells were 
stimulated with Poly(IC) (30 µg/ml) over the indicated time course, after which nuclear and 
cytoplasmic extracts were prepared. Levels of IRF6, GAPDH and Lamin A/C were determined by 
immunoblotting. Data are representative of 2 independent experiments. 
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4.2.7 Attempts to detect IL-23p19 protein in poly(IC)-stimulated keratinocyte supernatants 
and cell lysates 
Both gene knockdown and overexpression approaches showed that IRF6 promotes poly(IC)-
inducible IL-23p19 mRNA expression. To determine if keratinocytes secrete IL-23p19 protein upon 
poly(IC) stimulation, HaCaT cells were stimulated with poly(IC) for 4, 8 and 24 h and secreted IL-
23p19 was measured from supernatants using ELISA. Supernatants from LPS-stimulated HMDM 
were used as a positive control, since HMDMs are known to secrete IL-23 in response to LPS 
(Verreck, de Boer et al. 2004). As expected, HMDMs responded to LPS stimulation and showed a 
4-fold upregulation of IL-23p19 secretion (Figure 4.8A). However, IL-23p19 protein was not 
detected in HaCaT cell supernatants (data not shown). Functional IL-23 is a heterodimer of IL-
23p19 and IL-12p40 (Vignali and Kuchroo 2012). Since poly(IC) did not upregulate IL-12p40 
mRNA expression in keratinocytes, it was considered that IL-23p19 may either not be secreted out 
of the cell, or may be interacting with another protein. Either of these explanations could account 
for the failure to detect IL-23p19 in keratinocyte culture supernatants by ELISA. That is, the protein 
could be present in cell lysates but absent from culture supernatants, or the epitopes recognized by 
the IL-23p19 antibodies used in the sandwich ELISA could be masked by an interaction with 
another protein, such as EBI3. 
To determine if poly(IC) IL-23p19 could be detected within cell lysates, immunoblotting was 
performed on cell lysates from poly(IC)-stimulated primary keratinocytes. Recombinant IL-23 
protein was used as a positive control. In the case of recombinant protein, both the IL-23 
heterodimer (p19/p40; 55 kDa), as well as the IL-23p19 monomer (faint band, 19 kDa) were 
detected (Figure 4.8B). However, neither of these bands could be detected in either poly(IC)-
stimulated keratinocytes or LPS-stimulated HMDM. Given that IL-23p19 in LPS-stimulated 
HMDM culture supernatants was detectable by ELISA, it was concluded that immunoblotting with 
anti-IL-23p19 antibody was unlikely to be sufficiently sensitive to detect this protein in 
keratinocytes.  
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Figure 4.8. IL-23p19 protein was not detected in poly(IC)-stimulated keratinocyte 
supernatants or cell lysates. IL-23p19 ELISA was performed on culture supernatants from (A) 
HMDMs stimulated with LPS (10 ng/ml) for either 8 or 24 h. Data represents mean ± SD of 
experimental triplicates. (B) Recombinant IL-23 (10 ng), as well as whole cell lysates from primary 
human keratinocytes (PEK, +/- 30 µg/mL poly(IC) for 4 h) or HMDM (+/- 10 ng/mL LPS for 8 h), 
were subjected to SDS PAGE, followed by immunoblotting for IL-23p19, IRF6 and GAPDH. IL-23 
(p19/p40) and p19 monomer are indicated with arrows. Data in (A) are mean ± SD from a single 
experiment, whilst data in (B) are representative of 2 independent experiments.  
 
4.2.8 IFN-γ priming enhances keratinocyte responses to poly(IC) 
Since IL-23p19 could be detected in HMDM culture supernatants but not those of primary 
keratinocytes, I next considered the possibility that epithelial cells may require additional 
stimulation to secrete this cytokine. The pro-inflammatory cytokine IFN-is a classic primer of 
TLR responses in innate immune cells (Schroder, Sweet et al. 2006), and thus the effects of this 
cytokine were investigated. Keratinocytes were primed with 2.5 ng/ml IFN-for 24 h, after which 
poly(IC) responsiveness was examined. IFN-γ priming itself modestly increased the mRNA levels 
of IL-23p19 and CCL5 (Figure 4.9A and C). IFN-γ priming substantially enhanced (~ 30 fold) 
poly(IC)-inducible mRNA levels of IL-23p19 (Figure 4.9A), however this treatment regime did not 
result in detectable IL-23p19 secretion (data not shown). In addition to the effect of IFN-priming 
on inducible IL-23p19 mRNA levels, those of IFN-β (Figure 4.9B), CCL5 (Figure 4.9C) and 
CCL20 (Figure 4.9D) were also increased to varying levels. Thus, it was concluded that a second 
signal that robustly primed inducible IL-23p19 mRNA expression still did not permit detectable IL-
23p19 protein secretion. 
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Figure 4.9. IFN-γ priming enhances poly(IC)-regulated inflammatory responses in 
keratinocytes. Primary keratinocytes were primed with IFN-γ (2.5 ng/ml) for 24 h and then 
stimulated with poly(IC) (30 µg/ml) for 4, 8 and 24 h. Total RNA was collected at the indicated 
time points and mRNA levels of (A) IL-23p19, (B) IFN-β, (C) CCL5 and (D) CCL20 were 
quantified, relative to HPRT, using qPCR. Data represents mean ± range from 2 independent 
experiments 
 
4.2.9 Differentiation status of keratinocytes partially affects TLR3 responses after IFN-γ 
priming 
In the previous chapter, it was observed that differentiation status did not have pronounced effects 
on poly(IC)-inducible IL-8 release from keratinocytes. However, regulated IL-23p19 expression 
was not assessed in these experiments, nor was the effect of priming stimuli on differentiated cells. 
Therefore, the effect of IFN-γ priming on poly(IC)-regulated gene expression was monitored in 
proliferating versus differentiated keratinocytes. Consistent with the IL-8 data described previously 
(Figure 3.9), differentiation status alone did not significantly affect the poly(IC) responses 
examined. Also, as previously observed (Figure 4.9), IFN-γ priming generally enhanced poly(IC) 
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responses in keratinocytes. However, the effect of IFN-γ priming on regulated IFN-β gene 
expression was greatly reduced in differentiated keratinocytes (Figure 4.10A), whereas the reverse 
was true in the case of IL-23p19 mRNA expression (Figure 4.10B). This is consistent with 
increased IRF6 expression in differentiated keratinocytes (Figure 3.7) and previous data from this 
chapter implicating this transcription factor in positive and negative regulation of IL-23p19 and 
IFN-β mRNA expression, respectively. Due to time constraints, I did not examine whether poly(IC) 
promoted IL-23p19 protein secretion from IFN-γ primed that had previously been differentiated. 
The effects observed were selective, since keratinocyte differentiation status did not have any 
obvious effect on the capacity of IFN-γ to prime poly(IC)-inducible CCL5 (Figure 4.10C) or 
CCL20 (Figure 4.10D) expression. 
 
Figure 4.10. Differentiation status differentially affects the ability of IFN-γ to prime poly(IC) 
responses in keratinocytes. Proliferating (Y27632-treated; 5 μM for 24 h) and differentiated (Ca2+-
treated; 2 mM for 24 h) primary keratinocytes were primed with IFN-γ (2.5 ng/ml) for 24 h and 
then stimulated with poly(IC) (30 μg/ml) for 4 h. Total RNA was collected and mRNA levels of (A) 
IFN-β, (B) IL-23p19, (C) CCL5 and (D) CCL20 were quantified, relative to HPRT, using qPCR. 
Data represents mean ± SD from experimental triplicates and is representative of 2 independent 
experiments.  
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4.3 Summary and discussion of Chapter 4 
4.3.1 IRF6 involvement in regulation of IFN-β expression 
Members of the IRF family, such as IRF1, IRF3, IRF5 and IRF7 have been shown to be important 
regulators of TLR-inducible IFN-β transcription. The IFN-β promoter contains 4 characterized 
PREs: PRE I (-77 to -64), PRE II (-64 to -55), PRE III (-94 to -78) and PRE IV (-102 to -94) 
(Munshi, Yie et al. 1999). Two of these sites (PRE I and PRE III) are known to bind IRF1, IRF2, 
IRF3, IRF5 and IRF7 (Fan and Maniatis 1989, Leblanc, Cohen et al. 1990, Palombella and Maniatis 
1992, Thanos and Maniatis 1995, Kim and Maniatis 1997, Sato, Tanaka et al. 1998, Wathelet, Lin 
et al. 1998, Sato, Suemori et al. 2000, Escalante, Nistal-Villan et al. 2007, Panne, Maniatis et al. 
2007). IRF1, 3, 5 and 7 positively regulate transcription of IFN-β in different cell types (Reis, 
Harada et al. 1992, Sato, Tanaka et al. 1998, Honda, Yanai et al. 2005, Schoenemeyer, Barnes et al. 
2005, Honda and Taniguchi 2006), while IRF2 is a negative regulator (Hida, Ogasawara et al. 
2000). Phylogenetic analysis indicates that IRF6 is most similar to IRF5, showing 89% homology 
in aa sequence (Taniguchi, Ogasawara et al. 2001, Takaoka, Tamura et al. 2008). This suggests that 
IRF6 might also positively regulate IFN-β transcription. This conclusion was supported by 
promoter reporter studies in both HEK293 cells (Figure 4.1B) and HEK293-TLR3 cells (Figure 
4.2), however more direct functional analysis (gene silencing) showed that, if anything, IRF6 
negatively regulates poly(IC)-inducible IFN-β expression (Figures 4.3D and 4.4C). This functional 
evidence is also supported by correlative studies; keratinocyte differentiation upregulated IRF6 
mRNA and protein expression (Figure 3.7) and concomitantly reduced poly(IC)-inducible IFN-β 
expression in IFN--primed cells (Figure 4.10A). Taken together, my data do not support a role for 
IRF6 in promoting inducible IFN-β expression in keratinocytes.  
My findings highlight the need for caution when interpreting data from promoter-reporter studies. 
Although such systems provide a convenient functional read-out of transcriptional activity, the lack 
of chromatinization of transiently transfected DNA can result in artefacts (Reeves, Gorman et al. 
1985, Hebbar and Archer 2008), as seemed to be apparent here. The observed negative regulation of 
poly(IC)-inducible IFN-β expression by IRF6 (Figures 4.3D and 4.4C) warrants further 
investigation. IRF6 association with other IRFs has not been reported experimentally, nevertheless, 
IRF6 has been predicted to associate with IRF5 and IRF8 by affinity-capture mass spectrometry (Li, 
Wang et al. 2011). IRF5 has also been shown to associate with IRF3 (Barnes, Moore et al. 2001). 
Thus, it is possible that IRF6 can interact with IRF3 and that this heterodimer has reduced 
transcriptional activity as compared to the IRF3 homodimer. Alternatively, IRF6 may bind to PRE I 
and/or PRE III within the IFN-β promoter and interfere with binding by IRF3. These possibilities 
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could be investigated in the future by co-immunoprecipitation analysis and chromatin 
immunoprecipitation analysis, respectively.  
In contrast to the findings with IRF6 knock-down, gene silencing showed that IRF3 was required 
for poly(IC)-inducible IFN-β gene expression in keratinocytes (Figures 4.3D and 4.4C). This 
finding is consistent with an extensive literature in various cell types, including keratinocytes; 
TRIF-dependent signalling has been shown to activate IRF3 to promote transcription of type-1 IFNs 
(Honda and Taniguchi 2006). Considering that IRFs have cell-type specific functions (Chapter 1), 
this conclusion could not necessarily be assumed prior to undertaking these functional studies. A 
study in keratinocytes have also shown that IRF3 was required for poly(IC)-inducible TSLP 
expression but not IL-8 expression (Vu, Chen et al. 2011). This is consistent with my data where 
neither IRF3 nor IRF6 knockdown affected poly(IC)-inducible IL-8 expression (Figure 4.3J). In 
mouse macrophages, IRF3 has been shown to mediate poly(IC)-inducible CCL5 expression (Doyle, 
Vaidya et al. 2002), however, IRF3 knockdown did not affect CCL5 expression in keratinocytes 
(Figure 4.3F). Thus, in keratinocytes, other transcription factors may be involved in expression of 
target genes, such as IL-8 and CCL5. This requires investigation in future and is further discussed in 
Chapter 6. 
4.3.2 Regulation of poly(IC)-inducible IL-23p19 expression by IRF6 
Through both gain-of-function (Figure 4.5C) and loss-of function (Figures 4.3E and 4.4D) 
approaches, I showed that IL-23p19 is a downstream target gene of IRF6. IRF3 knockdown did not 
affect regulated IL-23p19 expression, which is consistent with a previous study showing that IRF3 
knockdown did not affect regulated expression of IL-23p19 protein in macrophages (Al-Salleeh and 
Petro 2008). A role for IRF6 in promoting inducible IL-23p19 expression was also supported by IL-
23p19 promoter-reporter studies in RAW264 cells (Figure 4.6C). Interestingly however, I 
encountered difficulties with interpretation of data using this approach. In initial experiments 
performed in HEK293-TLR3 cells, I observed that the IL-23p19 promoter displayed very high 
constitutive activity (Figure 4.6B). These cells do not constitutively express the IL-23p19 gene, so 
this finding was very surprising. Co-expression of IRF6 did not activate the IL-23p19 promoter and 
poly(IC) actually suppressed activity of the promoter in cells co-transfected with IRF6 (Figure 
4.6B). One possible interpretation of these data is that a strong transcriptional activator activates the 
IL-23p19 promoter in transfected HEK293-TLR3 cells, again, possibly because the transfected 
DNA is not chromatinized. In cells co-transfected with an IRF6 plasmid, IRF6 recruitment in 
response to treatment with poly(IC) could potentially interfere with the activity of this strong 
transcriptional activator. In a more physiological setting where the promoter is not transcriptionally 
active, then IRF6 recruitment would be predicted to drive IL-23p19 expression. This is certainly 
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consistent with my observations in transfected RAW264 cells. In these cells, the IL-23p19 promoter 
had low basal activity and in cells co-transfected with the IRF6 expression plasmid, poly(IC) 
enhanced promoter activity (Figure 4.6C). Interestingly, the effect of IRF6 in promoting poly(IC)-
inducible IL-23p19 expression appeared to be selective. Gene knock-down studies suggested that 
CCL20 may also be another IRF6 target, although the effect was not statistically significant (Figure 
4.3H). However, no effects of IRF6 knock-down on the other poly(IC) target genes studied were 
observed. At least some evidence was accrued to suggest that poly(IC) triggers nuclear translocation 
of IRF6 in keratinocytes (Figure 4.7), although the dual localization of IRF6 in both the cytoplasm 
and nucleus of keratinocytes complicates these studies somewhat. It is also likely that the sub-
cellular localization of IRF6 is dynamically regulated. In this case, use of the nuclear export 
inhibitor leptomycin B (Wolff, Sanglier et al. 1997) may provide a cleaner system to monitor IRF6 
nuclear translocation. Notably, one other study has also reported that poly(IC) triggers IRF6 nuclear 
translocation in MCF-10A cells (Bailey and Hendrix 2008). Assuming this is the case, more global 
approaches such as chromatin immunoprecipitation with an anti-IRF6 antibody in poly(IC)-treated 
keratinocytes are likely to identify TLR3-dependent IRF6 target genes beyond IL-23p19 (see 
Chapter 6 for further discussion on this).  
IRF6 knock-down only partially reduced inducible IL-23p19 expression in keratinocytes, and had 
no effect on regulated EBI3 expression. The IL-23p19 promoter contains both IRF and NF-κB 
binding sites (Figure 4.6A). NF-κB has previously been shown to bind to the IL-23p19 promoter 
and to positively regulate its expression in macrophages and DCs (Carmody, Ruan et al. 2007, 
Mise-Omata, Kuroda et al. 2007). Given the incomplete effect of IRF6 siRNAs in reducing 
inducible IL-23p19 expression, it is quite likely that NF-κB also activates this gene in response to 
poly(IC). This model is consistent with the dual role of NF-κB and IRF3 in driving TLR3-inducible 
IFN- expression in various cell types (Jiang, Mak et al. 2004, Aksoy, Vanden Berghe et al. 2005, 
Sankar, Chan et al. 2006, Takaoka, Tamura et al. 2008). The TLR-regulated expression of EBI3 has 
primarily been studied in macrophages and dendritic cells. Although promoter analyses revealed 
putative NF-κB and IRF binding sites (Wirtz, Becker et al. 2005), NF-κB was identified as the 
primary functional regulator of inducible EBI3 expression (Wirtz, Becker et al. 2005, Poleganov, 
Bachmann et al. 2008). This is consistent with my observation that knock-down of IRF6 or IRF3 
did not affect poly(IC)-inducible EBI3 expression in keratinocytes (Figure 4.3F). The differential 
role of IRF6 in regulating IL-23p19 versus EBI3 expression is also consistent with my previous 
observation that the time courses of poly(IC)-regulated expression of these two genes showed some 
differences (Chapter 3). 
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IL-23p19 is a member of the IL-12 super-family, and has been shown to heterodimerize with IL-
12p40 to form IL-23 (Vignali and Kuchroo 2012). However, poly(IC) did not induce IL-12p40 
mRNA expression in either primary keratinocytes or HaCaT Cells (Chapter 3). This was somewhat 
surprising because IL-12p40 is the only known binding partner for IL-23p19. IL-12 or IL-23 are 
formed intracellularly by heterodimerization of p35/p40 or p19/p40 subunits, respectively, and are 
secreted as functional heterodimers (Gubler, Chua et al. 1991, Oppmann, Lesley et al. 2000). IL-
23p19 protein was not detected in culture supernatants or keratinocyte lysates after poly(IC) 
stimulation. There are several possibilities that could account for this observation. Firstly, it is 
possible that a second signal is required to elicit IL-23p19 secretion. IFN- was investigated as one 
such signal that might permit inducible protein release by acting as a priming agent (Figure 4.9). 
Whilst IFN- priming certainly enhanced poly(IC)-regulated mRNA expression of IL-23p19 and 
other target genes, I could not detect IL-23p19 protein secretion upon priming. Differentiation 
status also enhanced inducible IL-23p19 mRNA levels in IFN--primed cells, but due to time 
constraints, I was not able to examine whether this translated to protein secretion upon poly(IC) 
stimulation. 
An alternative explanation is that one of the IL-23p19 epitopes recognized by the anti-IL-23p19 
antibodies used in the sandwich ELISA are masked due to an interaction with either self or another 
protein. Given the gene expression data, one attractive possibility is that IL-23p19 interacts with 
EBI3, which is another beta-subunit of the IL-12 family of cytokines (Devergne, Hummel et al. 
1996). Both EBI3 and IL-12p40 have a common binding partner, IL-12p35. The interaction 
between IL-12p35 and IL-12p40 is structurally very similar to that of IL-23p19 and IL-12p40 
(Lupardus and Garcia 2008); many of the aa residues in the IL-12p40 binding surface are shared by 
both proteins (Lupardus and Garcia 2008). However, the interaction between IL-12p35 and EBI3 is 
distinct from its interaction with IL-12p40 (Jones, Chaturvedi et al. 2012). Considering the 
similarities in the IL-12p35 and IL-23p19 subunits, it is possible that IL-23p19 interacts with EBI3 
in a distinct way as well. Such differences might thus be predicted to interfere with the recognition 
of IL-23p19 by one or both of the antibodies used in the sandwich ELISA. Another possibility is 
that IL-23p19 forms a functional homodimer, and that one of the epitopes is masked in this 
scenario. Some evidence suggests that IL-12p40 and IL-27p28 can function as homodimer or 
monomer, respectively (Ling, Gately et al. 1995, Gately, Carvajal et al. 1996, Brahmachari and 
Pahan 2009, Dibra, Cutrera et al. 2012, Garbers, Spudy et al. 2013), so there is at least some support 
for this concept with other IL-12 family members. In either case, IL-23p19 induction alone suggests 
a function for this gene independent of IL-12p40 or IL-23. These possibilities could be investigated 
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by cloning IL-23p19 and EBI3 expression plasmids and performing co-immunoprecipitation 
analysis to determine whether they interact. This warrants investigation in the future.  
4.3.3 Effects of IFN-γ-priming on poly(IC) responses in keratinocytes 
The pro-inflammatory cytokine IFN-γ is predominantly produced by NK cells and T-cells, and is a 
potent activator of macrophages (Schroder, Sweet et al. 2006). Consequently, excessive or 
dysregulated IFN-γ production has been linked to many inflammatory diseases. Similarly, IFN-γ 
primes and/or drives inflammatory responses in keratinocytes (Barker, Mitra et al. 1991, Groves, 
Ross et al. 1993, Pastore, Corinti et al. 1998, Albanesi, Scarponi et al. 2001). For example, it 
promotes the production of IL-8 and intercellular adhesion molecule 1 (Barker, Sarma et al. 1990, 
Barker, Jones et al. 1991, Li, Ireland et al. 1996), which are both involved in the recruitment of 
inflammatory cells into the skin (Kalish 1989, Barker, Jones et al. 1991, Nickoloff, Mitra et al. 
1993). Not surprisingly then, IFN-γ has been linked to inflammatory conditions of the skin, 
including psoriasis and dermatitis. For example, psoriatic lesions have been reported to have greater 
than 10 fold levels of IFN-γ, as compared to uninflamed epidermis (Kaneko, Suzuki et al. 1990). 
Furthermore, IFN-γ triggers growth arrest in normal keratinocytes, whereas it promotes 
proliferation of psoriatic keratinocytes (Nickoloff, Basham et al. 1984, Baker, Powles et al. 1988, 
Barker, Goodlad et al. 1993, Saunders and Jetten 1994). Thus, IFN-γ-primed keratinocytes are often 
used as in vitro cellular models for dissecting mechanisms involved in psoriasis (Fierlbeck, Rassner 
et al. 1990, Barker, McHale et al. 2004, Gudjonsson, Johnston et al. 2004). The IL-23/Th17 axis has 
also been implicated in the pathology of inflammatory skin conditions. For example, genetic 
variation in IL-12B, IL-12RB, IL-23A and IL-23R are protective against psoriasis (Capon, Di Meglio 
et al. 2007, Cargill, Schrodi et al. 2007) and elevated IL-23 levels have been reported in lesions of 
psoriatic patients (Lee, Trepicchio et al. 2004). Thus, my observation that IFN-γ priming alone 
caused a modest increase in IL-23p19 expression, and that this effect was further enhanced upon 
poly(IC) stimulation may be of relevance to dysregulated skin inflammation. IFN-γ priming also 
enhanced poly(IC)-induced expression of CCL5, which has also been shown to be highly expressed 
in psoriatic skin (Fukuoka, Ogino et al. 1998, Raychaudhuri, Jiang et al. 1999), and CCL20, which 
is produced in response to Th17 cytokines (Harper, Guo et al. 2009). One previous study in human 
bronchial epithelial cells showed that IFN-γ stimulation enhanced CCL5 secretion (Olszewska-
Pazdrak, Casola et al. 1998). IFN-γ was also reported to stabilize poly(IC)-inducible CCL5 mRNA 
expression in airway epithelial cells (Homma, Matsukura et al. 2010). This is consistent with my 
results in keratinocytes where IFN-γ priming itself upregulated CCL5 expression, which was further 
amplified by poly(IC) stimulation (Figure 4.9C). 
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In my experiments, poly(IC) was added to the media, therefore, it is presumed that TLR3 mediates 
the effects I observed. However, dsRNA in the cytoplasm is also recognised by the cytosolic RNA 
sensors, RIG-I and MDA5 (Kato, Takeuchi et al. 2008). One study reported that poly(IC)-mediated 
responses were enhanced in human keratinocytes primed with IL-1α, which is also an inflammatory 
sensitizer, due to the induction of cytosolic RNA receptors (Prens, Kant et al. 2008). It is thus 
possible that IFN-γ also induces the expression of cytosolic RNA receptors, and that this contributes 
to the priming effects that I observed in my studies. Keratinocytes did not respond to poly(IC) 
stimulation with IL-12p40 induction. However, whether IFN-γ enables IL-12p40 upregulation in 
keratinocytes was not examined. Since psoriatic keratinocytes are reported to express elevated 
levels of IL-23 (Baghestani, Sadeghi et al. 2010), it is possible that IFN-γ primes IL-12p40 
expression in keratinocytes, thereby contributing to increased inflammation during psoriasis. 
Therefore, the effect of IFN-γ priming on IL-12p40 expression needs to be examined.  
Interestingly, IFN-γ priming appeared to differentially affect poly(IC)-inducible expression of IFN-
β versus IL-23p19 expression upon cellular differentiation; inducible IFN-β expression was reduced 
upon differentiation, whereas IL-23p19 expression was increased (Figure 4.10A and B). As 
discussed above, this may relate to the inducible expression of IRF6 upon keratinocyte 
differentiation (Figure 3.7), since this transcription factor seemed to have opposing effects on the 
expression of these target genes (Figures 4.3D and E, 4.4C and D). Thus, it would be interesting to 
examine whether IFN-γ priming also promotes IRF6 expression or regulates its function (e.g. 
through post-translational modification). Consistent with such a model, IFN-γ has been shown to 
promote the expression of the keratinocyte differentiation markers IVL, transglutaminase type 1 and 
cornifin (Saunders and Jetten 1994, Takahashi, Asano et al. 1999). This might explain why IFN-γ-
primed untreated keratinocytes responded in a similar manner as IFN-γ-primed differentiated 
keratinocytes (Figures 4.10). That is, IFN-γ itself is providing a differentiation signal. 
In summary, in this chapter I have provided evidence that IRF6 regulates a sub-set of poly(IC)-
inducible genes in human keratinocytes. Preliminary evidence also suggests that IFN- may regulate 
IRF6 expression or function in differentiated keratinocytes. The selective regulation of IL-23p19 
may permit an IL-23-independent function for this IL-12 family sub-unit. This possibility is further 
discussed in Chapter 6. In the next chapter (Chapter 5), I explored a role for IRF6 in MyD88-
dependent TLR responses. 
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5 Investigation of the role of IRF6 in MyD88-dependent TLR signalling in 
keratinocytes 
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5.1 Introduction 
In my original analysis of TLR responsiveness of keratinocytes, I did not observe pronounced 
responses of these cells to TLR agonists that signal exclusively via MyD88 (Figures 3.2-3.4). 
However, agonists of TLR7 and TLR2/6 were not assessed in these original studies. The TLR7 
agonist imiquimod has been used as a therapeutic treatment for various skin conditions including 
basal cell carcinomas, genital warts and actinic keratosis (Bong, Bonnekoh et al. 2002, Geisse, Rich 
et al. 2002, Novak, Yu et al. 2008). TLR2/6 signalling is involved in the detection of Gram-positive 
bacteria such as S. aureus, which are common skin commensals (Krishna and Miller 2012). 
Therefore, it was considered important to know whether keratinocytes respond to TLR7 and/or 
TLR2/6 agonists, and if so, whether IRF6 is involved in these responses.  
In response to their cognate ligands, all TLRs, except for TLR3, recruit the adaptor protein MyD88, 
which contains a C-terminal TIR domain and an N-terminal death domain (Figure 1.1) (Hultmark 
1994, Wesche, Henzel et al. 1997, Burns, Martinon et al. 1998). In the case of TLR4 and TLR2, the 
protein MAL, also known as TIR domain-containing adaptor protein (TIRAP), acts as a bridging 
adaptor between MyD88 and the TLRs. Recently, TLR5 has also been shown to associate with 
MAL in IEC (Choi, Jung et al. 2013). MyD88 binds to the serine/threonine kinase IRAK4 by 
interacting with the death domain of the protein (Muzio, Ni et al. 1997, Wesche, Henzel et al. 
1997). IRAK4 and IRAK1 are then sequentially recruited to the receptor complex (Cao, Henzel et 
al. 1996, Li, Strelow et al. 2002). The binding of the IRAKs to the receptor complex enables IRAK-
1 phosphorylation and association with the E3 ubiquitin ligase TRAF-6 (Cao, Xiong et al. 1996, 
Yamin and Miller 1997, Lomaga, Yeh et al. 1999). The IRAK-1/IRAK-4/TRAF-6 complex then 
dissociates from the receptor complex, after which TRAF-6 interacts with the E2 ubiquitin-
conjugating enzyme complex consisting of Ubc13 and Uev1a (Deng, Wang et al. 2000). This 
interaction results in polyubiquitination at K63 of the ubiquitin molecule, autoubiquitination of 
TRAF6, and formation of a signalling scaffold (Deng, Wang et al. 2000). A member of the MAP3K 
family, TAK1, and its two adaptor proteins TAK-1 associated binding proteins 1 and 2 (TAB1 and 
TAB2) are then recruited (Deng, Wang et al. 2000, Wang, Deng et al. 2001). TAK1 undergoes 
phosphorylation and activates the p38 and JNK MAPK arms (Wang, Deng et al. 2001). Other 
MAP3Ks are involved in activating ERKs. Tumour progression locus 2 (TPL2) or MAP3K8 is a 
serine/threonine kinase that has been shown to activate ERK (Dumitru, Ceci et al. 2000, Cho, 
Melnick et al. 2005). TPL2 is phosphorylated by the IKK complex and activates ERK via the 
phosphorylation of MAPK/ERK kinase (MEK) (Banerjee, Gugasyan et al. 2006, Robinson, Beinke 
et al. 2007, Gantke, Sriskantharajah et al. 2011, Roget, Ben-Addi et al. 2012). These MAPKs 
activate the transcription factor AP-1 (Medzhitov, Preston-Hurlburt et al. 1997). In addition, TAK1 
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activates IKK, comprising of subunits α and β (IKKα and IKKβ), as well as NEMO/IKKγ. 
Activated IKK phosphorylates IκB and this promotes its degradation. This in turn permits the 
release and nuclear translocation of the transcription factor NF-κB (Wang, Deng et al. 2001). NF-
κB, AP-1 and other transcription factors then drive inducible expression of target pro-inflammatory 
genes such as IL-1β, IL-6 and TNF-α (Medzhitov, Preston-Hurlburt et al. 1997).  
In addition to activating NF-κB, MyD88-dependent signalling also activates various members of the 
IRF family (Chapter 1). The activation of different IRFs, depending on the cell type, enables 
MyD88-dependent TLR signalling pathways to impart cell-type-specific TLR responses. Since 
IRF6 is highly expressed by keratinocytes (Chapter 3), it may be involved in keratinocyte-specific 
MyD88-driven TLR signalling responses. In this chapter, I investigated whether keratinocytes are 
responsiveness to the MyD88-dependent TLR agonists imiquimod (TLR7 agonist) and the synthetic 
lipopeptide FSL-1 (TLR2/6 agonist). I also investigated whether differentiating or priming agents 
modulate TLR7 and TLR2/6 responses, and if so, whether IRF6 plays any role in such effects.  
5.2 Results 
5.2.1 Primary keratinocytes are responsive to the TLR7 agonist Imiquimod 
The TLR7 agonist imiquimod is commonly used as a topical cream to treat various mild to serious 
skin conditions (Novak, Yu et al. 2008, Walter, Schafer et al. 2013). The mechanism of action is not 
well understood, but presumably involves induction of inflammatory responses that help in skin 
repair. To determine if keratinocytes are responsive to imiquimod, keratinocytes were stimulated for 
4, 8 or 24 h with imiquimod, at a concentration previously shown to be stimulatory on other cell 
types (Schroder, Spille et al. 2007, Huang, Liu et al. 2010). As an initial read-out, IL-8 levels in 
culture supernatants were measured by ELISA (Figure 5.1A). Imiquimod induced robust IL-8 
secretion in these cells at all time points examined (> 30 fold). Regulated gene expression was next 
examined. Given the effect of imiquimod on regulated IL-8 production (Figure 5.1A), IL-8 mRNA 
levels were assessed. IFN-β and CCL5 were also examined, because these have been identified as 
MyD88-dependent IRF target genes in other systems (Tamura, Yanai et al. 2008). As anticipated, 
imiquimod robustly upregulated IL-8 mRNA levels (~ 35 fold at 8 h post-stimulation) in primary 
keratinocytes (Figure 5.1B). In contrast, IFN-β mRNA levels were only very modestly, but not 
significantly, increased across the time course (~ 2 - 3 fold) (Figure 5.1C), and CCL5 mRNA levels 
expression was upregulated ~ 4 fold at 24 h post-stimulation (Figure 5.1D). IL-23p19, which was 
identified as an IRF6 target gene in the previous chapter, was only very weakly regulated by 
imiquimod (~ 2 fold) (data not shown). 
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Figure 5.1. Primary keratinocytes are responsive to the TLR7 ligand imiquimod. Primary 
keratinocytes were stimulated with the TLR7 ligand imiquimod (25 µg/ml). At 4, 8 and 24 h post-
stimulation, culture supernatants were collected (A) and total RNA was prepared (B – D). (A) IL-8 
levels in culture supernatants were measured using ELISA. Data represents mean ± SD of 
experimental triplicates and is representative of two independent experiments. (B) IL-8, (C) IFN-β 
and (D) CCL5 mRNA levels, relative to the housekeeping gene HPRT, were quantified using qPCR. 
Data (relative to the 4 h unstimulated control) represents mean ± SEM from 3 independent 
experiments, * p < 0.05, ** p < 0.01 as compared to unstimulated control (two-way ANOVA, 
followed by Tukey’s test). 
 
5.2.2 IRF6 knockdown impairs TLR7-mediated IFN-β and CCL5 gene induction in primary 
keratinocytes  
The above data indicated that primary keratinocytes responded to the TLR7 ligand imiquimod with 
modest upregulation of IFN-β and CCL5. In order to determine if IRF6 is involved in these 
responses, a siRNA-mediated gene silencing approach was used (as described in Chapter 4). 
siSLC39A8, that targets another gene, the zinc transporter SLC39A8, was used as a control siRNA 
in these particular experiments. IRF6 knock-down reduced basal IRF6 mRNA expression (Figure 
5.2A). Interestingly, imiquimod also upregulated IRF6 mRNA expression; this response was also 
reduced by transfection with an IRF6 siRNA (Figure 5.2B). The modest level of imiquimod-
mediated IFN-β induction at 4 h post-stimulation (~ 3 fold) was ablated in siIRF6 transfected cells 
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(Figure 5.2C). IRF6 knockdown also diminished imiquimod-inducible CCL5 expression 
substantially (Figure 5.2D), whilst IL-8 expression was unaffected (Figure 5.2E). These data, 
therefore, suggest that imiquimod-inducible IFN-β and CCL5 expression in keratinocytes is driven 
by IRF6.  
 
 
Figure 5.2. IRF6 knock-down impairs TLR7-mediated IFN-β and CCL5 gene induction in 
primary keratinocytes. IRF6 expression in primary human keratinocytes was knocked down by 
reverse transfection using siRNA (200 pM). siSLC39A8 was used as a control siRNA targeting 
another gene. After 72 h, cells were stimulated with imiquimod (25 µg/mL) for 4 h or were left 
unstimulated. Total RNA was collected and mRNA expression, relative to HPRT, was quantified by 
qPCR for (A) IRF6 (basal), (B) IRF6 (inducible), (C) CCL5, (D) IFN-β and (E) IL-8. Data 
represents mean ± SEM from 4 independent experiments, * p<0.05, ** p<0.01 (compared to siRNA 
control) (Two-way ANOVA, followed by Tukey’s test). For (B) to (E), data are displayed relative 
to the imiquimod-stimulated siRNA control. 
 
5.2.3 Keratinocyte differentiation enhances imiquimod inducible CCL5 expression 
Interestingly, in the siRNA knock-down experiments, imiquimod did increase CCL5 mRNA levels 
at 4 h post-stimulation (Figure 5.2), in contrast to my previous observations (Figure 5.1). This 
suggested that the keratinocytes were either primed during transfection, or that they underwent a 
change in proliferation status which made them more sensitive to imiquimod. To determine if 
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differentiation status affected keratinocyte responsiveness to imiquimod, these cells were treated 
with Y27632 or Ca2+ for 24 h (as described in Chapter 3), prior to stimulation. mRNA levels of 
inducible IFN-β and CCL5 were quantitated by qPCR. The untreated and Ca2+-differentiated cells 
responded with some induction of IFN-β expression at 4 h post-stimulation as previously observed, 
however proliferating cells (Y27632-treated) did not show this response (Figure 5.3A). Similarly, 
keratinocyte differentiation status also affected imiquimod-inducible CCL5 expression. In 
proliferating cells (Y27632-treated), CCL5 mRNA expression was actually downregulated in 
response to imiquimod, while it was upregulated in differentiated cells (Figure 5.3B). Untreated 
cells, as observed previously (Figure 5.1D), did not show any CCL5 induction at 4 h post-
imiquimod stimulation (Figure 5.3B). These results therefore suggest that differentiation of 
keratinocytes enhances imiquimod responsiveness, including enabling a more rapid induction of 
CCL5 expression. 
 
Figure 5.3. Keratinocyte differentiation enhances imiquimod-inducible CCL5 expression. 
Keratinocytes were treated with Y27632 (5 µM) or Ca2+ (2 mM) for 24 h to maintain proliferation 
or to induce differentiation, respectively, or were left untreated. Cells were then stimulated with 
imiquimod (25 μg/ml) for 4 h. Total RNA was collected and mRNA levels of (A) IFN-β and (B) 
CCL5 were quantified, relative to HPRT, using qPCR. Data (relative to the untreated control) 
represents mean ± range from 2 independent experiments.  
 
5.2.4 IFN-γ priming does not affect imiquimod-inducible gene expression 
In the previous chapter, I found that IFN-γ priming enhanced TLR3-inducible expression of certain 
genes. Therefore, the next aim was to determine if IFN-γ priming also enhances TLR7-mediated 
responses as well. Primary keratinocytes were primed with IFN-γ for 24 h and then stimulated with 
imiquimod for 4, 8 and 24 h, after which inducible IFN-β and CCL5 mRNA levels were quantified. 
Treatment with imiquimod only modestly upregulated IFN-β and CCL5 expression, and these 
apparent increases were not statistically significant (Figure 5.4A-B). This observation is broadly 
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consistent with earlier findings (Figure 5.1), although in the earlier experiments IFN-β was 
regulated across the entire 24 h time course. IFN-γ alone upregulated mRNA levels of IFN-β and 
CCL5, but it did not enhance the subsequent response to imiquimod, for IFN-β (Figure 5.4A), and 
the priming effect on CCL5 was marginal (Figure 5.4B).  
 
Figure 5.4. IFN-γ priming does not enhance imiquimod-inducible gene expression. 
Keratinocytes were primed with IFN-γ (2.5 ng/ml) for 24 h, and were then stimulated with 
imiquimod (25 μg/ml) for 4 h. Total RNA was collected and mRNA levels of (A) IFN-β and (B) 
CCL5 were quantified, relative to HPRT, using qPCR. Data (relative to 4 h control) represents mean 
± SEM from 3 independent experiments.  
 
5.2.5 Differentiation status of keratinocytes has little effect on IFN-γ priming of TLR7 
responses 
Since differentiation of keratinocytes appeared to enhance imiquimod-inducible IFN-β and CCL5 
expression in keratinocytes, I next wanted to determine if differentiation status affects the capacity 
of IFN-γ to prime TLR7 responses. Thus, keratinocytes were treated with Y27632 or Ca2+ to 
maintain proliferation or induce differentiation, respectively. As previously observed (Figure 5.3), 
differentiation of keratinocytes enhanced imiquimod-regulated gene expression; however, this still 
did not enable IFN-γ to prime TLR7 responses (Figure 5.5A-B). This was partly because IFN-γ 
alone robustly upregulated CCL5 mRNA expression in differentiated keratinocytes. These data 
were also variable between the two experiments performed, possibly because untreated cells had a 
partially differentiated phenotype in one of the experiments. In summary, these data suggest that 
primary keratinocytes respond very weakly to imiquimod with IRF6-dependent induction of IFN-β 
and CCL5. 
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Figure 5.5. Differentiation of keratinocytes does not permit IFN-γ priming of TLR7 responses. 
Keratinocytes were treated with Y27632 (5 μM) or Ca2+ (2 mM) for 24 h to maintain proliferation 
or induce differentiation, respectively, or were left untreated. Cells were then primed with IFN-γ 
(2.5 ng/ml) for 24 h, after which they were stimulated with imiquimod (25 μg/ml) for 4 h. Total 
RNA was collected and mRNA levels of (A) IFN-β and (B) CCL5 were quantified, relative to 
HPRT, using qPCR. Data represents mean ± range from 2 independent experiments.  
 
5.2.6 Primary keratinocytes respond to the TLR2/6 agonist FSL-1 
Given that S. aureus is a common skin commensal and that it signals via TLR2/6 (Schroder, Morath 
et al. 2003, Vu, Baba et al. 2010), responses through this MyD88-dependent signalling platform 
were also investigated in this chapter. The synthetic lipopeptide FSL-1 (Okusawa, Fujita et al. 
2004), which signals via TLR2/6, was used for these studies. Hence, primary keratinocytes were 
stimulated with FSL-1 (100 ng/ml) for 4, 8 or 24 h, after which mRNA levels of IL-8, IFN-β, CCL5 
and IL-23p19 were quantified. FSL-1 strongly upregulated (10 fold) IL-8 expression (Figure 5.6A). 
This effect was similar to that previously observed with imiquimod (Figure 5.1A-B). In contrast, 
there was no obvious effect on IFN-β expression (Figure 5.6B). FSL-1 treatment substantially 
increased mRNA levels of CCL5 (20 fold) and very modestly, but not significantly, increased those 
of IL-23p19 (5 fold) (Figure 5.6C-D). Interestingly, FSL-1 did not have any effect on IRF6 mRNA 
expression (Figure 5.6E). 
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Figure 5.6. Primary keratinocytes respond to the TLR2/6 ligand FSL-1. Primary keratinocytes 
were stimulated with the TLR2/6 ligand FSL-1 (100ng/ml) for 4, 8 or 24 h. Total RNA was 
collected at the indicated time points and mRNA levels of (A) IL-8, (B) IFN-β, (C) CCL5, (D) IL-
23p19 and (E) IRF6 were quantified, relative to HPRT, using qPCR. Data represents mean ± SEM 
from 3 independent experiments. * p<0.05, *** p<0.001 (compared to unstimulated control) (two-
way ANOVA, followed by Tukey’s test). 
 
5.2.7 Effect of IRF6 knockdown on TLR2/6 responses in primary keratinocytes  
To determine if any of the FSL-1-induced responses were dependent on IRF6, IRF6 expression was 
knocked down in keratinocytes, using previously established approaches. Successful knock-down of 
IRF6 and IRF3 was confirmed at the mRNA level (Figure 5.7A-B). However, several repeat 
experiments confirmed the very surprising finding that siRNA transfection almost completely 
ablated the FSL-1 response (data not shown). A very modest FSL-1 response was retained in only 
one single experiment, and these data are presented here. FSL-1 inducible IL-8 expression was 
modestly reduced after knock-down of either IRF6 or IRF3 (Figure 5.7D). The FSL-1-mediated 
induction of CCL5 was also impaired after IRF6 knock-down, whereas IRF3 knockdown did have 
an effect (Figure 5.7E). Similarly, inducible IL-23p19 expression also appeared to be reduced by 
IRF6 knock-down (Figure 5.7F). Given the problems with this experimental approach, these data 
are difficult to interpret. Nonetheless, they suggest that FSL-1-inducible CCL5 and IL-23p19 
expression is IRF6-dependent in keratinocytes.  
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Figure 5.7. Effect of IRF6 knock-down on FSL-1 responses in primary keratinocytes. IRF6 
(using two different siRNAs) and IRF3 gene expression was silenced in primary human 
keratinocytes by reverse transfection using siRNA (200 pM). siSLC39A8 was used as a control 
siRNA targeting another gene. After 72 h, cells were stimulated with FSL-1 (100 ng/ml) for 4 h or 
were left unstimulated. Total RNA was collected and gene expression was quantified, relative to 
HPRT, for (A) IRF6 (basal), (B) IRF3, (C) IRF6 (inducible), (D) IL-8, (E) CCL5 and (F) IL-23p19 
by qPCR. Data represents mean ± SD of experimental triplicates. 
 
5.2.8 Investigation of FSL-1-mediated IRF6 nuclear expression in primary keratinocytes  
The next aim was to determine whether FSL-1 triggers IRF6 translocation into the nucleus in 
keratinocytes. Thus, primary keratinocytes were stimulated with FSL-1 over a time-course or were 
left untreated, after which immunofluorescence microscopy was performed to visualize IRF6 
localization. The cells were also stained with DAPI (nuclear) and Phalloidin (actin) to visualize cell 
morphology. Consistent with previous experiments (see Chapter 4), IRF6 was localized to both the 
nucleus and the cytoplasm in these cells (Figure 5.8A). Upon stimulation with FSL-1 for 4 h, IRF6 
expression levels, in both the nucleus and cytoplasm, appeared to be enhanced as compared to 
unstimulated cells (Figure 5.8B). This expression was quantified using Image J software. The mean 
fluorescence intensity per cell of IRF6 in the cytoplasm and in the nucleus was calculated using 
Phalloidin and DAPI to mark the boundaries. At least 6-8 random frames of cells (7-10 cells/frame) 
were and quantified, in a blinded fashion, from each experiment. This quantitative analysis 
confirmed that IRF6 expression was indeed enhanced in both cytoplasm and nucleus upon FSL-1 
stimulation (Figure 5.8C-D). This contrasts with the gene expression data in which FSL-1 did not 
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upregulate IRF6 mRNA expression (Figure 5.6E).  This suggests that FSL-1 treatment may 
stabilize IRF6 protein, thereby prolonging its half-life. Because of this phenomenon, it is not clear 
from these data as to whether FSL-1 does trigger IRF6 nuclear translocation. 
 
Figure 5.8. FSL-1 increases IRF6 protein expression in primary human keratinocytes. IRF6 
localization was determined in (A) control and (B) FSL-1-stimulated (100 ng/ml for 4 h) primary 
keratinocytes using immunofluorescence microscopy. The arrows indicate cytoplasmic staining and 
the arrowheads indicate nuclear staining of IRF6. Mean fluorescence intensity/cell in (C) the 
cytoplasm and (D) the nucleus in control and FSL-1-stimulated cells was calculated using ImageJ 
software. Data represents mean ± SEM of 3 independent experiments, using 6-8 different frames of 
cells per experiment, **** p<0.0001 (compared to control) (Wilcoxon signed rank test). 
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5.3 Summary and discussion of Chapter 5 
5.3.1 Involvement of IRF6 in TLR7 responses in keratinocytes 
Despite it’s clinical use in skin-related conditions, the mechanisms by which imiquimod mediates 
skin repair are not well understood. In primary human keratinocytes, imiquimod stimulation has 
previously been shown to activate NF-κB and to upregulate the proinflammatory genes IL-6, IL-8, 
TNF-α and IL-1β (Kono, Kondo et al. 1994, Kollisch, Kalali et al. 2005, Olaru and Jensen 2010, Li, 
Sohn et al. 2013). Consistent with this, I also found that imiquimod upregulated IL-8 mRNA 
expression and induced IL-8 secretion. TLR7 primarily detects ssRNA from viruses and is involved 
in the production if type-1 IFNs (Diebold, Kaisho et al. 2004, Lund, Alexopoulou et al. 2004). 
However, there may be a link between TLR7 and the dsDNA virus, HSV-1. HSV-1 is a causative 
pathogen for cold sores, keratitis, and genital herpes in skin (Grinde 2013). Interestingly, HSV-1 
infection was reported to upregulate TLR7 expression in human corneal epithelial cells (Li, Zhang 
et al. 2006), and imiquimod treatment provided protection against HSV infections (Harrison, Jenski 
et al. 1988, Bernstein and Harrison 1989, Harrison, Stanberry et al. 1991, Slade, Owens et al. 1998). 
HSV-infected macrophages and fibroblasts were reported to produce CCL5 in an NF-κB- and IRF3-
dependent manner, which may allow migration of other leukocytes to site of infection to initiate 
appropriate antiviral responses (Melchjorsen and Paludan 2003). My findings that imiquimod 
upregulated CCL5 and IFN-β mRNAs in an IRF6-dependent manner in keratinocytes may implicate 
this transcription factor in the therapeutic effects of imiquimod in this setting. 
As previously discussed (Chapter 1.2.1), IRFs impart cell-type specific responses in MyD88-
dependent signalling. TLR7 uses MyD88-dependent signalling to activate IRF5 in macrophages 
(Schoenemeyer, Barnes et al. 2005), while it uses IRF1 in cDCs (Negishi, Fujita et al. 2006, 
Mancuso, Gambuzza et al. 2009, Hoshino, Sasaki et al. 2010) and IRF7 in pDCs to activate 
transcription of type-1 IFN (Uematsu, Sato et al. 2005). This is due to differential IRF expression; 
IRF1 is highly expressed in cDCs (Negishi, Fujita et al. 2006, Schmitz, Heit et al. 2007), while 
IRF7 is highly expressed in pDCs (Honda, Yanai et al. 2005). Considering that IRF6 is highly 
expressed in keratinocytes, it is likely that TLR7 engages IRF6 for activation of target genes such as 
IFN-β and CCL5. My data support this conclusion, since IRF6 knockdown impaired the modest 
imiquimod-mediated induction of IFN-β and CCL5 that was observed in keratinocytes. In the 
previous chapter, I also showed that IRF6 can activate the IFN-β promoter (see section 4.2.1), and 
IRF6 has also been shown to enhance IRAK-1-mediated activation of the CCL5 promoter (A/Prof 
Glen Scholz, personal communication). Whether imiquimod stimulation enhances IRF6-mediated 
activation of the IFN-β and CCL5 promoters could therefore be investigated in further studies. The 
conclusion that MyD88 signalling drives IRF6 activation is further supported by the finding that 
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IRF6 interacts with IRAK-1, as shown by co-immunoprecipitation analyses (A/Prof Glen Scholz, 
personal communication). This is interesting in light of the fact that other members of the IRF 
family (e.g. IRF3, IRF5 and IRF7) have been shown to undergo Ser phosphorylation. The 
phosphorylation sites have been mapped to Ser-385 and Ser-386 in their C-terminal region of IRF3 
(Suhara, Yoneyama et al. 2000). This ser residue is also conserved and functional in IRF5 and IRF7 
(Marie, Smith et al. 2000, Cheng, Brzostek et al. 2006). Mutation of the corresponding Ser residues 
in IRF3 and IRF7 abolished IRF transcriptional activity (Marie, Smith et al. 2000, Suhara, 
Yoneyama et al. 2000). Multiple protein alignment analysis shows that the Ser sites that are present 
in IRF3, IRF5 and IRF7 are also conserved in IRF6 (Ser-413 and Ser-424) (A/Prof Glen Scholz, 
personal communication) (Figure 5.9). Mutational analysis has confirmed that both of these 
residues are required for maximal IRAK-1-mediated activation of IRF6 transcriptional activity in 
reporter gene assays (A/Prof Glen Scholz, personal communication). Thus, in the future, these 
mutants of IRF6 (Ser to Alanine for inactive; Ser to Glutamic acid for phosphomimetic) could be 
used for analysis of TLR7 signalling responses. This would help determine whether IRF6 
phosphorylation is required for TLR7 signalling, and may also help to identify the kinases in the 
TLR7 signalling pathway that activate IRF6 (presumably IRAK-1, but possibly others as well). In 
addition, gain-of-function studies are also required to determine if IRF6 overexpression in epithelial 
cells deficient in IRF6 protein (e.g. T24 cells, Figure 3.1C) can permit imiquimod-inducible IFN-β 
and CCL5 expression.  
 
 
Figure 5.9. Phosphorylation sites in IRF6. Protein sequence of human IRF3, 5, 6 and 7 were 
aligned using ClustalW programs. The Ser phosphorylation sites identified in IRF3 are conserved 
between all four IRFs and are highlighted in yellow. The known kinases that phosphorylates these 
IRFs are listed on the right.  
 
There were some intriguing aspects to the findings on TLR7 responsiveness in keratinocytes. 
Firstly, although imiquimod triggered robust upregulation of IL-8, the effect on IFN-β and CCL5 
was very modest. Assuming that the former gene is downstream of NF-B (Mukaida, Mahe et al. 
1990, Kunsch and Rosen 1993, Matsusaka, Fujikawa et al. 1993, Stein and Baldwin 1993, Kunsch, 
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Lang et al. 1994) and the latter are downstream of IRF6 (Figure 5.2C and D), this would suggest 
that there may be some mechanism that selectively constrains TLR7-mediated IRF6 activation in 
keratinocytes. Interestingly, TLR7 responses appeared to be somewhat enhanced when the cells 
underwent transfection, when compared to normally cultured cells. This suggests that the act of 
transfection primed or caused a change in these cells that made them more responsive to 
imiquimod. During transfections, the cells are cultured for 72 h in media without any Y27632, 
which maintains them in a proliferative state, prior to stimulation with imiquimod. Therefore, these 
transfected cells, in the absence of Y27632, may be undergoing differentiation prior to TLR7 
activation. This conclusion is supported by the observation that TLR7-mediated induction of IFN-β 
and CCL5 expression was enhanced in Ca2+-treated differentiated keratinocytes, as compared to 
Y27632-treated proliferating keratinocytes. Since I did not observe any difference in TLR7 mRNA 
levels upon differentiation (Figure 3.8), it is possible that the effect relates to the increased IRF6 
expression that occurs after differentiation (Figure 3.7A and C). My findings contrast with a recent 
study in primary human keratinocytes, which reported that TLR7 mRNA and TLR7 protein was 
increased upon differentiation (Li, Sohn et al. 2013). The time of differentiation used in this study 
differs from my own. Keratinocytes were differentiated for a prolonged time (14 d) (Li, Sohn et al. 
2013), as opposed to the 24 h used in my experiments. Thus, it is possible that increases in both 
TLR7 and IRF6 expression during keratinocyte differentiation permit enhanced imiquimod 
responsiveness. This warrants further investigation.  
5.3.2 Involvement of IRF6 in TLR2/6 responses in keratinocytes 
TLR2 is the principle receptor that recognizes lipoproteins from Gram-positive bacteria. Previous 
studies reported that primary human keratinocytes constitutively express functional TLR2 and 
produce IL-8 and β-defensins when stimulated with TLR2 agonists (Kawai, Shimura et al. 2002, 
Mempel, Voelcker et al. 2003). In my hands, I did not find any evidence that human keratinocytes 
respond to the TLR2/TLR1 agonists Pam3Cys and zymosan (Figures 3.2-3.4). In contrast, 
keratinocytes responded robustly to the TLR2/6 ligand FSL-1 (Figure 5.6). This was of interest 
because the TLR2/6 heterodimer has been reported to be required for the detection of S. aureus, a 
skin commensal that is also a significant human pathogen (Lowy 1998, Ozinsky, Underhill et al. 
2000, Chiller, Selkin et al. 2001, Morr, Takeuchi et al. 2002, von Aulock, Morath et al. 2003, 
Hoebe, Georgel et al. 2005, Bunk, Sigel et al. 2010, Vu, Baba et al. 2010). Upon S. aureus 
infection, keratinocytes have been shown to produce the pro-inflammatory cytokines TNF-α, IL-8 
and TSLP, as well as β-defensins (Mempel, Voelcker et al. 2003, Midorikawa, Ouhara et al. 2003, 
Sumikawa, Asada et al. 2006, Aufiero, Guo et al. 2007, Kisich, Howell et al. 2007, Vu, Baba et al. 
2010, Ommori, Ouji et al. 2013). The cell-wall component of S. aureus consists of both diacylated 
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and triacylated lipoproteins (Kurokawa, Lee et al. 2009, Tawaratsumida, Furuyashiki et al. 2009), 
however, the pro-inflammatory responses to S. aureus, such as TSLP induction, was reported to 
signal via TLR2/6 (Vu, Baba et al. 2010). Activation by S. aureus was also shown to be dependent 
on staphylococcal lipoprotein SitC which binds to TLR2 (Kurokawa, Lee et al. 2009, Muller, 
Muller-Anstett et al. 2010, Kurokawa, Kim et al. 2012). Although a role for TLR2 in S. aureus 
clearance is still debatable (Miller, O'Connell et al. 2006), Tlr2-/- deficient mice have been reported 
to succumb to S. aureus infection (Takeuchi, Hoshino et al. 2000), thus supporting the view that 
this receptor has an important in vivo function in response to this pathogen. 
My studies in this chapter focused on FSL-1 rather than S. aureus, as both these stimuli are 
recognized by TLR2/6 (Ozinsky, Underhill et al. 2000, Morr, Takeuchi et al. 2002, Okusawa, Fujita 
et al. 2004, Vu, Baba et al. 2010). S. aureus also contains SitC, a triacylated lipoprotein that was 
reported to signal independently of TLR2 (Muller, Muller-Anstett et al. 2010). This suggests that S. 
aureus may engage other PRRs in addition to TLR2/6, and that it may elicit TLR2/6-dependent and 
–independent responses. One possibility is that, in keratinocytes, TLR2/6 is the primary receptor 
that recognizes S. aureus and that this receptor complex sensitizes the cells to induce an initial rapid 
inflammatory response. For example, the upregulation of IRF6 protein expression by FSL-1 (and 
presumably S. aureus acting on TLR2/6) may permit enhanced inflammatory responses when a 
second PRR is engaged. Priming the cells with FSL-1, and then examining responses to other TLR 
ligands would reveal if this is indeed the case.  
Whereas FSL-1 had almost no effect on expression of IFN-β, it triggered pronounced upregulation 
of IL-8 and CCL5 expression in keratinocytes (Figure 5.6 B and C). Similarly IL-8 was upregulated 
by S. aureus in keratinocytes (Mempel, Voelcker et al. 2003), whilst CCL5 was reported to be S. 
aureus-inducible in epidermal Langerhans cells and oseteoblasts (Wright and Friedland 2004, 
Matsui, Wirotesangthong et al. 2007). Knockdown studies indicated that silencing of IRF6 and 
IRF3 modestly reduced inducible IL-8 expression. It would be interesting to examine whether 
combined silencing of these transcription factors would have a more pronounced effect then 
knockdown of each transcription factor alone. The modest effects of siRNAs targeting IRF6 and 
IRF3 may also reflect that IL-8 is a well-characterized NF-κB target gene (Mukaida, Mahe et al. 
1990, Kunsch and Rosen 1993, Matsusaka, Fujikawa et al. 1993, Stein and Baldwin 1993, Kunsch, 
Lang et al. 1994). IRF6 knockdown did appear to have a more pronounced effect on FSL-1-
inducible CCL5 expression, and the effect was selective since silencing of IRF3 had no clear effect. 
Unfortunately however, this result could not be replicated as, in subsequent experiments, FSL-1 
mediated CCL5 induction was not apparent. Even in the presented experiment, FSL-1-inducible 
CCL5 and IL-8 expression was very low by comparison to that observed in untransfected cells 
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(compare Figures 5.6A and 5.7D). The most obvious explanation is that the process of transfection 
somehow interferes with TLR2/6 responsiveness of these cells. Since CCL5 induction was lost in 
cells transfected without any siRNA, it is likely that this lack of response is due to the transfection 
procedure, and not due to the presence of siRNA. The transfection media contains lipofectamine, 
which comprises cationic liposomes that forms complexes with negatively charged nucleic acids, 
fuses with the cell membrane and is delivered into the cells (Felgner, Gadek et al. 1987, Zhao, 
Watarai et al. 1997). It is possible that the lipofectamine is somehow interfering with TLR2/6 
signalling, for example dysregulating expression or trafficking of this receptor complex. 
Lipofectamine only affected FSL-1 responses, and not poly(IC) or imiquimod responses, thus 
indicating that TLR responses were not broadly affected. Other transfection approaches, such as 
electroporation, could be used in the future to reinvestigate the impact of IRF6 knockdown on 
keratinocyte responses to FSL-1 (and S. aureus).  
TLR2 is differentially expressed in the different layers of the skin (Kawai, Shimura et al. 2002, 
Baker, Ovigne et al. 2003, Pivarcsi, Bodai et al. 2003). In normal skin, TLR2 is more highly 
expressed in the basal cell layers than in the upper epidermis (Baker, Ovigne et al. 2003). Since 
basal cells are proliferative in nature, as opposed to the terminally differentiated cells in the upper 
layers, it is possible that differentiation status affects TLR2/6 responsiveness. Given the findings on 
the effect of differentiation status on imiquimod responses, an attractive hypothesis is that 
proliferating keratinocytes in the basal layer are TLR2 responsive and TLR7 unresponsive, whilst 
the reverse is true for differentiated keratinocytes in the upper epidermis. Future studies on the 
effects of keratinocyte differentiation on TLR2 responses should thus be performed. If proliferative 
cells are indeed more responsive to FSL-1, then transfected cells could be cultured in media 
containing Y27632 to maintain them in a proliferating state. Assuming this model is correct, this 
would be predicted to restore TLR2/6 responses that are lost due to differentiation of the cells. 
Hence, these specific conditions might enable an assessment, through gene knockdown, of IRF6 
involvement in FSL-1 responses in keratinocytes. 
FSL-1 stimulation increased IRF6 protein expression in both the cytoplasm and the nucleus (Figure 
5.8 A). However, IRF6 mRNA was unaffected by FSL-1 stimulation (Figure 5.6 E). This 
complicates analysis of FSL-1-mediated IRF6 nuclear translocation, where a decrease in the 
cytoplasmic pool and an increase in the nuclear pool of IRF6 would be predicted. Future studies 
should therefore examine IRF6 nuclear translocation at earlier time points (e.g. 1 to 2 h), since it is 
possible that FSL-1 does not upregulate IRF6 protein expression by this time. As discussed in 
Chapter 4, it is also possible that IRF6 is very rapidly exported out of the nucleus, making it 
difficult to capture nuclear accumulation of IRF6. Treating cells with the nuclear export inhibitor 
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leptomycin B prior to FSL-1 stimulation may be a more suitable approach to monitor IRF6 
translocation. Live imaging using a GFP-tagged IRF6 construct represents another avenue that 
could be pursued in the future. 
In summary, in this chapter, I identified a possible role for IRF6 in mediating MyD88-dependent 
CCL5 induction in primary keratinocytes. Together with my findings in Chapter 4, these data 
suggest that IRF6 has distinct roles in MyD88-dependent and TRIF-dependent TLR signalling. This 
is further discussed in Chapter 6. 
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6.1 Introduction 
The major findings from this thesis were that (1) IRF6 is highly expressed in keratinocytes; (2) 
keratinocytes respond to the TLR3, TLR7 and TLR2/6 agonists poly(IC), imiquimod and FSL-1, 
respectively; (3) IRF6 selectively drives polyIC-inducible IL-23p19 expression; (4) IRF6 drives 
imiquimod-inducible IFN-β and CCL5 expression; and (5) FSL-1 may also promote IRF6-
dependent CCL5 expression. These data suggest a role for IRF6 in both TRIF-dependent and 
MyD88-dependent TLR signalling and this will be discussed further in this chapter. In addition, 
some preliminary data relating to future directions for this project will also be presented and 
discussed. 
 
6.2 Roles of IRF6 in TRIF-dependent TLR signalling in keratinocytes  
6.2.1 The functions of TLR3 in keratinocytes 
Keratinocytes were highly sensitive to the synthetic dsRNA analogue poly(IC), which drives TLR3-
dependent signalling (Kollisch, Kalali et al. 2005, Miller, Sorensen et al. 2005, Dai, Sayama et al. 
2006, Lebre, van der Aar et al. 2007). In humans, dsRNA viruses are not usually pathogens of the 
skin, and do not typically infect keratinocytes. Nonetheless, TLR3 also has a role in host responses 
to the dsDNA virus HSV-1, a prevalent pathogen of the skin (Chew, Taylor et al. 2009). Human 
patients with heterozygous or homozygous mutations in TLR3 are susceptible to HSV-1 
encephalitis (Zhang, Jouanguy et al. 2007, Guo, Audry et al. 2011, Sancho-Shimizu, Perez de Diego 
et al. 2011, Lafaille, Pessach et al. 2012). Therefore, human keratinocytes may use TLR3 to initiate 
appropriate inflammatory responses to this particular pathogen. Furthermore, TLR3 function is not 
limited to pathogen recognition. Studies on human keratinocytes have also revealed a role for TLR3 
in detecting DAMPs, such as RNA, released from damaged cells (Lai, Di Nardo et al. 2009). More 
recently, TLR3 was shown to detect UV-damaged U1 non-coding RNA upon exposure to UVB 
radiation, resulting in the release of inflammatory cytokines, such as TNF-α and IL-6 (Bernard, 
Cowing-Zitron et al. 2012). UV radiation was also found to activate NF-κB signalling in an IKK-
independent manner (Lewis and Spandau 2007) and promote the secretion of pro-inflammatory 
cytokines, such as IL-6 and TNF-α (Abeyama, Eng et al. 2000, Grandjean-Laquerriere, Gangloff et 
al. 2002). Interestingly, studies have linked altered pro-inflammatory signalling and cytokine 
release to UV-induced skin disorders, including SCC (Muthusamy and Piva 2010). UV-damage has 
also been shown to activate MAPK p38 and JNK signalling (described in Section 5.1) (Chouinard, 
Valerie et al. 2002, Hildesheim, Awwad et al. 2004, Schieke, Ruwiedel et al. 2005), but whether 
TLR3 is involved in these responses is unknown at this stage. The MAPK pathways are involved in 
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the maintenance of proliferation, differentiation and homeostasis in the epidermis (Marcinkowska, 
Wiedlocha et al. 1997, Mitev and Miteva 1999, Zhang, Pelech et al. 2001), however, they also 
promote the growth of SCC (Tsang and Crowe 1999). For example, in vivo studies in 
immunocompromised mice showed that adenoviral inhibition of endogenous p38 suppressed SCC 
growth, while a JNK inhibitor suppressed the proliferation of human head and neck SCC cells 
(Gross, Boyle et al. 2007, Junttila, Ala-Aho et al. 2007). IRF6, a critical factor for keratinocyte 
differentiation, has been reported to be downregulated in progressive tumours (discussed further in 
Section 6.3.4) (Botti, Spallone et al. 2011). Although I found that TLR3 signalling induced IRF 
expression (Figures 4.3I and 4.7D), it is possible that prolonged activation of these signalling 
pathways in response to UV radiation may have a different effect, for example downregulating 
IRF6 expression leading to SCC growth and proliferation. Alternatively, UV radiation likely has 
additional effects to TLR3 signalling, which may target IRF6 for degradation. 
There is also evidence that TLR3 plays a role in responses during physical injury. TLR3 mRNA and 
protein was upregulated in wounded skin and was required for TNF-α and IL-6 production at 
wound edges (Lai, Di Nardo et al. 2009, Lin, Fang et al. 2011). Furthermore, Tlr3-/- mice showed 
delayed wound closure (Lin, Fang et al. 2011). Tlr3 deficiency resulted in decreased chemokine 
secretion, leading to defective recruitment of neutrophils and macrophages to the site of injury (Lin, 
Fang et al. 2011, Lin, Wang et al. 2012). TLR3 activation also upregulated the expression of genes 
associated with maintenance of epidermal structure, such as ATP-binding cassette sub-family A 
member 12, glucocerebrosidase, acid sphingomyelinase, and transglutaminase 1 (Borkowski, Park 
et al. 2013). Collectively, these data indicate that TLR3 has a critical role in detecting cell damage 
signals and initiating wound healing and cell repair processes.  
 
6.2.2 The role of IRF6 in TLR3 signalling  
In this thesis, I provided evidence that IRF6 is downstream of TLR3 signalling and selectively 
regulates the expression of IL-23p19, however the mechanism of IRF6 activation by poly(IC) is still 
unknown. Poly(IC) stimulation upregulated IRF6 mRNA and protein (Figures 4.3I and 4.7D), and 
appeared to promote its nuclear translocation (Figure 4.7). Therefore, one possibility of IRF6 
activation is that it is directly activated by TLR3 signalling to initiate responses. TLR3 signalling 
also rapidly upregulated IFN-β mRNA expression (4 h post stimulation) in an IRF6-independent 
and IRF3-dependent manner (Figures 4.3D and 4.4C). Intriguingly, IRF6 dependent responses 
were delayed and peaked at 24 h post stimulation (Figure 3.3) and concurrently, IRF6 nuclear 
translocation was also evident at a later time point (6 h post-stimulation) (Figure 4.7D). Thus, it is 
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also possible that TLR3 signalling leads to IFN-β expression, which acts as an autocrine factor to 
regulate IRF6-dependent responses. These possibilities require further investigation. IRF6 
presumably has a role in the regulated expression of poly(IC)-inducible target genes, other than IL-
23p19. A recent study used both ChIP-seq and gene knockdown approaches in differentiating 
human keratinocytes to identify IRF6 target genes (Botti, Spallone et al. 2011). Although most of 
the target genes found by this approach were associated with keratinocyte 
proliferation/differentiation pathways, there were some genes that could potentially be downstream 
of TLR signalling. For example, two members of the IL-1 cytokine family, IL-37 and IL-36γ, were 
significantly downregulated in the absence of IRF6 (Botti, Spallone et al. 2011). The biological 
functions of both these cytokines are not well understood, but interestingly, HSV infection of 
keratinocytes elicited IL-36γ production (Kumar, McDonnell et al. 2000). Poly(IC) has also been 
shown to induce IL-36γ expression in keratinocytes, suggesting a potential role for this cytokine 
downstream of TLR3 signalling in skin (Lian, Milora et al. 2012). IL-37, like other members of the 
IL-1 family, is also produced as a precursor and must be cleaved by caspase-1 to enable regulated 
release (Nold, Nold-Petry et al. 2010). IL-37 over-expression in mouse models suppressed LPS-
inducible inflammatory cytokines in macrophages, alveolar and colonic epithelial cells 
(Eidenschenk, Crozat et al. 2010, McNamee, Masterson et al. 2011). Thus, IL-37 appears to have an 
anti-inflammatory role. Whether TLR3 signalling in keratinocytes drives IRF6-dependent 
expression of these cytokines remains to be determined.  
Since TLR3 signalling has been implicated in wound healing, this raises the question of whether 
IRF6 has a similar role. Mutations in IRF6 cause cleft lip/palate disorders such as VWS and PPS 
(Koillinen, Wong et al. 2001). IRF6 mutations are also associated with non-syndromic cleft 
lip/palate (NSCLP), however this mutation occurs in only 12% of these cases, as opposed to 70% in 
VWS and 97% in PPS (Kondo, Schutte et al. 2002, Blanton, Cortez et al. 2005, Scapoli, Palmieri et 
al. 2005, Vieira, Avila et al. 2005, de Lima, Hoper et al. 2009). Comparative analysis of these 
patients suggests a possible role for IRF6 in wound healing. A study compared patients with VWS 
and NSCLP after corrective cleft surgery and found that patients with VWS are more likely to have 
wound complications (Jones, Canady et al. 2010). The study compared 17 VWS patients to 68 
patients with NSCLP and found that 47% of patients with VWS had wound complications, as 
opposed to 19% in NSCLP patients. Although the patient numbers were low and the effects cannot 
be definitively linked to IRF6, the study still raises the possibility that IRF6 does have a non-
redundant role in wound healing in humans. This conclusion is supported by one in vitro study, 
which showed that IRF6 mRNA was upregulated in normal keratinocytes during scratch wounding 
(Fitsialos, Chassot et al. 2007). In a preliminary experiment, I also examined the expression of Irf6 
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in mouse tissues during different stages of wound healing. I found that Irf6 expression was lost in 
the area around the wound, while the surrounding tissue expressed this protein (Figure 6.1). This 
contrasts somewhat with the above findings of upregulated IRF6 mRNA expression in normal 
keratinocytes during scratch wound assays (Fitsialos, Chassot et al. 2007), although that study 
examined mRNA expression, not protein. In fact, I observed a loss of Irf6 at the wound edges. The 
cells at the wound edges are likely to be rapidly proliferating basal cells, which normally do not 
express Irf6, so this is perhaps unsurprising. Nonetheless, the expression of IRF6 in the surrounding 
area, as well its expression during restoration of normal tissue architecture may help coordinate an 
appropriate wound healing response. 
 
Figure 6.1. IRF6 IHC in wounded skin of mice. Excisions (1 cm2) were made on the back of the 
mice and wounded skin, along with some surrounding skin, were removed 2, 3, 5, 14 d post injury. 
IHC was performed on the wounded skin at indicated d post-recovery, using an anti-IRF6 antibody. 
The wound area of the skin is indicated by arrowheads, and IRF6 staining (brown) is indicated 
using arrows. At d 14, the wound was healed, therefore, only surrounding tissue is shown. The 
surrounding area was also stained with an isotype control. Samples for IHC were kindly provided 
by A/Prof Kiarash Khosrotehrani (UQCCR). 
 
6.2.3 Possible role(s) of IL-23p19 in skin homeostasis and pathology 
IL-23 is a key pro-inflammatory cytokine driving psoriasis of skin (Tonel, Conrad et al. 2010). This 
is not surprising, because it is an important cytokine regulator of Th17 cell development (Happel, 
Zheng et al. 2003, Murphy, Langrish et al. 2003, Ghilardi, Kljavin et al. 2004, Schulz, Kohler et al. 
2008, Riol-Blanco, Lazarevic et al. 2010), and clinical studies have shown a central role for the 
Th17 axis in psoriasis (Blauvelt 2008). Genetic studies have also linked variation in the IL-23p19, 
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IL-12B and IL-23R genes with psoriasis (Capon, Di Meglio et al. 2007, Cargill, Schrodi et al. 2007, 
Nair, Duffin et al. 2009). Keratinocytes and dermal DCs secrete IL-23, which then activates Th17 
cells to produce the pro-inflammatory cytokines IL-17, IL-21 and IL-22 (Lee, Trepicchio et al. 
2004, Piskin, Sylva-Steenland et al. 2006, Wilson, Boniface et al. 2007, Manel, Unutmaz et al. 
2008). These cytokines further activate keratinocytes, which secrete pro-inflammatory cytokines, 
chemokines and antimicrobial peptides. The secretion of the CCL20 chemokine by keratinocytes 
also recruits Th17 cells, thereby sustaining and amplifying skin inflammation (Harper, Guo et al. 
2009). Therapeutic approaches targeting IL-23 are now being developed to treat psoriatic lesions 
and other inflammatory disorders (Kimball, Gordon et al. 2008, Leonardi, Kimball et al. 2008, 
Kimball, Gordon et al. 2011). Most existing literature would suggest that IL-23 has a negative role 
in wound healing. For example, IL-17 expression delayed wound closure and an anti-IL-17 
blocking antibody restored wound closure (Rodero, Hodgson et al. 2013). Furthermore, Il-12p40-/- 
mice showed accelerated wound healing capabilities (Matias, Saunus et al. 2011). However, this is 
not always the case; IL-23 was reported to be required for the normal healing of myocardia after 
ischemic injury (Savvatis, Pappritz et al. 2013). It is possible that there is an alternative role for IL-
23p19, as opposed to IL-23, in wound healing. Consistent with the selective upregulation of IL-
23p19 mRNA expression in keratinocytes in response to poly(IC) that I observed (Chapter 3), IL-
23p19 was selectively upregulated in UV-damaged keratinocytes (Kennedy-Crispin, Billick et al. 
2012). Hence, there is a possibility that IL-23p19 may have a distinct role to IL-23 during 
keratinocyte injury and skin repair.  
In this thesis, I found that poly(IC) robustly induced the mRNA expression of IL-23p19 and EBI3, 
but not other members of IL-12 cytokine family in keratinocytes. Therefore, it is unlikely that 
keratinocytes secrete IL-23, which is a combination of IL-12p40 and IL-23p19. Although IL-23p19 
and EBI3 have not previously been reported to heterodimerize, it is possible that they do interact 
since they are α and β sub-units of this cytokine family. EBI3-containing cytokines of the IL-12 
cytokine family (IL-27 and IL-35) have more immunosuppressive roles (Banchereau, Pascual et al. 
2012). Therefore it is tempting to speculate that a IL-23p19/EBI3 heterodimer, if it indeed exists, 
may have an immunosuppressive role in skin injury or inflammatory disorders like psoriasis. IL-
12p40 has been reported to form a functional homodimer, which has been shown to suppress Treg 
cells (Ling, Gately et al. 1995, Gately, Carvajal et al. 1996, Brahmachari and Pahan 2009).  
Therefore, it is also possible that IL-23p19 could form a homodimer that may have a role in 
suppression of Th17 cell development and/or function. Also, IL-27p28 has been reported to 
function as a monomer, IL-30, which binds to the gp130 receptor and acts as a natural antagonist of 
signalling in the absence of EBI3 (Dibra, Cutrera et al. 2012, Garbers, Spudy et al. 2013). Thus, a 
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third possibility is that IL-23p19 functions as a monomer in antagonizing inflammatory responses in 
the absence of IL-12p40. Experimental evidence is now required to establish where any of these 
hypotheses hold true. The IL-23R, which recognizes IL-23p19, is primarily expressed by T cells 
and NK cells (Parham, Chirica et al. 2002); while WSX-1 receptor, which recognizes EBI3, is 
expressed by various leukocyte populations including T cells, NK cells, monocytes and mast cells 
(Pflanz, Hibbert et al. 2004). This suggests that T cells and NK cells would be the likely cellular 
targets of the IL-23p19/EBI3 heterodimer, the IL-23p19/IL-23p19 homodimer or the IL-23p19 
monomer.  
 
6.2.4 A proposed model for IRF6 involvement in TLR3 signalling 
The proposed model for IRF6 involvement in TLR3-regulated keratinocyte responses is 
summarised in Figure 6.2. In brief, detection of dsRNA released from damaged cells such as UVB-
damaged cells, initiates wound repair via TLR3 (Lai, Di Nardo et al. 2009, Bernard, Cowing-Zitron 
et al. 2012). This results in the selective upregulation of IL-23p19 and EBI3, the former in an IRF6-
dependent manner. IL-23p19 alone, or as a heterodimer with EBI3, has an immunosuppressive role 
in skin inflammation, thereby contributing to wound healing.  
 
6.3 The roles of IRF6 in MyD88-dependent TLR signalling in keratinocytes 
6.3.1 Why are most of the MyD88-dependent TLRs inactive in keratinocytes?  
Other studies have demonstrated that keratinocytes express functional TLRs (Baker, Ovigne et al. 
2003, Mempel, Voelcker et al. 2003, Pivarcsi, Bodai et al. 2003, Pivarcsi, Koreck et al. 2004, 
Kollisch, Kalali et al. 2005). In this thesis, I found that keratinocytes primarily responded to the 
TLR3 ligand poly(IC), the TLR7 ligand Imiquimod and the TLR2/6 ligand FSL-1, whilst most of 
the other TLR ligands were inactive. This contrasts somewhat with previous literature (Baker, 
Ovigne et al. 2003, Mempel, Voelcker et al. 2003, Pivarcsi, Bodai et al. 2003, Kollisch, Kalali et al. 
2005), where some of the TLR ligands that were inactive in my studies induced robust 
inflammatory responses in the former studies (as discussed in detail in Section 3.3.2). Given that 
IL-8 was used as my primary screen for TLR responsiveness and that this is a generic target of most 
TLRs (Eckmann, Kagnoff et al. 1993, Schulte, Wattiau et al. 1996, Kollisch, Kalali et al. 2005, 
Olaru and Jensen 2010), it seems unlikely that the receptors are active and that I was examining the 
wrong downstream target. The lack of response to most MyD88-dependent TLR agonists begs the 
question of what the physiological reason is for this lack of response. 
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Figure 6.2. A proposed model for IRF6 involvement in TLR3 signalling. An overview of this 
model, as well as existing evidence to support it, is as follows: (1) TLR3 is activated by dsRNA 
released during cell-damage relays signalling via TRIF to initiate signalling (Kawai and Akira 2007, 
Lai, Di Nardo et al. 2009, Bernard, Cowing-Zitron et al. 2012); (2) TRIF-dependent signalling 
activates kinases, possibly TBK-1, to enable phosphorylation of IRF6 (preliminary data using 
mutated IRF6 with phosphomimetic glutamic acid replacement of Ser residues, data not shown); (3) 
Poly(IC) promotes IRF6 nuclear translocation (Figure 4.7) (Bailey and Hendrix 2008); (4) IRF6 is 
required for Poly(IC)-inducible IL-23p19 expression (Figures 4.3-4.5) while it activates EBI3 in an 
IRF6-independent manner, likely via NF-κB (Figure 4.3) (Wirtz, Becker et al. 2005, Poleganov, 
Bachmann et al. 2008); (5) Poly(IC) induces IFN-β in an IRF3-dependent fashion (Figures 4.3-4.4); 
(6) Autocrine factors, such as IFN-β, may activate IRF6 through autocrine signalling; (7) IL-23p19, 
produced in an IRF6-dependent manner, may function as a monomer, homodimer or interact with 
EBI3 to form a heterodimer (experimental evidence required), resulting in functions in wound 
repair.  
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The epidermis of the skin is constitutively exposed to microbes as a result of its microflora. 
Therefore, immune responses must be tightly controlled to avoid inappropriate inflammation (Lai 
and Gallo 2008, Miller 2008, Feldmeyer, Werner et al. 2010, Terhorst, Kalali et al. 2010). 
Keratinocytes must, therefore, employ tolerance mechanisms to ensure that inflammatory responses 
are elicited upon detection of pathogenic microorganisms, rather than commensals. One mechanism 
that enables this is the differential expression of TLRs in the outer versus inner layers of the 
epidermis (Miller, Sorensen et al. 2005, Begon, Michel et al. 2007, Li, Sohn et al. 2013), and this 
will be discussed further in Section 6.4.1. However, TLRs are not necessarily absent from 
keratinocytes in the outermost layers, suggesting that other mechanisms may be at play. One study 
on IECs showed that these cells were largely unresponsive to TLR2-dependent bacterial ligands, 
although they expressed TLR1, 2 and 6 (Melmed, Thomas et al. 2003). It also reported that these 
cells express high levels of Tollip, an inhibitor of TLR signalling (Melmed, Thomas et al. 2003). 
This suggests that IECs are refractory to TLR-signalling, by virtue of high basal levels of Tollip. 
Keratinocytes may also express high levels of inhibitory molecules that constrain MyD88-
dependent signalling, which could account for my observations (Figures 3.3-3.4). Although it is 
possible that additional stimuli, such as IFN-γ, may permit responsiveness, my studies with 
imiquimod do not support such a model (Figures 5.4-5.5). However, due to time constraints, the 
effect of IFN-γ priming on other MyD88-dependent TLR ligands was not investigated. Hence, this 
possibility cannot be excluded.  
 
6.3.2 The role of IRF6 in MyD88-dependent TLR signalling 
In my studies, I identified a role for IRF6 in MyD88-dependent TLR signalling. IRF6 was required 
for TLR7-inducible IFN-β and CCL5 mRNA expression (Figure 5.2), and may also mediate 
TLR2/6-dependent CCL5 and IL-23p19 expression (Figure 5.7). Potential role(s) of IL-23p19 in 
skin inflammation were discussed above (Section 6.2.3). CCL5, a member of the CC chemokine 
family, recruits leukocytes to the sites of inflammation (Lapteva and Huang 2010, Katsounas, 
Schlaak et al. 2011). CCL5 acts via the CCR5 receptor, which is primarily expressed by T cells, 
macrophages, DCs and microglia (Granelli-Piperno, Moser et al. 1996, Raport, Gosling et al. 1996, 
Albright, Shieh et al. 1999). CCL5/CCR5 preferentially activates T cells (Stanford and Issekutz 
2003) and gene knockout studies in mice have shown that Ccl5 is important for T cell proliferation 
and inflammatory responses (IFN-γ, IL-2) (Makino, Cook et al. 2002). In skin, CCL5 has been 
associated with immune disorders of the skin such as AD by virtue of its capacity to promote Th2 
responses (Yamada, Izutani et al. 1996, Giustizieri, Mascia et al. 2001, Kaburagi, Shimada et al. 
2001). Moreover, CCL5 expression was elevated in AD skin as compared to normal skin (Yamada, 
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Izutani et al. 1996). IFN-β is critical for anti-viral responses and is a key target of TLRs such as 
TLR7 that recognize viral components (Bonjardim, Ferreira et al. 2009). However, the biological 
function of IFN-β is not limited to anti-viral activities alone. IFN-β also has anti-proliferative and 
immunomodulatory effects both in vivo and in vitro (Bekisz, Baron et al. 2010). It inhibits 
proliferation of keratinocytes (Yaar, Karassik et al. 1985, Bielenberg, McCarty et al. 1999), and 
IFN-based therapy has been used for the treatment of several tumours, including SCCs (Nickoloff, 
Basham et al. 1985, Naito, Baba et al. 1992, Ismail and Yusuf 2014). Human SCCs expressed 
reduced levels of IFN-β and genes downstream of IFN-signalling, STATα/β when compared to 
normal skin (Clifford, Menter et al. 2000). These studies suggest a role for reduced IFN-β 
expression in the progression of SCC. Since both TLR7 and IRF6 can regulate SCC development 
(discussed in Sections 6.3.3 and 6.3.4), the IRF6-dependent induction of IFN-β expression upon 
TLR7 activation (e.g. in response to imiquimod), may contribute to therapeutic effects against SCC. 
Other than IFN-β, CCL5 and IL-23p19, IRF6 may also have other target genes downstream of 
MyD88-dependent TLR signalling. Two potential candidates are IL-37 and IL-36γ (discussed in 
Section 6.2.2). Another potential IRF6 target gene that may be relevant in MyD88-dependent TLR 
signalling is CXCL16 (Botti, Spallone et al. 2011). CXCL16 is a chemotractant for leukocytes that 
express its receptor CXC receptor 6, such as T cells, NK T cells, Th1 cells (Matloubian, David et al. 
2000, Wilbanks, Zondlo et al. 2001). CXCL16 has also been shown to mediate phagocytosis of 
bacteria such as E. coli and S. aureus and is also elevated in skin inflammatory conditions, such as 
psoriasis (Tohyama, Sayama et al. 2007, Oh, Schramme et al. 2009, Gunther, Carballido-Perrig et 
al. 2012). Thus, CXCL16 is an important chemokine mediating inflammatory responses in 
epidermis. Whether the genes encoding these cytokines lie downstream of MyD88-dependent (and 
IRF6-dependent) TLR signalling in keratinocytes is worthy of further investigation.  
The trans-activating capacity of IRFs is regulated by their phosphorylation status (Ozato, Tailor et 
al. 2007). IRF6 also possesses Ser residues that are conserved with those that are phosphorylated in 
other IRFs (S413 and S424, Figure 5.9), suggesting that IRF6 may be phosphorylated by kinases 
downstream of TLR signalling (Honda and Taniguchi 2006). Co-immunoprecipitation studies from 
the laboratory of A/Prof. Glen Scholz have shown that IRF6 transiently interacts with IRAK-1 
(A/Prof. Glen Scholz, personal communication), a key serine/threonine kinase required for MyD88-
dependent signalling (Cao, Henzel et al. 1996, Takeda and Akira 2004). Thus, MyD88-dependent 
TLR signalling may activate IRF6 via IRAK-1. Whereas IRF5 and IRF7 have been reported to 
directly interact with MyD88 (Kawai, Sato et al. 2004, Balkhi, Fitzgerald et al. 2008), IRF6 did not 
interact with MyD88 in co-immunoprecipitation studies (A/Prof. Glen Scholz, personal 
communication). Mutational analysis of S413 and S424 in IRF6 suggest that both residues are 
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important for trans-activator function, with S424 being the likely target for phosphorylation by 
IRAK-1 (A/Prof. Glen Scholz, personal communication). However, more detailed biochemical 
analysis is required to validate this model.  
 
6.3.3 The roles of TLR7 in skin pathology  
The TLR7 agonist imiquimod is a potent immunomodulator that has been used to treat several skin 
disorders, including SCC, basal cell carcinoma and even malignant melanoma (Bong, Bonnekoh et 
al. 2002, Geisse, Rich et al. 2002, Novak, Yu et al. 2008). It is presumed that TLR7-driven 
inflammatory responses enable the recruitment of key inflammatory cells, particularly T-cells, 
which then elicit cellular responses against cancerous cells (Panelli, Stashower et al. 2007, Clark, 
Huang et al. 2008, Huang, Hijnen et al. 2009, Yokogawa, Takaishi et al. 2013). The leukocyte 
recruitment profile of imiquimod also results in the dilution of the percentage of Treg cells in the 
skin, thus restoring effective T-cell responses that are usually inhibited by Treg cells (Clark, Huang 
et al. 2008). Imiquimod also regulates the functions of recruited cells. It upregulates expression of 
genes associated with cytotoxic T-cell functions, such as perforin and granzyme, which aids in 
killing of cancerous cells (Huang, Hijnen et al. 2009), and drives the production of IL-12 and IL-23 
that mediate Th1 and Th17 development and activation (Yokogawa, Takaishi et al. 2013). In mouse 
models, imiquimod treatment enabled Th17 cell-mediated elimination of melanoma cells via IFN-γ 
production (Muranski, Boni et al. 2008). Interestingly, topical imiquimod application also 
aggravated psoriasis in humans (Gilliet, Conrad et al. 2004, Wu, Siller et al. 2004), and induced 
psoriasis-like lesions in mice through IL-23/Th17 axis (van der Fits, Mourits et al. 2009). Therefore, 
TLR7 appears to have a protective role against SCC development, while excessive activation 
through this receptor may predispose to the development of psoriasis. 
 
6.3.4 The role of IRF6 in TLR7 signalling  
Downregulation of IRF6 expression in SCC has been reported to correlate with tumour invasiveness 
(Botti, Spallone et al. 2011). The decrease in IRF6 expression correlated with methylation at a 
specific CpG dinucleotide island within the IRF6 promoter (Botti, Spallone et al. 2011). Another 
study in keratinocytes has also linked IRF6 to the pro-differentiation and tumour suppressive 
functions of Notch signalling (Restivo, Nguyen et al. 2011). Finally, IRF6 was shown to be 
downstream of p63, a known tumour suppression protein (Moretti, Marinari et al. 2010). These 
studies thus suggest that loss of IRF6 expression could predispose to tumour development and/or 
progression. IRF6 functions in tumour suppression is not limited to just keratinocytes. IRF6 
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downregulation was also associated with more progressive and invasive breast cancer (Bailey, 
Khalkhali-Ellis et al. 2005). In mammary epithelial cells, phosphorylation status of IRF6 may be a 
key determinant of its own expression. Phosphorylation of IRF6 led to its proteosomal degradation 
resulting in cell proliferation, whereas non-phosphorylated IRF6 triggered cell cycle arrest and 
cellular differentiation (Bailey, Abbott et al. 2008). Thus, hyper-phosphorylation of IRF6 may result 
in loss of IRF6 expression and tumour progression, particularly since one study has provided 
evidence that IRF6 positively regulates its own expression (Botti, Spallone et al. 2011). This is 
interesting in light of the likely role of IRF6 phosphorylation in relaying MyD88-dependent 
signalling (see Section 6.3.2) and thus possible therapeutic effects against SCCs. It suggests that 
IRF6 phosphorylation may have differential roles in regulating tumour cell survival. On the one 
hand, TLR7-mediated IRAK-1-dependent IRF6 phosphorylation may elicit inflammatory responses 
to promote tumour clearance, while IRF6 phosphorylation by an unknown kinase may result in 
IRF6 degradation, uncontrolled cell proliferation and tumour development. An understanding of 
which specific kinases target IRF6 will undoubtedly provide further insights into these processes. 
 
6.3.5 Role of TLR2/6 signalling in keratinocytes  
The skin is exposed to many commensal bacteria, some of which can cause mild to serious skin and 
soft tissue infections upon invasion into basal layers (Cogen, Nizet et al. 2008, Grice and Segre 
2011). For example, S. aureus commonly causes folliculitis, impetigo and skin abscesses of the skin 
(Lowy 1998, Cogen, Nizet et al. 2008). Patients with AD, a Th2-driven inflammatory condition of 
the skin, are predisposed to S. aureus infections (Leyden, Marples et al. 1974, Hanifin and Rogge 
1977, White and Noble 1986, Lubbe 2003). Patients with AD show reduced TLR2 expression and 
weakened barrier structure, which presumably allows opportunistic pathogens such as S. aureus to 
invade and cause pathology (Murata, Ogata et al. 1996, Pilgram, Vissers et al. 2001, Palmer, Irvine 
et al. 2006, Niebuhr, Lutat et al. 2009, De Benedetto, Rafaels et al. 2011, Kuo, Carpenter-Mendini 
et al. 2013). Interestingly, TLR2 has been shown to enhance tight junction barriers in both mouse 
and human epidermis, thereby permitting epidermal barrier defence (Kuo, Carpenter-Mendini et al. 
2013).  This suggests an additional role for TLR2 in epithelial function, in addition to direct 
recognition of Gram-positive pathogens such as S. aureus (Kuo, Carpenter-Mendini et al. 2013). 
Topical immunomodulators, such as pimecrolimus, have been used as an effective treatment for AD 
(Reitamo, Remitz et al. 2002, Stuetz, Baumann et al. 2006). Pimecrolimus is a calcineurin pathway 
inhibitor, and thus inhibits T cell activation and subsequent inflammatory responses (Grassberger, 
Baumruker et al. 1999, Kalthoff, Chung et al. 2002, Winiski, Wang et al. 2002, Winiski, Wang et 
al. 2007, Ehrchen, Sunderkotter et al. 2008). However, a recent study showed the pimecrolimus 
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enhanced anti-microbial peptide expression via the TLR2/6 pathway in keratinocytes (Buchau, 
Schauber et al. 2008). Pimecrolimus-mediated TLR2/6 activation also aided in the clearance of S. 
aureus and decreased the expression of IL-10 and IL-1β (Buchau, Schauber et al. 2008). This 
suggests that pimecrolimus may elicit both anti-microbial and anti-inflammatory responses via 
TLR2/6 signalling. 
 
6.3.6 Role of IRF6 in anti-bacterial responses of keratinocytes  
In light of the above studies, it would have been interesting to examine the role of the TLR2/6-IRF6 
axis in promoting anti-bacterial responses against S. aureus. Such experiments were not performed 
because of time constraints, however I did perform some very preliminary studies with another 
Gram-positive pathogen, Group A Streptococcus (GAS). GAS is also a common skin commensal, 
which can cause mild to serious infections, such as Necrotizing fasciitis and impetigo, upon 
invasion (Cogen, Nizet et al. 2008). GAS infection of HaCaT cells was reported to upregulate 
mRNA expression of IL-1α, IL-1β, IL-6 and IL-8 (Wang, Ruiz et al. 1997). Initially, I examined 
whether primary keratinocytes are able to clear intracellular GAS, which would suggest activation 
of anti-microbial pathways. I infected primary keratinocytes with the GAS strain JRS4 at an 
multiplicity of infection (MOI) of 30 and monitored intracellular bacterial loads at 4 and 8 h post 
infection. I found that JRS4 was able to survive in keratinocytes, and by 8 h post infection, the 
bacterial loads were reduced ~4 fold (Figure 6.3A). To determine whether IRF6 was involved in 
the clearance of JRS4, I knocked IRF6 expression down in these cells and then infected them with 
JRS4 for 4 and 8 h. IRF6 or IRF3 knock down did not affect JRS4 survival in keratinocytes (Figure 
6.3B). This suggests that IRF6 is not required for JRS4 clearance from keratinocytes. However, 
IRF6 may be involved in initiating inflammatory responses (e.g. CCL5 expression) in response to 
Gram-positive pathogens such as GAS and S. aureus to enable appropriate leukocyte recruitment, 
and this requires further investigation.  
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Figure 6.3. IRF6 does not affect intracellular survival of GAS within primary keratinocytes. 
Primary keratinocytes were infected with the GAS strain JRS4 at an MOI of 30 for 2 h. 
Extracellular bacteria exclusion was performed by adding gentamicin in media. (A) Cell-lysates 
were harvested 4 and 8 h post-infection, plated overnight on THY agar plates and intra-cellular 
bacterial loads were determined by colony counting. Data represents mean ± SD of experimental 
triplicates and is representative of 3 independent experiments. (B) IRF6 and IRF3 expression in 
primary human keratinocytes were knocked down using transfection with specific siRNA. These 
cells were then infected with the GAS strain JRS4 at an MOI of 30 for 4 and 8 h. Intracellular 
bacterial loads were determined as in (A). Data represents mean ± SD of experimental triplicates. 
 
6.3.7 A proposed model for the role of IRF6 in MyD88-dependent TLR signalling 
A proposed model for IRF6 involvement in MyD88-dependent TLR responses in keratinocytes is 
summarised in Figure 6.4. In brief, imiquimod signalling via TLR7 or Gram-positive bacteria 
signalling via TLR2/6 engages the MyD88-IRF6 axis to drive expression of specific target genes 
such as IFN-β and CCL5. This may contribute to leukocyte recruitment and inflammation to enable 
either anti-tumour responses (TLR7) or pathogen clearance (TLR2/6). 
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Figure 6.4. A proposed model for IRF6 involvement in MyD88-dependent TLR signalling. (1) 
TLR7, activated by ssRNA viruses or by topical application of imiquimod, engages MyD88-
dependent signalling (Kawai and Akira 2006); (2) TLR2/6, activated by Gram-positive bacteria 
such as S. aureus, also engages MyD88-dependent signalling (Kawai and Akira 2006, Vu, Baba et 
al. 2010); (3) MyD88-dependent signalling activates the serine/threonine IRAK-1, which interacts 
with IRF6 (A/Prof. Glen Scholz, personal communication); (4) IRF6 is phosphorylated by IRAK-1 
at S424 (A/Prof. Glen Scholz, personal communication); (5) IRF6 may translocate into the nucleus 
in response to these stimuli (Figure 5.8). (6) IRF6 promotes TLR7-mediated IFN-β and CCL5 
mRNA expression (Figure 5.2), as well as (7) TLR2/6-dependent CCL5 expression (Figure 5.7, 
A/Prof. Glen Scholz, personal communication).  
 
6.4 Comparison of TRIF- and MyD88-dependent TLR responses in keratinocytes  
6.4.1 IRF6 expression in proliferating versus differentiated keratinocytes 
As mentioned in Section 6.3.1, keratinocytes may employ specific tolerance mechanisms to prevent 
excessive MyD88-driven inflammation. One reported mechanism by which this occurs is via 
Final Discussion 
124 
 
differential expression of TLRs in the outer differentiated cells versus inner proliferating cells 
(Miller, Sorensen et al. 2005, Begon, Michel et al. 2007, Li, Sohn et al. 2013). That is, the more 
differentiated cells in the outer layers of skin have been reported to express higher levels of TLRs 
recognizing viral components, for example TLR7 (Miller, Sorensen et al. 2005, Begon, Michel et al. 
2007, Li, Sohn et al. 2013). In contrast, TLRs detecting bacterial components were reported to be 
more highly expressed in cells within the basal layers, thus enabling initiation of inflammatory 
responses upon bacterial invasion of the skin (Baker, Ovigne et al. 2003, Pivarcsi, Bodai et al. 2003, 
Miller, Sorensen et al. 2005, Begon, Michel et al. 2007). However, my data suggested that TLR 
expression in differentiated and proliferating cells were mostly comparable, at least at the mRNA 
level (Figure 3.8). In contrast, IRF6 expression was higher in differentiated cells as compared to 
proliferating cells (Figure 3.7), which is consistent with existing literature (Richardson, Dixon et al. 
2006, Moretti, Marinari et al. 2010, Botti, Spallone et al. 2011, Restivo, Nguyen et al. 2011, Biggs, 
Rhea et al. 2012). This regulated expression of IRF6 may help to fine-tune TLR-driven 
inflammatory responses. Interestingly, I found that the keratinocyte differentiation state did not 
affect TLR3 responses (Figures 3.9 and 4.10), whereas TLR7 responses were stronger in 
differentiated cells as compared to proliferating cells (Figure 5.3). This suggests that keratinocyte 
differentiation may selectively permit MyD88-dependent TLR signalling. In a preliminary 
experiment further examining this hypothesis, I observed that the TLR1/2 agonist Pam3Cys, which 
did not activate inflammatory gene expression in keratinocytes (Figures 3.3-3.4), did upregulate 
CCL5 expression in keratinocytes after differentiation (data not shown). It is tempting to speculate 
that the enhanced responsiveness of differentiated keratinocytes to MyD88-dependent TLR agonist 
is mediated through enhanced IRF6 expression. 
 
6.4.2 Interplay between IFN-γ priming and differentiation status on TLR responses  
Since primary keratinocytes were largely unresponsive to most MyD88-dependent TLR ligands, I 
considered the possibility that priming these cells with an additional pro-inflammatory stimulus 
such as IFN- would permit responsiveness. IFN-γ priming itself had little effect on MyD88-
dependent TLR responses (Figure 5.4), and I therefore examined the effect of IFN-γ priming after 
keratinocytes had been differentiated. Although differentiated keratinocytes responded strongly to 
imiquimod (Figure 5.3), IFN-γ priming did not further enhance TLR7 responses in these cells 
(Figure 5.5). However, IFN-γ priming did differentially regulate TLR3-dependent IFN-β and IL-
23p19 induction upon differentiation. Whereas poly(IC)-inducible IFN-β and IL-23p19 expression 
was not greatly affected by differentiation status in unprimed cells (Figure 4.10A and B), these 
responses were affected when cells were primed with IFN-γ. That is, IFN-γ primed, differentiated 
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keratinocytes showed decreased IFN-β and increased IL-23p19 gene expression when compared to 
IFN-γ primed, proliferating keratinocytes (Figure 4.10A and B). Given that poly(IC)-inducible 
IFN-β and IL-23p19 mRNA expression was differentially affected by IRF6 (Figures 4.3D and E, 
4.4C and D), it is tempting to speculate that IFN-γ priming selectively enhances IRF6 function in 
differentiated keratinocytes. Overall, my data suggests that there are key differences in MyD88- 
versus TRIF-dependent TLR signalling in keratinocytes upon differentiation (Figure 6.5). Since 
TLR mRNA expression in proliferating and differentiated keratinocytes were similar (Figure 3.8), 
downstream signalling molecules, such as IRF6, may contribute to these effects. 
 
Figure 6.5. A proposed model for IRF6 involvement TLR signalling during keratinocyte 
differentiation. (1) IRF6 expression is increased during differentiation (Figure 3.7), while TLR 
mRNA expression is unaffected (Figure 3.8); (2) In proliferating cells, TLR2 expression is higher 
(Baker, Ovigne et al. 2003, Pivarcsi, Bodai et al. 2003, Begon, Michel et al. 2007), and therefore 
they are more responsive to the TLR2/6 agonist FSL-1 (compared to differentiated cells) (Figures 
5.6 and 5.7); (3) In contrast to TLR2, TLR7 expression is higher in differentiated cells (Li, Sohn et 
al. 2013), and TLR7-mediated responses are enhanced (compared to proliferating cells) (Figures 
5.1-5.3); (4) In response to poly(IC), IFN-γ primed, differentiated keratinocytes showed decreased 
IFN-β and increased IL-23p19 gene expression when compared to IFN-γ primed, proliferating 
keratinocytes (Figure 4.10). 
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6.5 Future Directions 
6.5.1 Limitations of this thesis and future experiments 
In this section, I outline some of the major limitations of this thesis, and also highlight additional 
experiments that are required to further test hypotheses proposed in this chapter. 
One key deficiency of my studies is that, although I characterized TLR-regulated gene expression in 
keratinocytes, I did not perform complementary studies examining proximal TLR signalling events, 
for example NF-κB and MAPK activation. From gene knockdown studies, I found that IRF6 only 
partially controls poly(IC)-inducible IL-23p19 expression in keratinocytes. The IL-23p19 promoter 
contains binding sites for both IRF and NF-κB (Figure 4.6A), and NF-κB has previously been 
shown to regulate IL-23p19 expression in macrophages and DCs (Carmody, Ruan et al. 2007, Mise-
Omata, Kuroda et al. 2007). Therefore, it is possible that IRF6 cooperates with NF-κB to regulate 
poly(IC)-inducible IL-23p19 expression. Thus, poly(IC)-mediated NF-κB activation in 
keratinocytes could have been assessed by gel shift assays and/or immunoblotting (IB degradation 
and/or p65 phosphorylation). Moreover, inhibitors of the NF-κB pathway could have been used to 
determine whether this affected poly(IC)-inducible IL-23p19 gene expression, either alone or in 
combination with IRF6 knock-down. Interestingly, MyD88-dependent ligands did trigger robust 
mRNA expression of IL-8 and subsequent release of this chemokine, whereas induction of IFN-β, 
CCL5 and IL-23p19 was modest by comparison (Figures 5.1, 5.6). This would suggest that MyD88 
ligands do efficiently activate NF-κB in these cells, since IL-8 is a classic NF-κB target gene 
(Mukaida, Mahe et al. 1990, Kunsch and Rosen 1993, Matsusaka, Fujikawa et al. 1993, Stein and 
Baldwin 1993, Kunsch, Lang et al. 1994), whereas IRF-dependent signalling may be somehow 
constrained. This could have also been assessed through direct monitoring of proximal signalling 
pathways in response to MyD88-dependent TLR agonists. 
There are several outstanding issues regarding the involvement of IRF6 in TLR3 signalling. Firstly, 
the mechanism by which TRIF signalling activates IRF6 is unknown. TBK1 is a central kinase in 
TRIF signalling, yet this kinase did not synergize with IRF6 in activating the IFN- promoter 
(A/Prof Glen Scholz, personal communication). Notably however, I found that IRF6 did not 
positively regulate poly(IC)-inducible IFN- expression (Figures 4.3D and 4.4C), so the effect of 
co-transfection of TBK1 and IRF6 on IL-23p19 promoter activity could be examined in the future. 
It is also possible that IRF6 regulates IL-23p19 through secondary mechanisms, for example via 
autocrine IFN-. In this case, other kinases may be involved in regulating IRF6 function. Since 
S413 and S424 within IRF6 have already been identified as key aa regulating the function of this 
transcription factor (A/Prof Glen Scholz, personal communication), it is quite likely that 
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phosphorylation of one or both of these residues is required for activation of the IL-23p19 promoter. 
Hence, specific IRF6 mutants predicted to abolish function (S413A, S424A, S413A/S424A) or to 
be constitutively active (S413E, S424E, S413E/S424E) could be used to examine effects on the 
endogenous IL-23p19 gene (e.g. overexpression in T24 cells, see Figure 4.5) or the IL-23p19 
promoter (e.g. promoter-reporter studies in RAW264.7 cells, see Figure 4.6). IL-23p19 promoter-
reporter studies in RAW264 cells could also be used to screen for upstream kinases regulating 
IRF6. Another outstanding issue relating to the studies on poly(IC) responses in keratinocytes 
concerns the selective regulation of IL-23p19 and EBI3. Since EBI3 and IL-23p19 encode α and β 
sub-units of the IL-12 family, it is possible that IL-23p19 and EBI3 can interact to form a functional 
heterodimer. Co-immunoprecipitation studies in cells transfected with IL-23p19 and EBI3 
expression constructs represent a logical first step in examining this hypothesis. If an interaction 
could be confirmed, it would certainly be interesting to determine whether this heterodimer 
regulates cell repair and wound healing in an in vivo model.  
With respect to MyD88-dependent TLR signalling, I showed that keratinocytes respond to both 
TLR7 and TLR2/6 agonists. A link between this TLR signalling arm and IRF6 is also supported by 
the observation that IRAK-1 interacts transiently with IRF6 (A/Prof. Glen Scholz, personal 
communication). Interestingly, I found that the differentiation status of keratinocytes appeared to 
affect TLR7-inducible gene expression. A detailed time-course of IRF6 and TLR7 expression 
during differentiation would enable a better understanding of the molecular mechanisms 
contributing to this effect. The reverse phenomenon may be true for TLR2 responsiveness, since the 
expression of this receptor is reportedly higher in keratinocytes in the basal layer, as compared to 
differentiated cells (Baker, Ovigne et al. 2003, Pivarcsi, Bodai et al. 2003, Begon, Michel et al. 
2007). Thus, it would be of interest to examine the effect of keratinocyte differentiation on TLR2/6 
responses, and to compare and contrast these findings with TLR7 responsiveness. If proliferative 
cells do indeed respond better to FSL-1, IRF6 gene knockdown studies could be performed by 
adding Y27632 to the media of transfecting keratinocytes to maintain them in a proliferative state. 
This may provide a more robust system to examine TLR2/6 responses in keratinocytes, as well as 
the specific involvement of IRF6. Additionally, whether TLR2/6 and/or TLR7 signalling promote 
IRF6 nuclear translocation in proliferating and differentiated keratinocytes requires careful 
examination. Finally, the roles of IRF6 in regulating both inflammatory and antimicrobial responses 
against Gram-positive pathogens such as S. aureus and GAS should be investigated to gain an 
understanding of what role, if any, this transcription factor plays in host responses to pathogens of 
the skin.  
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6.5.2 Conclusion 
In summary, I have shown that IRF6 is an epithelial cell-specific member of the IRF family, and 
that it is particularly highly expressed in keratinocytes. I have identified putative roles for IRF6 in 
both MyD88-dependent and TRIF-dependent TLR signalling in these cells. My data thus posit IRF6 
as an important signalling component of pro-inflammatory responses in keratinocytes. Ultimately, 
the findings from this project should enhance our understanding of the molecular mechanisms 
contributing to both effective host defence and dysregulated inflammation in the skin.
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